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Background: Thyrotoxicosis has multiple etiologies, manifestations, and potential 47 
therapies. Appropriate treatment requires an accurate diagnosis and is influenced by 48 
coexisting medical conditions and patient preference. This article describes evidence-49 
based clinical guidelines for the management of thyrotoxicosis that would be useful to 50 
generalist and subspecialty physicians and others providing care for patients with this 51 
condition. 52 
Methods: The American Thyroid Association (ATA) previously co-sponsored guidelines 53 
for the management of thyrotoxicosis that were published in 2011.   Considerable new 54 
literature has been published since 2011, the ATA felt updated evidence-based guidelines 55 
were needed, and assembled a task force of expert clinicians who authored this report. 56 
The task force examined relevant literature using a systematic PubMed search 57 
supplemented with additional published materials. An evidence-based medicine approach 58 
that incorporated the knowledge and experience of the panel was used to update the 2011 59 
text and recommendations. The strength of the recommendations and the quality of 60 
evidence supporting each was rated according to the approach recommended by the 61 
Grading of Recommendations, Assessment, Development, and Evaluation Group. 62 
Results: Clinical topics addressed include the initial evaluation and management of 63 
thyrotoxicosis; management of Graves’ hyperthyroidism using radioactive iodine, 64 
antithyroid drugs, or surgery; management of toxic multinodular goiter or toxic adenoma 65 
using radioactive iodine or surgery; Graves’ disease in children, adolescents, or pregnant 66 
patients; subclinical hyperthyroidism; hyperthyroidism in patients with Graves’ 67 
orbitopathy; and management of other miscellaneous causes of thyrotoxicosis.  New 68 
paradigms since publication of the 2011 guidelines are presented for the evaluation of the 69 
etiology of thyrotoxicosis, the management of Graves’ hyperthyroidism with antithyroid 70 
drugs, the management of pregnant hyperthyroid patients, and the preparation of patients 71 
for thyroid surgery.  The sections on less common causes of thyrotoxicosis have been 72 
expanded.  73 
Conclusions: One hundred twenty-four evidence-based recommendations were 74 
developed to aid in the care of patients with thyrotoxicosis and to share what the task 75 
force believes is current, rational, and optimal medical practice. 76 
Introduction 77 
 Thyrotoxicosis is a condition having multiple etiologies, manifestations, and 78 
potential therapies. The term ‘‘thyrotoxicosis’’ refers to a clinical state that results from 79 
inappropriately high thyroid hormone action in tissues generally due to inappropriately 80 
high tissue thyroid hormone levels. The term ‘‘hyperthyroidism,’’ as used in these 81 
guidelines, is a form of thyrotoxicosis due to inappropriately high synthesis and secretion 82 
of thyroid hormone(s) by the thyroid. Appropriate treatment of thyrotoxicosis requires an 83 
accurate diagnosis. For example, thyroidectomy is an appropriate treatment for some 84 
forms of thyrotoxicosis and not for others. Additionally, beta blockers may be used in 85 
almost all forms of thyrotoxicosis, whereas antithyroid drugs (ATDs) are useful in only 86 
some. 87 
 In the United States, the prevalence of hyperthyroidism is approximately 1.2% 88 
(0.5% overt and 0.7% subclinical); the most common causes include Graves’ disease 89 
(GD), toxic multinodular goiter (TMNG), and toxic adenoma (TA) (1). Scientific 90 
advances relevant to this topic are reported in a wide range of literature, including 91 
subspecialty publications in endocrinology, pediatrics, nuclear medicine, and surgery, 92 
making it challenging for clinicians to keep abreast of new developments. Although 93 
guidelines for the diagnosis and management of patients with thyrotoxicosis were 94 
published previously by the American Thyroid Association (ATA) and the American 95 
Association of Clinical Endocrinologists (AACE) in 2011 , the ATA determined that 96 
thyrotoxicosis represents a priority area in need of updated evidence-based practice 97 
guidelines. 98 
 The target audience for these guidelines includes general and subspecialty 99 
physicians and others providing care for patients with thyrotoxicosis. In this document, 100 
we outline what we believe is current, rational, and optimal medical practice. It is not the 101 
intent of these guidelines to replace clinical judgment, individual decision making, or the 102 
wishes of the patient or family. Rather, each recommendation should be evaluated in light 103 
of these elements in order that optimal patient care is delivered. In some circumstances, it 104 
may be apparent that the level of care required may be best provided in centers where 105 
there is specific expertise, and that referral to such centers should be considered. 106 
Methods of Development of Evidence-Based Guidelines 107 
Administration 108 
 The ATA Executive Council selected a chairperson to lead the task force and this 109 
individual (D.S.R.) identified the other 10 members of the panel in consultation with the 110 
ATA board of directors. Membership on the panel was based on clinical expertise, 111 
scholarly approach, and representation of adult and pediatric endocrinology, nuclear 112 
medicine, and surgery. The task force included individuals from North America, South 113 
America, and Europe. Panel members declared whether they had any potential conflict of 114 
interest at the initial meeting of the group and periodically during the course of 115 
deliberations. Funding for the guidelines was derived solely from the general funds of the 116 
ATA and thus the task force functioned without commercial support. 117 
 The task force reviewed the 2011 guidelines and published editorials regarding 118 
those guidelines, and developed a revised list of the most common causes of 119 
thyrotoxicosis and the most important questions that a practitioner might pose when 120 
caring for a patient with a particular form of thyrotoxicosis or special clinical condition. 121 
One task force member was assigned as the primary writer for each topic.  One or more 122 
task force members were assigned as secondary writers for each topic, providing their 123 
specific expertise and critical review for the primary writer.  The relevant literature was 124 
reviewed using a systematic PubMed search for primary references and reviews 125 
published after the submission of the 2011 guidelines, supplemented with additional 126 
published materials found on focused PubMed searches.  Recommendations were based 127 
on the literature and expert opinion where appropriate. A preliminary document and a 128 
series of recommendations concerning all of the topics were generated by each primary 129 
writer and then critically reviewed by the task force at large. The panel agreed 130 
recommendations would be based on consensus of the panel and that voting would be 131 
used if agreement could not be reached. Task force deliberations took place between 132 
2014 and 2016 during several lengthy committee meetings, and through electronic 133 
communication. 134 
Rating of the recommendations 135 
 These guidelines were developed to combine the best scientific evidence with the 136 
experience of seasoned clinicians and the pragmatic realities inherent in implementation. 137 
The task force elected to rate the recommendations according to the system developed by 138 
the Grading of Recommendations, Assessment, Development, and Evaluation Group (3-139 
6). The balance between benefits and risks, quality of evidence, applicability, and 140 
certainty of the baseline risk are all considered in judgments about the strength of 141 
recommendations (7). Grading the quality of the evidence takes into account study 142 
design, study quality, consistency of results, and directness of the evidence. The strength 143 
of a recommendation is indicated as a strong recommendation (for or against) that applies 144 
to most patients in most circumstances with benefits of action clearly outweighing the 145 
risks and burdens (or vice versa), or a weak recommendation or a suggestion that may not 146 
be appropriate for every patient, depending on context, patient values, and preferences. 147 
The quality of the evidence is indicated as low-quality evidence, moderate-quality 148 
evidence, or high-quality evidence, based on consistency of results between studies and 149 
study design, limitations, and the directness of the evidence.  In several instances, the 150 
evidence was insufficient to recommend for or against a test or a treatment, and the task 151 
force made a statement labeled “no recommendation.”  Table 1 describes the criteria to 152 
be met for each rating category. Each recommendation is preceded by a description of the 153 
evidence and, in some cases, followed by a remarks section including technical 154 
suggestions on issues such as dosing and monitoring. 155 
Presentation of recommendations 156 
 The organization of the task force’s recommendations is presented in Table 2. The 157 
page numbers and the location key can be used to locate specific topics and 158 
recommendations. Specific recommendations are presented within boxes in the main 159 
body of the text. Location keys can be copied into the Find or Search function in a file or 160 
Web page to rapidly navigate to a particular section. A listing of the recommendations 161 
without text is provided as Appendix A. 162 
Results 163 
[A] Background 164 
[A1] Causes of thyrotoxicosis 165 
 In general, thyrotoxicosis can occur if (i) the thyroid is excessively stimulated by 166 
trophic factors; (ii) there is constitutive activation of thyroid hormone synthesis and 167 
secretion leading to autonomous release of excess thyroid hormone; (iii) thyroid stores of 168 
preformed hormone are passively released in excessive amounts owing to autoimmune, 169 
infectious, chemical, or mechanical insult; or (iv) there is exposure to extra-thyroidal 170 
sources of thyroid hormone, which may be either endogenous (struma ovarii, metastatic 171 
differentiated thyroid cancer) or exogenous (factitious thyrotoxicosis).  172 
 Hyperthyroidism is generally considered overt or subclinical, depending on the 173 
biochemical severity of the hyperthyroidism, although in reality the disease represents a 174 
continuum of overactive thyroid function.  Overt hyperthyroidism is defined as a  175 
subnormal (usually undetectable)  serum thyroid-stimulating hormone (TSH) with 176 
elevated serum levels of triiodothyronine (T3) and/or free thyroxine estimates (free T4).  177 
Subclinical hyperthyroidism is defined as a low or undetectable serum TSH with values 178 
within the normal reference range for both T3 and free T4. Both overt and subclinical 179 
disease may lead to characteristic signs and symptoms, although subclinical 180 
hyperthyroidism is usually considered more mild.  Overzealous or suppressive thyroid 181 
hormone administration may cause either type of thyrotoxicosis, particularly subclinical 182 
thyrotoxicosis.  Endogenous overt or subclinical thyrotoxicosis is  caused by excess 183 
thyroid hormone production and release or by inflammation and release of hormone by 184 
the gland. 185 
 Endogenous hyperthyroidism is most commonly due to Graves’ Disease (GD) or 186 
nodular thyroid disease.  GD is an autoimmune disorder in which thyrotropin receptor 187 
antibodies (TRAb) stimulate the TSH receptor, increasing thyroid hormone production 188 
and release. The development of nodular thyroid disease includes growth of established 189 
nodules, new nodule formation, and development of autonomy over time (8). In toxic 190 
adenomas (TA), autonomous hormone production can be caused by somatic activating 191 
mutations of genes regulating thyroid growth and hormone synthesis.  Germline 192 
mutations in the gene encoding the TSH receptor can cause sporadic or familial 193 
nonautoimmune hyperthyroidism associated with a diffuse enlargement of the thyroid 194 
gland (9). Autonomous hormone production may progress from subclinical to overt 195 
hyperthyroidism, and the administration of pharmacologic amounts of iodine to such 196 
patients may result in iodine-induced hyperthyroidism (10). GD is the most common 197 
cause of hyperthyroidism in the United States (11,12). Although toxic nodular goiter is 198 
less common than GD, its prevalence increases with age and in the presence of dietary 199 
iodine deficiency. Therefore, toxic nodular goiter may actually be more common than 200 
GD in older patients, especially in regions of iodine deficiency (13,14). Unlike toxic 201 
nodular goiter, which is progressive (unless triggered by excessive iodine intake), 202 
remission of mild GD has been reported in up to 30% of patients without treatment (15). 203 
 Less common causes of thyrotoxicosis include the entities of painless and 204 
subacute thyroiditis, which occur due to inflammation of thyroid tissue with release of 205 
preformed hormone into the circulation. Painless thyroiditis caused by lymphocytic 206 
inflammation appears to occur with a different frequency depending on the population 207 
studied: in Denmark it accounted for only 0.5% of thyrotoxic patients, it was 6% of 208 
patients in Toronto and 22% of patients in Wisconsin (16-18). 209 
 Painless thyroiditis may occur during lithium (19), cytokine (e.g., interferon-210 
alpha) (20), or tyrosine kinase inhibitor therapy (21), and in the postpartum period it is 211 
referred to as postpartum thyroiditis (22).   A painless destructive thyroiditis (not usually 212 
lymphocytic) occurs in 5–10% of amiodarone-treated patients (23). Subacute thyroiditis 213 
is thought to be caused by viral infection and is characterized by fever and thyroid pain 214 
(24). 215 
 216 
[A2] Clinical consequences of thyrotoxicosis 217 
 The cellular actions of thyroid hormone are mediated by T3, the active form of 218 
thyroid hormone. T3 binds to a specific nuclear receptor that regulates the expression of 219 
many genes. Non-genomic actions of thyroid hormone also regulate numerous important 220 
physiologic functions.  221 
 Thyroid hormone influences almost every tissue and organ system. It increases 222 
tissue thermogenesis and basal metabolic rate (BMR) and reduces serum cholesterol 223 
levels and systemic vascular resistance. Some of the most profound effects of increased 224 
thyroid hormone levels are on the cardiovascular system (25). Untreated or partially 225 
treated thyrotoxicosis is associated with loss of weight, osteoporosis, atrial fibrillation, 226 
embolic events, muscle weakness, tremor, neuropsychiatric symptoms and rarely 227 
cardiovascular collapse and death (26,27).  There is only moderate correlation between 228 
the degree of thyroid hormone elevation  and clinical signs and symptoms. Symptoms 229 
and signs that result from increased adrenergic stimulation include tachycardia and 230 
anxiety and may be more pronounced in younger patients and those with larger goiters 231 
(28). The signs and symptoms of mild, or subclinical, thyrotoxicosis are similar to those 232 
of overt thyrotoxicosis, but differ in magnitude.   Measurable changes in basal metabolic 233 
rate, cardiovascular hemodynamics, and psychiatric and neuropsychological function can 234 
be present in mild thyrotoxicosis (29).  235 
 236 
[B] How should clinically or incidentally discovered thyrotoxicosis be evaluated and 237 
initially managed? 238 
[B1] Assessment of disease severity 239 
 Assessment of thyrotoxic manifestations, and especially potential cardiovascular 240 
and neuromuscular complications, is essential in formulating an appropriate treatment 241 
plan. While it might be anticipated that the severity of thyrotoxic symptoms is 242 
proportional to the elevation in the serum levels of free T4 and T3, in one small study of 243 
25 patients with GD, the Hyperthyroid Symptom Scale did not strongly correlate with 244 
free T4 or T3 and was inversely correlated with age (28). The importance of age as a 245 
determinant of the prevalence and severity of hyperthyroid symptoms has been recently 246 
confirmed (30). Cardiac evaluation may be necessary, especially in the older patient, and 247 
may require an echocardiogram, electrocardiogram, Holter monitor, or myocardial 248 
perfusion studies (31). This should not postpone therapy of the thyrotoxicosis. In addition 249 
to the administration of beta-blockers (31), treatment may be needed for concomitant 250 
myocardial ischemia, congestive heart failure, or atrial arrhythmias (25).  Anticoagulation 251 
may be necessary in patients in atrial fibrillation (32). Goiter size, obstructive symptoms, 252 
and the severity of Graves’ orbitopathy (GO), the inflammatory disease that develops in 253 
the orbit in association with autoimmune thyroid disorders, can be discordant with the 254 
degree of hyperthyroidism or hyperthyroid symptoms. 255 
 All patients with known or suspected hyperthyroidism should undergo a 256 
comprehensive history and physical examination, including measurement of pulse rate, 257 
blood pressure, respiratory rate, and body weight. In addition, one should assess thyroid 258 
size, tenderness, symmetry, and nodularity; pulmonary, cardiac, and neuromuscular 259 
function (29,31,33); and presence or absence of peripheral edema, eye signs, or pretibial 260 
myxedema. 261 
[B2] Biochemical evaluation 262 
 Serum TSH measurement has the highest sensitivity and specificity of any single 263 
blood test used in the evaluation of suspected thyrotoxicosis and should be used as an 264 
initial screening test (34). However, when thyrotoxicosis is strongly suspected, diagnostic 265 
accuracy improves when a serum TSH, free T4, and total T3 are assessed at the initial 266 
evaluation. The relationship between free T4 and TSH, when the pituitary-thyroid axis is 267 
intact, is an inverse log-linear relationship; therefore, small changes in free T4 result in 268 
large changes in serum TSH concentrations. Serum TSH levels are considerably more 269 
sensitive than direct thyroid hormone measurements for assessing thyroid hormone 270 
excess (35).  271 
 In overt hyperthyroidism, serum free T4 and/or T3 are elevated, and serum TSH is 272 
subnormal  (usually <0.01 mU/L in a third generation assay). In mild hyperthyroidism, 273 
serum T4 and free T4 can be normal, only serum T3 may be elevated, and serum TSH will 274 
be low or undetectable.  These laboratory findings have been called ‘‘T3-toxicosis’’ and 275 
may represent the earliest stages of hyperthyroidism caused by Graves’ disease or an 276 
autonomously functioning thyroid nodule. As with T4, total T3 measurements are 277 
impacted by protein binding. Assays for estimating free T3 are less widely validated and 278 
less robust than those for free T4. Therefore, measurement of total T3 is frequently 279 
preferred over free T3 in clinical practice. Subclinical hyperthyroidism is defined as a 280 
normal serum free T4 and normal total T3 or free T3, with subnormal serum TSH 281 
concentration. Laboratory protocols that store sera and automatically retrieve the sample 282 
and add on free T4 and total T3 measurements when the initial screening serum TSH 283 
concentrations are low, avoid the need for subsequent blood draws. 284 
 In the absence of a TSH-producing pituitary adenoma or thyroid hormone 285 
resistance, or spurious assay results due to interfering antibodies, a normal serum 286 
TSH level precludes the diagnosis of thyrotoxicosis.  The term ‘‘euthyroid 287 
hyperthyroxinemia’’ has been used to describe a number of entities, primarily thyroid 288 
hormone-binding protein disorders, which cause elevated total serum T4 concentrations 289 
(and frequently elevated total serum T3 concentrations) in the absence of hyperthyroidism 290 
(36). These conditions include elevations in T4 binding globulin (TBG) or transthyretin 291 
(TTR) (37); the presence of an abnormal albumin which binds T4 with high capacity 292 
(familial dysalbuminemic hyperthyroxinemia); a similarly abnormal TTR; and, rarely, 293 
immunoglobulins which directly bind T4 or T3. TBG excess may occur as a hereditary X-294 
linked trait, or be acquired as a result of pregnancy or estrogen administration, hepatitis, 295 
acute intermittent porphyuria, or during treatment with 5-flourouracil, perphenazine, or 296 
some narcotics. Other causes of euthyroid hyperthyroxinemia include those drugs that 297 
inhibit T4 to T3 conversion, such as amiodarone (23) or high-dose propranolol (31), acute 298 
psychosis (38), extreme high altitude (39), and amphetamine abuse (40). Estimates of 299 
free thyroid hormone concentrations frequently also give erroneous results in these 300 
disorders. Spurious free T4 elevations may occur from heterophilic antibodies or in the 301 
setting of heparin therapy, due to in vitro activation of lipoprotein lipase and release of 302 
free fatty acids that displace T4 from its binding proteins.  303 
 Heterophilic antibodies can also cause spurious high TSH values, and this should 304 
be ruled out by repeating the TSH in another assay, measurement of TSH in serial 305 
dilution, or direct measurement of human anti-mouse antibodies (HAMA). 306 
 Ingestion of high doses of biotin may cause spurious results in assays that utilize a 307 
steptavidin-biotin separation technique (41,42).  In immunometric assays, frequently used 308 
to measure TSH, excess biotin displaces biotinylated antibodies and causes spuriously 309 
low results, while in competitive binding assays, frequently used to measure free T4, 310 
excess biotin competes with biotinylated analogue and results in falsely high results.  311 
Patients taking high doses of biotin or supplements containing biotin, who have elevated 312 
T4 and suppressed TSH should stop taking biotin and have repeat measurements  at least 313 
2 days later. 314 
 After excluding euthyroid hyperthyroxinemia, TSH-mediated hyperthyroidism 315 
should be considered when thyroid hormone concentrations are elevated and TSH is 316 
normal or elevated. A pituitary lesion on MRI and a disproportionately high ratio of the 317 
serum level of the alpha-subunit of the pituitary glycoprotein hormones to TSH supports 318 
the diagnosis of a TSH-producing pituitary adenoma (43). A family history and genetic 319 
testing for mutations in the T3-receptor supports the diagnosis of thyroid hormone 320 
resistance (44).  321 
[B3] Determination of etiology 322 
■ RECOMMENDATION 1 323 
The etiology of thyrotoxicosis should be determined. If the diagnosis is not apparent 324 
based on the clinical presentation and initial biochemical evaluation, diagnostic testing 325 
is indicated and can include, depending on available expertise and resources, (1) 326 
measurement of TRAb, (2) determination of the radioactive iodine uptake (RAIU), or 327 
(3) measurement of thyroidal blood flow on ultrasonography. An iodine-123 or 328 
technetium-99m pertechnetate scan should be obtained when the clinical presentation 329 
suggests a toxic adenoma or toxic multinodular goiter. Strong recommendation, 330 
moderate-quality evidence. 331 
 In a patient with a symmetrically enlarged thyroid, recent onset of orbitopathy, 332 
and moderate to severe hyperthyroidism, the diagnosis of GD is likely and further 333 
evaluation of hyperthyroidism causation is unnecessary. In a thyrotoxic patient with a 334 
non-nodular thyroid and no definite orbitopathy, measurement of TRAb or a radioactive 335 
iodine uptake can be used to distinguish GD from other etiologies.  In a study using a 336 
model of a theoretical population of 100,000 enrollees in a managed care organization in 337 
the United States, the use of TRAb measurements to diagnose GD compared to RAIU 338 
measurements  reduced costs by 47% and resulted in a 46% quicker diagnosis (45). 339 
 A radioactive iodine uptake measures the percentage of administered radioiodine 340 
(RAI) that is concentrated into thyroid tissue after a fixed interval, usually 24 hours. 341 
Technetium uptake measurements utilize pertechnetate that is trapped by the thyroid, but 342 
not organified. A technetium (TcO4) uptake measures the percentage of administered 343 
technetium that is trapped by the thyroid after a fixed interval, usually 20 minutes.   344 
 Uptake measurements are indicated when the diagnosis is in question (except 345 
during pregnancy and usually during lactation (see section [T4]) and distinguishes causes 346 
of thyrotoxicosis having elevated or normal uptake over the thyroid gland from those 347 
with near-absent uptake (Table 3).  Uptake is usually elevated in patients with GD and 348 
normal or high in toxic nodular goiter, unless there has been a recent exposure to iodine 349 
(e.g., radiocontrast). The RAIU will be near zero in patients with painless, postpartum, or 350 
subacute thyroiditis, factitious ingestion of thyroid hormone or recent excess iodine 351 
intake. The RAIU may be low after exposure to iodinated contrast in the preceding 1–2 352 
months or with ingestion of a diet unusually rich in iodine such as seaweed soup or kelp. 353 
However, RAIU is rarely <1% unless the iodine exposure is reoccurring as during 354 
treatment with amiodarone. When exposure to excess iodine is suspected (e.g., when the 355 
RAIU is lower than expected from the clinical history), assessment of urinary iodine 356 
concentration (spot urine iodine adjusted for urine creatinine concentration or a 24-357 
hour urine iodine concentration) may be helpful.  The uptake over the neck will also be 358 
absent in a patient with struma ovarii, where the abnormal thyroid tissue is located in an 359 
ovarian teratoma. 360 
 Thyroid scans provide a planar image of the thyroid gland using a gamma camera, 361 
to assess potential variability in the concentration of the radioisotope within thyroid 362 
tissue.  RAI scans may be obtained coincident with the RAIU and technetium scans may 363 
be obtained coincident with the technetium uptake. While technetium scans result in a 364 
low range of normal uptake and high background activity, total body radiation exposure 365 
is less than for 123I scans; either type of scan can be useful in determining the etiology of 366 
hyperthyroidism in the presence of thyroid nodularity. 367 
 A thyroid scan should be obtained if the clinical presentation suggests a toxic 368 
adenoma or toxic multinodular goiter. The pattern of RAIU in GD is diffuse unless there 369 
are coexistent nodules or fibrosis. The pattern of uptake in a patient with a single TA 370 
generally shows focal uptake in the adenoma with suppressed uptake in the surrounding 371 
and contralateral thyroid tissue. The image in TMNG demonstrates multiple areas of 372 
focal increased and suppressed uptake.  If autonomy is extensive, the image may be 373 
difficult to distinguish from that of GD (46). Additionally, GD and non-toxic nodular 374 
goiter may coincide resulting in positive TRAb levels and a nodular ultrasound or 375 
heterogeneous uptake images (47).  376 
 Where expertise is available, ultrasonography with color Doppler flow can 377 
distinguish thyroid hyperactivity (increased flow) from destructive thyroiditis (48).  378 
Quantitative Doppler evaluation requires careful adjustments to prevent artifacts and 379 
measures the peak systolic velocity from intrathyroidal arteries or the inferior thyroidal 380 
artery (49). This test may be particularly useful when radioactive iodine is 381 
contraindicated, such as during pregnancy or breastfeeding. Doppler flow has also been 382 
used to distinguish between subtypes of amiodarone-induced thyrotoxicosis (see Section 383 
[V2]), and between GD and destructive thyroiditis (see Section [W2]). 384 
 The ratio of total T3 to total T4 can also be useful in assessing the etiology of  385 
 386 
thyrotoxicosis when scintigraphy is contraindicated. Because a hyperactive gland  387 
 388 
produces more T3 than T4, T3 will be elevated above the upper limit of normal more than 389 
 390 
 T4 in thyrotoxicosis caused by hyperthyroidism, whereas T4 is elevated more than T3 in  391 
 392 
thyrotoxicosis caused by thyroiditis (50); in one study the ratio of total T3/total T4  393 
 394 
(ng/mcg) was >20 in GD and toxic nodular goiter, and <20 in painless or postpartum  395 
 396 
thyroiditis (51). A high T4 to T3 ratio may be seen in thyrotoxicosis factitia (from 397 
  398 
exogenous levothyroxine). 399 
 The choice of initial diagnostic testing depends on cost, availability, and local 400 
expertise. TRAb is cost-effective because if it is positive it confirms the diagnosis of the 401 
most common cause of thyrotoxicosis, but if negative it does not distinguish among other 402 
etiologies, and it can be negative in very mild GD.  If third generation TRAb assays are 403 
not readily available, RAIU is preferred for initial testing.   404 
 Diagnostic testing may be influenced by the choice of therapy (see Section [C]).  405 
For example, measuring TRAb in a patient with GD who plans on taking methimazole 406 
(MMI) with the hope of achieving a remission will provide a baseline measurement for 407 
disease activity. Obtaining a RAIU in a patient who prefers radioactive iodine treatment 408 
will provide both diagnostic information and facilitate the calculation of the radioactive 409 
iodine dose (see Section [D2]). 410 
 In most patients, distinction between subacute and painless thyroiditis is not 411 
difficult. Subacute thyroiditis is generally painful, the gland is firm to hard on palpation, 412 
and the erythrocyte sedimentation rate (ESR) is usually >50 and sometimes over 100 413 
mm/h. Patients with painless thyroiditis presenting within the first year after 414 
childbirth (postpartum thyroiditis), often have a personal or family history of 415 
autoimmune thyroid disease, and typically have measurable serum concentrations of 416 
antithyroid peroxidase antibodies (52). 417 
 Thyroglobulin is released along with thyroid hormone in subacute, painless, and 418 
palpation thyroiditis (following manipulation of the thyroid gland during surgery), 419 
whereas its release is suppressed in the setting of exogenous thyroid hormone 420 
administration. If not elucidated by the history, factitious ingestion of thyroid hormone 421 
can be distinguished from other causes of thyrotoxicosis by a low serum thyroglobulin 422 
level,  a near-zero RAIU, and a T3 to T4 ratio (ng/mcg) <20 if due to exogenous 423 
levothyroxine. (53). In patients with antithyroglobulin antibodies, which interfere with 424 
thyroglobulin measurement, an alternative but not widely available approach is 425 
measurement of fecal T4 (54); mean values were 1.03 nmol/g in euthyroid patients, 426 
1.93 nmol/g in Graves’ hyperthyroidism, and 12-24 nmol/g in factitious 427 
throtoxicosis.  428 
 Technical remarks: There are two methods for measuring TRAb (55).  Third-429 
generation TBI assays are competition-based assays which measure inhibition of binding 430 
of a labeled monoclonal anti-human TSHR antibody (or labeled TSH) to recombinant 431 
TSHR.  Such assays detect blocking as well as neutral and stimulating immunoglobulins. 432 
The newer TSI assays detect increased cAMP production, e.g. from Chinese hamster 433 
ovary cells transfected with hTSHR, and are positive in 96% of patients with GD (56). 434 
Older TSI assays were more specific but less sensitive than TBI assays.  In the setting of 435 
thyrotoxicosis, third generation TBI assays have a sensitivity of 97% and a specificity of 436 
99% (57)   437 
 [B4] Symptomatic management 438 
■ RECOMMENDATION 2 439 
Beta-adrenergic blockade is recommended in all patients with symptomatic 440 
thyrotoxicosis, especially elderly patients and thyrotoxic patients with resting heart 441 
rates in excess of 90 bpm or coexistent cardiovascular disease. Strong 442 
recommendation, moderate-quality evidence. 443 
 In a randomized controlled trial of MMI alone versus MMI and a beta-adrenergic 444 
blocking agent, after 4 weeks, patients taking beta-adrenergic blockers had lower heart 445 
rates, less shortness of breath and fatigue and had improved “physical functioning” on the 446 
SF-36 health questionnaire (58). 447 
 Technical remarks: Since there is not sufficient β-1 selectivity of the available 448 
beta-blockers at the recommended doses, these drugs are generally contraindicated in 449 
patients with bronchospastic asthma. In patients with quiescent bronchospastic asthma in 450 
whom heart rate control is essential, or in patients with mild obstructive airway disease or 451 
symptomatic Raynaud’s phenomenon, a relative β-1 selective agent can be used 452 
cautiously, with careful monitoring of pulmonary status (Table 4). Occasionally, very 453 
high doses of beta-blockers are required to manage symptoms of thyrotoxicosis and to 454 
reduce the heart rate to near the upper limit of normal (31), but most often low to 455 
moderate doses (Table 4) give sufficient symptom relief. Oral administration of calcium 456 
channel blockers, both verapamil and diltiazem, have been shown to effect rate control in 457 
patients who do not tolerate or are not candidates for β-adrenergic blocking agents. 458 
 459 
[C] How should overt hyperthyroidism due to GD be managed? 460 
■ RECOMMENDATION 3 461 
Patients with overt Graves’ hyperthyroidism should be treated with any of the 462 
following modalities: Radioactive iodine therapy, antithyroid drugs, or thyroidectomy. 463 
Strong recommendation, moderate-quality evidence. 464 
 Once it has been established that the patient is hyperthyroid and the cause is GD, 465 
the patient and physician must choose between three effective and relatively safe initial 466 
treatment options: RAI therapy, ATDs, or thyroidectomy (59). In the United States, RAI 467 
has been the therapy most preferred by physicians but a trend has been present in recent 468 
years to increase use of ATDs and reduce the use  of RAI. A 2011 survey of clinical 469 
endocrinologists showed that 59.7% of respondents from the United States selected RAI 470 
as primary therapy for an uncomplicated case of GD, compared to 69% in a similar 471 
survey performed 20 years earlier (60).  In Europe, Latin America, and Japan, there has 472 
been a greater physician preference for ATDs (61). The long-term quality of life (QoL) 473 
following treatment for GD was found to be the same in patients randomly allocated to 474 
one of the three treatment options (62). Currently, there is no scientific evidence to 475 
support the recommendation of alternative therapies for the treatment of hyperthyroidism 476 
(63).   477 
 Technical remarks: Once the diagnosis has been made, the treating physician and 478 
patient should discuss each of the treatment options, including the logistics, benefits, 479 
expected speed of recovery, drawbacks, potential side effects, and costs (64). This sets 480 
the stage for the physician to make recommendations based on best clinical judgment and 481 
allows the final decision to incorporate the personal values and preferences of the patient.  482 
The treatment selection should also take into account the local availability and the 483 
associated costs. Whenever surgery is selected as treatment one should consider the use 484 
of expert high-volume thyroid surgeons with on average lower risk of complications; lack 485 
of that expertise should be considered against the known risk of alternative choices.  486 
Long term continuous treatment of hyperthyroidism with ATDs may be considered in 487 
selected cases (65,66). 488 
Clinical situations that favor a particular modality as treatment for Graves’ 489 
hyperthyroidism (Table 5): 490 
a. RAI therapy: Women planning a pregnancy in the future (in more than 6 months 491 
following RAI administration, provided thyroid hormone levels are normal), 492 
individuals with comorbidities increasing surgical risk, and patients with 493 
previously operated or externally irradiated necks, or lack of access to a high-494 
volume thyroid surgeon, and patients with contraindications to ATD use or 495 
failure to achieve euthyroidism during treatment with ATDs.  Patients with 496 
periodic thyrotoxic hypokalemic paralysis, right heart failure pulmonary 497 
hypertension, or congestive heart failure should also be considered good 498 
candidates for RAI therapy.  499 
b. ATDs: Patients with high likelihood of remission (patients, especially women, with 500 
mild disease, small goiters, and negative or low-titer TRAb); pregnancy; the 501 
elderly or others with comorbidities increasing surgical risk or with limited life 502 
expectancy;  individuals in nursing homes or other care facilities who may have 503 
limited longevity and are unable to follow radiation safety regulations; patients 504 
with previously operated or irradiated necks; patients with lack of access to a 505 
high-volume thyroid surgeon; patients with moderate to severe active GO; and 506 
patients who need more rapid biochemical disease control. 507 
c. Surgery: Women planning a pregnancy in <6 months provided thyroid hormone 508 
levels are normal ( i.e., possibly before thyroid hormone levels would be normal 509 
if RAI were chosen as therapy); symptomatic compression or large goiters ( ≥ 80 510 
g); relatively low uptake of radioactive iodine; when thyroid malignancy is 511 
documented or suspected (e.g., suspicious or indeterminate cytology); large 512 
thyroid nodules especially if greater than 4 cm or if nonfunctioning, or 513 
hypofunctioning on iodine-123 or technetium-99m pertechnetate scanning; 514 
coexisting hyperparathyroidism requiring surgery; especially if TRAb levels are 515 
particularly high; and patients with moderate to severe active GO.   516 
Contraindications to a particular modality as treatment for Graves’ 517 
hyperthyroidism: 518 
a. RAI therapy: Definite contraindications include pregnancy, lactation, coexisting 519 
thyroid cancer, or suspicion of thyroid cancer, individuals unable to comply with 520 
radiation safety guidelines and used with informed caution in women planning a 521 
pregnancy within 4–6 months. 522 
b. ATDs: Definite contraindications to ATD therapy include previous known major 523 
adverse reactions to ATDs. 524 
c. Surgery: Factors that may mitigate against the choice of surgery include substantial 525 
comorbidity such as cardiopulmonary disease, end-stage cancer, or other 526 
debilitating disorders, or lack of access to a high volume thyroid surgeon. 527 
Pregnancy is a relative contraindication and surgery should only be used in the 528 
circumstance when rapid control of hyperthyroidism is required and antithyroid 529 
medications cannot be used. Thyroidectomy is best avoided in the first and third 530 
trimesters of pregnancy because of teratogenic effects associated with anesthetic 531 
agents and increased risk of fetal loss in the first trimester and increased risk of 532 
preterm labor in the third. Optimally, thyroidectomy is performed in the second 533 
trimester. Although it is the safest time, it is not without risk (4.5%–5.5% risk of 534 
preterm labor) (67,68). Thyroid surgery in pregnancy is also associated with a 535 
higher rate of complications, including hypoparathyroidism and recurrent 536 
laryngeal nerve injury (68). 537 
Patient values that may impact choice of therapy: 538 
a. RAI therapy: Patients choosing RAI therapy as treatment for GD would likely 539 
place relatively higher value on definitive control of hyperthyroidism, the 540 
avoidance of surgery, and the potential side effects of ATDs, as well as a 541 
relatively lower value on the need for lifelong thyroid hormone replacement, rapid 542 
resolution of hyperthyroidism, and potential worsening or development of GO 543 
(69). 544 
b. ATDs: Patients choosing ATD as treatment for GD would place relatively higher 545 
value on the possibility of remission and the avoidance of lifelong thyroid 546 
hormone treatment, the avoidance of surgery, and exposure to radioactivity and a 547 
relatively lower value on the avoidance of ATD side effects (see section [E]), and 548 
the possibility of disease recurrence. 549 
c. Surgery: Patients choosing surgery as treatment for GD would likely place a 550 
relatively higher value on prompt and definitive control of hyperthyroidism, 551 
avoidance of exposure to radioactivity, and the potential side effects of ATDs and 552 
a relatively lower value on potential surgical risks, and need for lifelong thyroid 553 
hormone replacement. 554 
 555 
[D] If RAI therapy is chosen, how should it be accomplished? 556 
[D1] Preparation of patients with GD for RAI therapy 557 
■ RECOMMENDATION 4 558 
Because RAI treatment of GD can cause a transient exacerbation of hyperthyroidism, 559 
beta-adrenergic blockade should be considered even in asymptomatic patients who are 560 
at increased risk for complications due to worsening of hyperthyroidism, i.e., elderly 561 
patients and patients with co-morbidities. Weak recommendation, low-quality 562 
evidence. 563 
■ RECOMMENDATION 5 564 
In addition to beta-adrenergic blockade (see Recommendation 2 and 4), pretreatment 565 
with MMI prior to RAI therapy for GD should be considered in patients who are at 566 
increased risk for complications due to worsening of hyperthyroidism. MMI should be 567 
discontinued 2-3 days prior to RAI.  Weak recommendation, moderate-quality 568 
evidence.  569 
■ RECOMMENDATION 6 570 
In patients who are at increased risk for complications due to worsening of 571 
hyperthyroidism, resuming MMI 3-7 days after RAI administration should be 572 
considered. Weak recommendation, low-quality evidence. 573 
■ RECOMMENDATION 7 574 
Medical therapy of any comorbid conditions should be optimized prior to RAI 575 
therapy. Strong recommendation, low-quality evidence.  576 
 RAI has been used to treat hyperthyroidism for more than seven decades. It is 577 
well tolerated and complications are rare, except for those related to orbitopathy (see 578 
section [U]). Thyroid storm occurs only rarely following the administration of RAI (70-579 
72). In one study of patients with thyrotoxic cardiac disease treated with RAI as the sole 580 
modality, no clinical worsening in any of the cardinal symptoms of thyrotoxicosis was 581 
seen (73). However, RAI can induce a short-term increase of thyroid hormone levels 582 
(74,75). To prevent a clinical exacerbation of hyperthyroidism, the use of MMI or 583 
carbimazole, the latter of which is not marketed in the United States, before and after 584 
RAI treatment may be considered in patients with severe hyperthyroidism, the elderly, 585 
and those with substantial comorbidity that puts them at greater risk for complications of 586 
worsening thyrotoxicosis (75,76). The latter includes patients with cardiovascular 587 
complications such as atrial fibrillation, heart failure, or pulmonary hypertension and 588 
those with renal failure, infection, trauma, poorly controlled diabetes mellitus, and 589 
cerebrovascular or pulmonary disease (70). These comorbid conditions should be 590 
addressed with standard medical care and the patient rendered medically stable before the 591 
administration of RAI if possible.  If possible iodinated radiocontrast should be 592 
avoided.  In addition, beta-adrenergic blocking drugs should be used judiciously in these 593 
patients in preparation for RAI therapy (25,77). MMI (75) and carbimazole (78) have 594 
shown to reduce thyroid hormone levels after RAI treatment in randomized controlled 595 
trials. However, a recent meta-analysis of randomized controlled trials also found that 596 
MMI, carbimazole and propylthiouracil reduce the success rate if given in the week 597 
before or after RAI treatment (71). Use of higher activities of RAI may offset the reduced 598 
effectiveness of RAI therapy following antithyroid medication (75,76). 599 
 A special diet is not required before RAI therapy, but nutritional supplements that 600 
may contain excess iodine and seaweeds should be avoided for at least 7 days. A low-601 
iodine diet may be useful for those with relatively low RAIU to increase the proportion of 602 
RAI trapped. 603 
 Technical remarks: Patients that might benefit from adjunctive MMI or 604 
carbimazole may be those who are poorly tolerating hyperthyroid symptoms. Such 605 
patients frequently have free T4 2–3 times the upper limit of normal. Young and middle 606 
aged, otherwise healthy patients who are clinically well-compensated despite significant 607 
biochemical hyperthyroidism can generally receive RAI without pretreatment. If given as 608 
pretreatment, MMI and carbimazole should be discontinued before the administration of 609 
RAI. Discontinuation of ATDs for 2-3 days prevents a short-term increase of thyroid 610 
hormone levels (79), which is found after 6 days (75,76). In elderly patients or in those 611 
with underlying cardiovascular disease, resuming MMI or carbimazole 3-7 days after 612 
RAI administration should be considered, and generally tapered as thyroid function 613 
normalizes. In one study, if MMI was restarted 7 days after RAI, the free T4 measured 3 614 
weeks after RAI was 6% lower than the values at the time of RAI administration, and if 615 
MMI was not restarted after RAI, the free T4 values were 36% higher than the values at 616 
the time of RAI administration (80). Over several decades, there have been reports that 617 
pretreatment with lithium reduces the activity of RAI necessary for cure of Graves’ 618 
hyperthyroidism and may prevent the thyroid hormone increase seen upon ATD 619 
withdrawal (81-83). However, this is not used widely, and there is insufficient evidence 620 
to recommend the practice. In selected patients with Graves’ hyperthyroidism who would 621 
have been candidates for pretreatment with ATDs due to comorbidities or excessive 622 
symptoms, but who are allergic to ATDs, the duration of hyperthyroidism may be 623 
shortened by administering iodine (e.g. SSKI) beginning one week after RAI 624 
administration (84).  625 
[D2] Administration of RAI in the treatment of GD 626 
■ RECOMMENDATION 8 627 
Sufficient activity of RAI should be administered in a single application, typically a 628 
mean dose of 10–15 mCi (370-555 MBq), to render the patient with GD hypothyroid. 629 
Strong recommendation, moderate-quality evidence. 630 
■ RECOMMENDATION 9 631 
A pregnancy test should be obtained within 48 hours prior to treatment in any woman 632 
with childbearing potential who is to be treated with RAI. The treating physician 633 
should obtain this test and verify a negative result prior to administering RAI. Strong 634 
recommendation, low-quality evidence  635 
 The goal of RAI therapy in GD is to control hyperthyroidism by rendering the 636 
patient hypothyroid; this treatment is very effective, provided sufficient radiation dose is 637 
deposited in the thyroid. This can be accomplished equally well by either administering a 638 
fixed activity or by calculating the activity based on the size of the thyroid and its ability 639 
to trap RAI (85). 640 
 The first method is simple, while the second method requires two unknowns to be 641 
determined: the uptake of RAI and the size of the thyroid. The therapeutic RAI activity 642 
can then be calculated using these two factors and the quantity of radiation (µCi or Bq) to 643 
be deposited per gram (or cc) of thyroid (e.g., activity (µCi) = gland weight (g)×150-200 644 
µCi/g×[1/24 hour uptake in % of administered activity]). The activity in µCi or Bq is 645 
converted to mCi or MBq by dividing the result by 1000. The most frequently used 646 
uptake is calculated at 24 hours, and the size of the thyroid is determined by palpation or 647 
ultrasound. One study found that this estimate by experienced physicians is accurate 648 
compared with anatomic imaging (86); however, other investigators have not confirmed 649 
this observation (87).  650 
 Alternately, a more detailed calculation can be made to deposit a specific 651 
radiation dose (in rad or Gy) to the thyroid. Using this approach, it is also necessary to 652 
know the effective half-life of RAI (88). This requires additional time and computation 653 
and, because the outcome has not shown to be better, this method is seldom used in the 654 
United States. Evidence shows that to achieve a hypothyroid state, >150 µCi/g (5.55 655 
MBq/g) needs to be delivered (88-90). Patients who are on dialysis or who have 656 
jejunostomy or gastric feeding tubes require special care and management when being 657 
administered RAI treatment (91). 658 
 The success of RAI therapy in GD strongly depends on the administered 659 
activities. In patients without adjunctive ATD, randomized controlled trials found 61% 660 
success with 5.4 mCi (200 MBq) (92), 69% with 8.2 mCi (302 MBq) (93), 74% with 10 661 
mCi (370 MBq) (94), 81% with 15 mCi (555 MBq) (94) and 86% with 15.7 mCi (580 662 
MBq) (95) RAI. Due to the high rate of patients requiring retreatment, RAI therapy with 663 
low activities is generally not recommended.  664 
 A long-term increase in cardiovascular and cerebrovascular deaths has been 665 
reported after RAI therapy not resulting in hypothyroidism as opposed to unchanged 666 
mortality in RAI-treated patients on levothyroxine therapy, reflecting the role of 667 
persistent hyperthyroidism as opposed to that of RAI therapy on mortality (96,97). A 668 
recent meta-analysis found no increase in the overall cancer risk after RAI treatment for 669 
hyperthyroidism; however, a trend towards increased risk of thyroid, stomach and kidney 670 
cancer was seen, requiring further research (98). In some men, there is a modest fall in 671 
the testosterone to luteinizing hormone (LH) ratio after RAI therapy that is subclinical 672 
and reversible (99). Conception should be delayed  in women until  stable euthyroidism 673 
is established (on thyroid hormone replacement following successful thyroid ablation).  674 
This typically takes 4-6 months or longer. Conception should be delayed 3–4 months 675 
in men to allow for turnover of sperm production. However, once the patient (both 676 
genders) is euthyroid, there is no evidence of reduced fertility and offspring of treated 677 
patients show no congenital anomalies compared to the population at large (100). 678 
 Technical remarks: Rendering the patient hypothyroid can be accomplished 679 
equally well by administering either a sufficient fixed activity or calculating an activity 680 
based on the size of the thyroid and its ability to trap iodine. Fetuses exposed to RAI after 681 
the 10th to 11th week of gestation may be born athyreotic (101,102) and are also at a 682 
theoretical increased risk for reduced intelligence and/or cancer. In breast-feeding 683 
women, RAI therapy should not be administered for at least 6 weeks after lactation stops 684 
to ensure that RAI will no longer be actively concentrated in the breast tissues. A delay of 685 
3 months will more reliably ensure that lactation-associated increase in breast sodium 686 
iodide symporter activity has returned to normal (103). Breast feeding should not be 687 
resumed after RAI therapy. 688 
■ RECOMMENDATION 10 689 
The physician administering RAI should provide written advice concerning radiation 690 
safety precautions following treatment. If the precautions cannot be followed, 691 
alternative therapy should be selected. Strong recommendation, low-quality 692 
evidence.  693 
 All national and regional radiation protection rules regarding RAI treatment 694 
should be followed (104,105). In the United States, the treating physician must ensure 695 
and document that no adult member of the public is exposed to 0.5 mSv (500 milli-696 
roentgen equivalent in man [mrem]) when the patient is discharged with a retained 697 
activity of 33 mCi (1.22 GBq) or greater, or emits ≥ 7 mrem/h (70 µSv/h) at 1 m. 698 
 Technical remarks: Continuity of follow-up should be provided and can be 699 
facilitated by communication between the referring physician and the treating physician, 700 
including a request for therapy from the former and a statement from the latter that the 701 
treatment has been administered. 702 
[D3] Patient follow-up after RAI therapy for GD 703 
■ RECOMMENDATION 11 704 
Follow-up within the first 1–2 months after RAI therapy for GD should include an 705 
assessment of free T4, total T3, and TSH. Biochemical monitoring should be continued 706 
at 4–6 week intervals for 6 months, or until the patient becomes hypothyroid and is 707 
stable on thyroid hormone replacement. Strong recommendation, low-quality 708 
evidence.  709 
 Most patients respond to RAI therapy with a normalization of thyroid function 710 
tests and improvement of clinical symptoms within 4–8 weeks. Hypothyroidism may 711 
occur from 4 weeks on, with 40% of patients being hypothyroid by 8 weeks and >80% by 712 
16 weeks (106). This transition can occur rapidly but more commonly between 2 and 6 713 
months, and the timing of thyroid hormone replacement therapy should be determined by 714 
results of thyroid function tests, clinical symptoms, and physical examination. Transient 715 
hypothyroidism following RAI therapy can rarely occur, with subsequent complete 716 
recovery of thyroid function or recurrent hyperthyroidism (107). In such patients the 717 
thyroid gland often remains palpable. 718 
 Beta-blockers that were instituted prior to RAI treatment should be tapered when 719 
free T4 and total T3 have returned to the reference range. As free T4 and total T3 improve, 720 
MMI can usually be tapered, which allows an assessment of the response to RAI. 721 
 Most patients eventually develop hypothyroidism following RAI, which is 722 
indicated by a free T4 below normal range. At this point, levothyroxine should be 723 
instituted. TSH levels may not rise immediately with the development of hypothyroidism, 724 
and should not be used initially to determine the need for levothyroxine. When thyroid 725 
hormone replacement is initiated, the dose should be adjusted based on an assessment of 726 
free T4. The required dose may be less than the typical full replacement, and careful 727 
titration is necessary owing to nonsuppressible residual thyroid function. Overt 728 
hypothyroidism should be avoided, especially in patients with active GO (see section 729 
U2). Once euthyroidism is achieved, lifelong annual thyroid function testing is 730 
recommended at least annually, or if the patietn experiences symptoms of 731 
hypothyroidism or hyperthyroidism. 732 
 Technical remarks: Since TSH levels may remain suppressed for a month or 733 
longer after hyperthyroidism resolves, the levels should be interpreted cautiously and 734 
only in concert with free T4 and total T3. 735 
[D4] Treatment of persistent Graves’ hyperthyroidism following RAI therapy 736 
■ RECOMMENDATION 12 737 
When hyperthyroidism due to GD persists after 6 months following RAI therapy, 738 
retreatment with RAI is suggested. In selected patients with minimal response 3 739 
months after therapy additional RAI may be considered. Weak recommendation, 740 
low-quality evidence. 741 
 Technical remarks: Response to RAI therapy can be assessed by monitoring the 742 
size of the gland, thyroid function, and clinical signs and symptoms. The goal of 743 
retreatment is to control hyperthyroidism with certainty by rendering the patient 744 
hypothyroid. Patients who have persistent, suppressed TSH with normal total T3 and free 745 
T4 may not require immediate retreatment but should be monitored closely for either 746 
relapse or development of hypothyroidism. In the small percentage of patients with 747 
hyperthyroidism refractory to several applications of RAI, surgery should be considered 748 
(108). 749 
 750 
[E] If antithyroid drugs are chosen as initial management of GD, how should the 751 
therapy be managed? 752 
 ATDs have been employed for seven decades (109). The goal of the therapy is to 753 
render the patient euthyroid as quickly and safely as possible. These medications do not 754 
cure Graves’ hyperthyroidism. However, when given in adequate doses, they are very 755 
effective in controlling the hyperthyroidism; when they fail to achieve euthyroidism, the 756 
usual cause is nonadherence (110). The treatment itself might have a beneficial 757 
immunosuppressive role, either to primarily decrease thyroid specific autoimmunity, or 758 
secondarily, by ameliorating the hyperthyroid state, which may restore the dysregulated 759 
immune system back to normal (111).  In fact, the rate of remission with ATD therapy is 760 
much higher (112) than the historical rates of spontaneous remission (113).   761 
[E1] Initiation of antithyroid drug therapy for the treatment of GD 762 
■ RECOMMENDATION 13 763 
Methimazole should be used in virtually every patient who chooses ATD therapy for 764 
GD, except during the first trimester of pregnancy when propylthiouracil (PTU) is 765 
preferred, in the treatment of thyroid storm, and in patients with minor reactions to 766 
MMI who refuse radioactive iodine therapy or surgery. Strong recommendation, 767 
moderate-quality evidence. 768 
■ RECOMMENDATION 14 769 
Patients should be informed of side effects of ATDs and the necessity of informing the 770 
physician promptly if they should develop pruritic rash, jaundice, acolic stools or dark 771 
urine, arthralgias, abdominal pain, nausea, fatigue, fever, or pharyngitis. Preferably, 772 
this should be in writing.  Before starting ATDs and at each subsequent visit, the 773 
patient should be alerted to stop the medication immediately and call their physician 774 
when there are symptoms suggestive of agranulocytosis or hepatic injury. Strong 775 
recommendation, low-quality evidence. 776 
■ RECOMMENDATION 15 777 
Prior to initiating ATD therapy for GD, we suggest that patients have a baseline 778 
complete blood count, including white count with differential, and a liver profile 779 
including bilirubin and transaminases. Weak recomendation, low-quality evidence. 780 
 In the United States, MMI and PTU are available, and in some countries, 781 
carbimazole, a precursor of MMI, is widely used. Carbimazole is rapidly converted to 782 
MMI in the serum (10 mg of carbimazole is metabolized to approximately 6 mg of 783 
MMI). They work in an identical fashion and both will be referred to as MMI in this text. 784 
Both are effective as a single daily dose. At the start of MMI therapy, initial doses of 10–785 
30 mg daily are used to to restore euthyroidism, and then the dose can be titrated down to 786 
a maintenance level (generally 5–10 mg daily) (109,114). The dose of MMI should be 787 
targeted to the degree of thyroid dysfunction, as too low a dose will not restore a 788 
euthyroid state in patients with severe disease (115), and an excessive dose can cause 789 
iatrogenic hypothyroidism in patients with mild disease (116).   In addition, adverse drug 790 
reactions are more frequent with higher MMI doses.  Thus, it is important to use an MMI 791 
dose that will achieve the clinical goal of normalization of thyroid function reasonably 792 
rapidly, while minimizing adverse drug effects.   The task force suggests the following 793 
as a rough guide to initial MMI daily dosing: 5-10 mg if free T4 is 1-1.5 times the upper 794 
limit of normal (ULN); 10-20 mg for free T4 1.5-2 times the ULN; 30-40 mg for free T4 795 
2-3 times the ULN.  These rough guidelines should be tailored to the individual patient, 796 
incorporating additional information on symptoms, gland size and total T3 levels where 797 
relevant. Serum T3 levels are important to monitor initially, as some patients normalize 798 
their free T4 levels with MMI but have persistently elevated serum T3, indicating 799 
continuing thyrotoxicosis (117). 800 
 801 
 MMI has the benefit of once-a-day administration and a reduced risk of major 802 
side effects compared to PTU. PTU has a shorter duration of action and is usually 803 
administered two or three times daily, starting with 50–150 mg three times daily, 804 
depending on the severity of the hyperthyroidism. As the clinical findings and thyroid 805 
function tests return to normal, reduction to a maintenance PTU dose of 50 mg two or 806 
three times daily is usually possible. When more rapid biochemical control is needed in 807 
patients with severe thyrotoxicosis, an initial split dose of MMI (e.g., 15 or 20 mg twice a 808 
day) may be more effective than a single daily dose, as the duration of action of MMI 809 
may be less than 24 hours (118) .  Higher doses of antithyroid medication are sometimes 810 
administered continuously and combined with L-thyroxine in doses to maintain euthyroid 811 
levels (so-called block and replace therapy). However, this approach is not generally 812 
recommended, as it has been shown to result in a higher rate of ATD side effects 813 
(109,119). 814 
 The use of potassium iodine (KI) as a beneficial adjunct to ATD therapy for 815 
Graves’ disease has been investigated in previous studies (120).  Indeed, a recent RCT 816 
described the administration of 38 mg of potassium iodide (KI) together with 15 mg of 817 
MMI daily, which resulted in better control of hyperthyroidism and fewer adverse 818 
reactions compared to 30 mg of MMI given alone (121). 819 
[E2] Adverse effects of Antithyroid Drugs 820 
 In general, adverse effects of ATDs can be divided into common, minor allergic 821 
side effects and rare but serious allergic/toxic events such as agranulocytosis, vasculitis, 822 
or hepatic damage.  In a recent systematic review of eight studies that included 667 GD 823 
patients receiving MMI or PTU, 13% of patients experienced adverse events (122).  The 824 
minor allergic reactions included pruritus or a limited, minor rash, in 6% of patients 825 
taking MMI and 3% of patients taking PTU (122).   Hepatocellular injury occurred in 826 
2.7% of patients taking PTU and 0.4% of patients taking MMI.  In a separate study of 827 
449 GD patients receiving MMI or PTU, 24% developed a cutaneous reaction, 3.8% 828 
developed transaminase elevations more than 3-fold above normal, and 0.7% developed 829 
agranulocytosis (absolute neutrophil count (ANC) < 500) (123).  Cutaneous reactions 830 
were more common with PTU or higher dose MMI (30 mg/day), compared to lower dose 831 
MMI (15 mg per day).  Hepatotoxicity was more common with PTU.  Cutaneous 832 
reactions appeared after a median of 18-22 days of treatment, significantly earlier than 833 
transaminase elevations (median 28 days).  The percentage of patients discontinuing 834 
ATD therapy was 17% in the low dose MMI group, 29% in the high dose MMI group, 835 
and 34% in the PTU group (123). 836 
[E3] Agranulocytosis 837 
 Although ATD associated agranulocytosis is uncommon, it is life-threatening.  838 
PTU at any dose appears to be more likely to cause agranulocytosis, compared to low 839 
doses of MMI (124-126). Three recent reports of large numbers of ATD-treated patients 840 
who developed hematologic complications provide information on risk factors, treatment, 841 
and outcomes (127-129).  Two studies were from Japan and one was from Denmark. In 842 
both countries the majority of patients are treated with MMI, so data are more limited for 843 
PTU-associated agranulocytosis.  In the first study, a retrospective cohort analysis of over 844 
50,000 GD patients, 55 developed agranulocytosis, of whom 5 had pancytopenia, for an 845 
estimated cumulative incidence of 0.3% in 100 days (127), with a median interval to 846 
onset of 69 days.  All 50 patients with agranulocytosis alone were successfully treated 847 
with granulocyte colony stimulating factor (G-CSF), steroids, or supportive care, but one 848 
of five patients with pancytopenia died.  No predictive risk factors for the development of 849 
agranulocytosis could be identified.  The second study was based on a national database 850 
for adverse drug reactions, which may have included some patients reported in the first 851 
study (128).  Seven-hundred-fifty-four GD patients who developed ATD-induced 852 
hematologic complications were reported, for an estimated incidence of 0.1 – 0.15%.  Of 853 
them, 725 patients received MMI, 28 received PTU, and one received both drugs.  854 
Eighty-nine percent developed agranulocytosis and 11% developed pancytopenia or 855 
aplastic anemia.  At the onset of agranulocytosis, the average MMI dose was 25 mg/day 856 
and the average PTU dose was 217 mg/day.  The average age of patients developing 857 
agranulocytosis was slightly older (45 vs 40 years), an observation that has been made by 858 
others.  Seventy-two percent developed agranulocytosis within 60 days of starting ATD, 859 
and 85% within 90 days.  In 7% of patients, agranulocytosis occured later than 4 months 860 
after starting ATD, but some of these patients had discontinued the medication for long 861 
periods of time and developed agranulocytosis after a second or subsequent exposure.  862 
Thirty of the events (4%) were fatal. In the third study from Denmark, the frequency of 863 
agranulocytosis was 0.27% with PTU and 0.11% with MMI (129).  As in prior studies, 864 
the median duration of therapy prior to the development of agranulocytosis was 36 and 865 
38 days for MMI and PTU, respectively. 866 
[E4] Hepatotoxicity 867 
 Hepatotoxicity is another major adverse effect of ATD therapy. MMI 868 
hepatotoxicity has been described as typically cholestatic, but hepatocellular disease may 869 
be seen (130,131). In contrast, PTU can cause fulminant hepatic necrosis that may be 870 
fatal; liver transplantation has been necessary in some patients taking PTU (132). It is for 871 
this reason that in 2010 the FDA issued a safety alert regarding the use of PTU, and an 872 
analysis of FDA Medwatch data (133) concluded that children are more susceptible to 873 
hepatotoxic reactions from PTU than are adults.   874 
 A recent pharmacoepidemiologic study from Taiwan challenges the concept that 875 
MMI hepatotoxicity is usually cholestatic, while PTU hepatotoxicity is most often 876 
hepatocellular (134).  Among  71,379 new users of ATDs with a median follow-up of 877 
196 days, MMI was associated with a higher rate of a diagnosis of non-infectious 878 
hepatitis than PTU (0.25% versus 0.08%, respectively), whereas cholestasis was not 879 
different (0.019% versus 0.016%).  A diagnosis of liver failure was more common 880 
after PTU (0.048% versus 0.026% in MMI treated patients). Similar findings were 881 
also recently reported from China (135).  These surprising results from Asia, which are in 882 
contrast to other data from the U.S. (133,136), suggest that prior data on MMI-related 883 
hepatotoxicity from small case series may need to be reconsidered.  In the study from 884 
Denmark (129), hepatotoxic reactions were not classified as cholestatic or hepatocellular, 885 
but the frequency of “liver failure” was similar for MMI (0.03%) and PTU (0.03%). 886 
 887 
[E5] Vasculitis 888 
 Aside from hematologic and hepatic adverse effects, there are other rare side 889 
effects with ATDs.   PTU, and rarely MMI can cause causes antineutrophil cytoplasmic 890 
antibody (pANCA)-positive small vessel vasculitis (137,138) as well as drug induced 891 
lupus (139).  The risk appears to increase with duration of therapy as opposed to other 892 
adverse effects seen with ATDs that typically occur early in the course of treatment 893 
(140,141).  Typically, granulocyte myeloperoxidase is the targeted antigen of the ANCA, 894 
but antibodies to many other proteins are seen as well (142).  ANCA positive vasculitis is 895 
more common in patients of Asian ethnicity, and the majority of reports come from that 896 
part of the world (143).  While up to 40% of patients taking PTU develop ANCA 897 
positivity, the vast majority of such individuals do not develop clinical vascutitis (144).  898 
When the drug is discontinued, the ANCA slowly disappear in most individuals (144).  899 
Children seem to be more likely to develop PTU-related ANCA positive vasculitis (133).  900 
In most cases, the vasculitis resolves with drug discontinuation, although 901 
immunosuppressive therapy may be necessary (145).  902 
 Rare cases of insulin autoimmune syndrome with symptomatic hypoglycemia 903 
have been reported in patients treated with MMI (146,147).   904 
 Technical remarks: Baseline blood tests to aid in the interpretation of future 905 
laboratory values should be considered before initiating ATD therapy. This is suggested 906 
in part because low white cell counts are common in patients with GD and in African 907 
Americans (10% of whom have a neutrophil count under 2000 (148)), and abnormal liver 908 
enzymes are frequently seen in patients with thyrotoxicosis (149). While there is no 909 
evidence that neutropenia or liver disease increases the risk of complications from 910 
ATDs, the opinion of the task force is that a baseline absolute neutrophil count 911 
<1000/mm3 or liver transaminase enzyme levels elevated more than fivefold above the 912 
upper limit of normal should prompt serious reconsideration of initiating ATD therapy. It 913 
is advisable to provide information concerning side effects of ATDs to the patient both 914 
verbally and in writing to assure their comprehension, and document that this has been 915 
done. This information can be found online (150,151). 916 
[E6] Monitoring of patients taking antithyroid drugs 917 
 There is a need for periodic clinical and biochemical evaluation of thyroid status 918 
in patients taking ATDs, and it is essential that the patient understand its importance. An 919 
assessment of serum free T4 and total T3 should be obtained about 2 to 6 weeks after 920 
initiation of therapy, depending on the severity of the thyrotoxicosis, and the dose of 921 
medication adjusted accordingly. Serum T3 should be monitored because the serum free 922 
T4 levels may normalize despite persistent elevation of serum total T3. Serum TSH may 923 
remain suppressed for several months after starting therapy and is therefore not a good 924 
parameter for monitoring therapy early in the course. 925 
 Once the patient is euthyroid, the dose of MMI can usually be decreased by 30-926 
50%, and biochemical testing repeated in 4-6 weeks.  Once euthyroid levels are achieved 927 
with the minimal dose of medication, clinical and laboratory evaluation can be 928 
undertaken at intervals of 2–3 months. If a patient is receiving long-term MMI (> 18 929 
months), this interval can be increased to 6 months (see below).  930 
■ RECOMMENDATION 16 931 
A differential white blood cell count should be obtained during febrile illness and at 932 
the onset of pharyngitis in all patients taking antithyroid medication. Strong 933 
recommendation, low-quality evidence. 934 
■ RECOMMENDATION 17 935 
There is insufficient evidence to recommend for or against routine monitoring of white 936 
blood cell counts in patients taking ATD’s.  No recommendation, insufficient 937 
evidence to assess benefits and risks.  938 
 There is no consensus concerning the utility of periodic monitoring of white blood 939 
cell counts and liver function tests in predicting early onset of adverse reaction to the 940 
medication (152). While routine monitoring of white blood cell counts may detect early 941 
agranulocytosis, this practice is not likely to identify cases, as the frequency is quite low 942 
(0.2%–0.5%) and the condition is usually sudden in onset. In a recent analysis of 211 943 
patients with ATD-induced agranulocytosis who had at least one prior granulocyte count 944 
measured, 21% had a normal white blood count within a week, and 53% within two 945 
weeks, before developing agranulocytosis (128).  However, other patients did display a 946 
gradual decline in white blood cell count prior to developing agranulocytosis, suggesting 947 
that monitoring might have been useful in some affected patients (152). Because patients 948 
are typically symptomatic, measuring white blood cell counts during febrile illnesses and 949 
at the onset of pharyngitis has been the standard approach to monitoring. If monitoring is 950 
employed, the maximum benefit would be for the first 90 days of therapy, when the vast 951 
majority of agranulocytosis occurs. In a patient developing agranulocytosis or other 952 
serious side effects while taking either MMI or PTU, use of the other medication is 953 
contraindicated owing to risk of cross-reactivity between the two medications (153).  The 954 
contraindication to use PTU might be reconsidered in life-threatening thyrotoxicosis (i.e., 955 
thyroid storm) in a MMI-treated patient who has developed agranulocytosis, especially if 956 
the duration of therapy is brief (154). 957 
■ RECOMMENDATION 18 958 
Liver function and hepatocellular integrity should be assessed in patients taking MMI 959 
or PTU who experience pruritic rash, jaundice, light-colored stool or dark urine, joint 960 
pain, abdominal pain or bloating, anorexia, nausea, or fatigue. Strong 961 
recommendation, low-quality evidence. 962 
 Hyperthyroidism can itself cause mildly abnormal liver function tests in up to 963 
30% of patients (149).  PTU itself may cause transient elevations of serum transaminases 964 
in up to one-third of patients. Significant elevations to threefold above the upper limit of 965 
normal are seen in up to 4% of patients taking PTU (155), a prevalence higher than with 966 
MMI. As noted above, PTU can also cause fatal hepatic necrosis, leading to the 967 
suggestion by some that patients taking this ATD have routine monitoring of their liver 968 
function, especially during the first 6 months of therapy. A 2009 review of the literature 969 
(136) found that PTU hepatotoxicity occurred after a median of 120 days after initiation 970 
of therapy. It is difficult to distinguish these abnormalities from the effect of persistent 971 
thyrotoxicosis unless they are followed prospectively. In patients with improving 972 
thyrotoxicosis, a rising alkaline phosphatase with normalization of other liver function 973 
does not indicate worsening hepatic toxicity (156), as the origin of the alkaline 974 
phosphatase is from bone, not liver. The onset of PTU-induced hepatotoxicity may be 975 
acute, difficult to appreciate clinically, and rapidly progressive. If not recognized, it can 976 
lead to liver failure and death (115,157-159). Routine monitoring of liver function in all 977 
patients taking ATDs has not been found to prevent severe hepatotoxicity. If monitoring 978 
is employed, the maximum benefit would be for the first 120 days of therapy, when the 979 
vast  majority of instances of hepatotoxicity occur. 980 
 Technical remarks: PTU should be discontinued if transaminase levels (found 981 
incidentally or measured as clinically indicated) reach >3 times the upper limit of normal 982 
or if levels elevated at the onset of therapy increase further.  After discontinuing the 983 
drug, liver function tests should be monitored weekly until there is evidence of 984 
resolution. If resolution is not evident, prompt referral to a gastroenterologist or 985 
hepatologist for specialty care is warranted. Except in cases of severe PTU-induced 986 
hepatotoxicity, MMI can be used to control the thyrotoxicosis without ill effect 987 
(160,161). 988 
■ RECOMMENDATION 19 989 
There is insufficient information to recommend for or against routine monitoring of 990 
liver function tests in patients taking ATD’s.  No recommendation, insufficient 991 
evidence to assess benefits and risks. 992 
[E7] Management of allergic reactions 993 
■ RECOMMENDATION 20 994 
Minor cutaneous reactions may be managed with concurrent antihistamine therapy 995 
without stopping the ATD. Persistent symptomatic minor side effects of antithyroid 996 
medication should be managed by cessation of the medication and changing to RAI or 997 
surgery, or switching to the other ATD when RAI or surgery are not options. In the 998 
case of a serious allergic reaction, prescribing the alternative drug is not 999 
recommended. Strong recommendation, low-quality evidence. 1000 
 1001 
 A recent study provided evidence that switching from one ATD to the other is 1002 
safe in the case of minor side effects, although patients may develop similar side effects 1003 
with the second ATD (123).  In this study, 71 patients with an adverse event from either 1004 
MMI or PTU switched to the other ATD, with doses individually determined.  Median 1005 
dose of the second ATD was 15 mg/d for MMI (range 10 – 30) and 300 mg/day for PTU 1006 
(range 150 – 450). Thirty-four percent of patients switched to PTU and 30% of patients 1007 
switched to MMI developed side effects, generally the same type as occurred on the 1008 
original ATD, while the remaining patients tolerated the second ATD without 1009 
complications (123).  There is also one recent case report of a more severe reaction to 1010 
MMI consisting of rash, pruritis, tongue and throat swelling that was successfully 1011 
managed with antihistamine therapy, but this is not generally recommended due to the 1012 
risk of analphylaxis (162). 1013 
 [E8] Duration of antithyroid drug therapy for GD 1014 
■ RECOMMENDATION 21 1015 
Measurement of TRAb levels prior to stopping ATD therapy is suggested, as it aids in 1016 
predicting which patients can be weaned from the medication, with normal levels 1017 
indicating greater chance for remission. Strong recommendation, moderate-quality 1018 
evidence. 1019 
■ RECOMMENDATION 22 1020 
If MMI is chosen as the primary therapy for GD, the medication should be continued 1021 
for approximately 12–18 months, then discontinued if the TSH and TRAb levels are 1022 
normal at that time. Strong recommendation, high-quality evidence. 1023 
■ RECOMMENDATION 23 1024 
If a patient with GD becomes hyperthyroid after completing a course of MMI, 1025 
consideration should be given to treatment with RAI or thyroidectomy. Continued 1026 
low-dose MMI treatment for longer than 12–18 months may be considered in patients 1027 
not in remission who prefer this approach. Weak recommendation, low-quality 1028 
evidence. 1029 
 A patient is considered to be in remission if they have had a normal serum TSH, 1030 
free T4, and total T3 for 1 year after discontinuation of ATD therapy. The remission rate 1031 
varies considerably between geographical areas. In earlier studies in the United States, 1032 
about 20%–30% of patients were reported to have a lasting remission after 12–18 months 1033 
of medication, (59), but more recent data are not available. The remission rate may be 1034 
higher in Europe and Japan; a long-term European study indicated a 50–60% remission 1035 
rate after 5–6 years of treatment (163), and a study in Japan reported a 68% remission 1036 
rate after 2 years of treatment (164). A meta-analysis shows the remission rate in adults is 1037 
not improved by a course of ATDs longer than 18 months (119). A lower remission rate 1038 
has been described in men, smokers (especially men), and those with large goiters (≥ 80 1039 
g) (165-169).  Higher initial doses of MMI (60-80 mg/day) do not improve remission 1040 
rates, but increase the risk of side effects, and are not recommended (170).   1041 
 TRAb assessment at the end of the course of ATD therapy is a useful method of 1042 
dividing patients into 2 groups:  one with persistent elevations who are unlikely to be in 1043 
remission, and another group with low or undetectable TRAb, who have a higher 1044 
probability of permanent remission (171,172).   In the group with elevated TRAb, relapse 1045 
rates approach 80-100%, while in the latter group, relapse rates are in the 20-30% range 1046 
(171,172).   1047 
[E9] Persistently elevated TRAb 1048 
  Patients with persistently high TRAb  could continue ATD therapy (and repeat 1049 
TRAb after  an additional 12-18 months) or opt for alternate definitive therapy with RAI 1050 
or surgery.  In selected patients (i.e., younger patients with mild stable disease on a low 1051 
dose of MMI), long-term MMI is a reasonable alternative approach (65,173).  Another 1052 
study by the same author reported that MMI doses of 2.5 – 10 mg/day for a mean of 14 1053 
years were safe and effective for the control of GD in 59 patients (174). A recent 1054 
retrospective analysis compared long term outcomes (mean follow up period of 6-7 1055 
years) of patients who had relapsed after a course of ATDs, who were treated with either 1056 
RAI and levothyroxine or long-term ATD therapy (175). Those patients treated with RAI 1057 
(n=114) more often had persistent thyroid eye disease, continuing thyroid dysfunction, 1058 
and experienced more weight gain compared to those patients receiving long-term ATD 1059 
treatment (n=124). 1060 
 If continued MMI therapy is chosen, TRAb levels might be monitored every 1-2 1061 
years, with consideration of MMI discontinuation if TRAb levels become negative over 1062 
long term follow up.   For patients choosing long-term MMI therapy, monitoring of 1063 
thyroid function every 4-6 months is reasonable, and patients can be seen for follow up 1064 
visits every 6-12 months.   1065 
[E10] Negative TRAb 1066 
 If TRAb is negative and thyroid function is normal at the end of 12-18 months 1067 
of MMI therapy, it is reasonable to discontinue the drug.  If a patient experiences a 1068 
relapse in follow up, RAI therapy or surgery should be considered.  1069 
 Technical remarks: In patients with negative TRAb, relapses tend to occur 1070 
relatively later than those that develop in patients whose MMI is stopped when TRAb is 1071 
still positive (171,176), although 5% occurred within the first 2 months (167).  Therefore, 1072 
in this population, thyroid function testing should be monitored at 2 to 3-month intervals 1073 
for the first 6 months, then at 4 to 6-month intervals for the next 6 months, then every 6 1074 
to 12 months, in order to detect relapses as early as possible. The patient should be 1075 
counseled to contact the treating physician if symptoms of hyperthyroidism are 1076 
recognized.  Should a relapse occur, patients should be counseled about alternatives for 1077 
therapy, which would include another course of MMI, RAI, or surgery.  If ATD therapy 1078 
is chosen, patients should be aware that agranulocytosis can occur with a second 1079 
exposure to a drug, even many years later, despite an earlier uneventful course of therapy 1080 
(177,178).   If the patient remains euthyroid for more than 1 year (i.e., they are in 1081 
remission), thyroid function should be monitored at least annually, as relapses can occur 1082 
years later (171), and some patients eventually become hypothyroid (179). 1083 
 1084 
[F] If thyroidectomy is chosen for treatment of GD, how should it be accomplished? 1085 
[F1] Preparation of patients with GD for thyroidectomy 1086 
■ RECOMMENDATION 24 1087 
If surgery is chosen as treatment for GD, patients should be rendered euthyroid prior 1088 
to the procedure with ATD pretreatment, with or without beta-adrenergic blockade. A 1089 
potassium iodide containing preparation should be given in the immediate 1090 
preoperative period. Strong recommendation, low-quality evidence. 1091 
■ RECOMMENDATION 25 1092 
Calcium and 25-OH-vitamin D should be assessed preoperatively and repleted if 1093 
necessary, or given prophylactically.  Calcitriol supplementation should be considered 1094 
preoperatively in patients at increased risk for transient or permanent 1095 
hypoparathyroidism. Strong recommendation, low-quality evidence. 1096 
■ RECOMMENDATION 26 1097 
In exceptional circumstances, when it is not possible to render a patient with GD 1098 
euthyroid prior to thyroidectomy, the need for thyroidectomy is urgent, or when the 1099 
patient is allergic to ATDs, the patient should be adequately treated with beta-1100 
blockade, potassium iodide, glucocorticoids, and potentially cholestyramine in the 1101 
immediate preoperative period. The surgeon and anesthesiologist should have 1102 
experience in this situation. Strong recommendation, low-quality evidence. 1103 
 Thyroid storm may be precipitated by the stress of surgery, anesthesia, or thyroid 1104 
manipulation and may be prevented by pretreatment with ATDs. Whenever possible, 1105 
thyrotoxic patients who are undergoing thyroidectomy should be rendered euthyroid by 1106 
MMI before undergoing surgery (180). Preoperative potassium iodide, saturated solution 1107 
of potassium iodide (SSKI), or Lugol’s solution should be used before surgery in most 1108 
patients with GD. This treatment is beneficial as it decreases thyroid blood flow, 1109 
vascularity, and intraoperative blood loss during thyroidectomy (181,182).  In a recent 1110 
series of 162 patients with GD and 102 patients with TMNG, none of whom received 1111 
SSKI preoperatively, there were no significant differences in operative times, blood loss, 1112 
or postoperative complications between the two groups; the authors concluded that 1113 
omitting preoperative SSKI for GD patients does not impair patient outcomes (183). 1114 
Given that this study was performed at a single high-volume institution, its findings may 1115 
not be generalizable; comparison was made between two different pathologies, and there 1116 
was no comparison group of patients with GD who received SSKI. It is unclear also 1117 
whether it was adequately powered to detect a significant difference, if one existed. 1118 
However this study mitigates concern when thyroidectomy is scheduled and SSKI is not 1119 
given because of shortages, scheduling issues, patient allergy or patient intolerance. In 1120 
addition, rapid preparation for emergent surgery can be facilitated by the use of 1121 
corticosteroids (184), and potentially cholestyramine (185-187). 1122 
 Technical remarks: Potassium iodide can be given as 5–7 drops (0.25–0.35 mL) 1123 
of Lugol’s solution (8 mg iodide/drop) or 1–2 drops (0.05–0.1 mL) of SSKI (50 mg 1124 
iodide/drop) three times daily mixed in water or juice for 10 days before surgery. 1125 
 Recent data suggest that supplementing oral calcium and/or vitamin D 1126 
preoperatively may reduce the risk of postoperative hypocalcemia due to parathyroid 1127 
injury or increased bone turnover (188).  Oltmann et al compared 45 Graves’ patients 1128 
treated with 1 g oral calcium carbonate three times a day for two weeks prior to surgery 1129 
to 38 Graves’ patients who underwent thyroidectomy without treatment, as well as 38 1130 
euthyroid controls; rates of biochemical and symptomatic hypocalcemia were 1131 
significantly higher in non-treated Graves’ patients compared to the two other treatment 1132 
groups (189).  Another study that focused on postoperative hypocalcemia after thyroid 1133 
surgery for thyroid cancer, not hyperthyroidism, identified a reduction in postoperative 1134 
symptomatic hypocalcemia when patients have preoperative serum 25-hydroxy vitamin 1135 
D levels >20 ng/ml (>8 nmol/l) prior to the operating room (190). A meta-analysis of risk 1136 
factors for postoperative hypocalcemia identified preoperative vitamin D deficiency as a 1137 
risk factor for postoperative hypocalcemia, as well as GD itself (188).  In two studies 1138 
included in another meta-analysis, supplementing calcitriol for a brief period 1139 
preoperatively helped reduce transient post-thyroidectomy hypocalcemia (191-193).  1140 
 [F2] The surgical procedure and choice of surgeon 1141 
■ RECOMMENDATION 27 1142 
If surgery is chosen as the primary therapy for GD, near-total or total thyroidectomy is 1143 
the procedure of choice. Strong recommendation, moderate-quality evidence. 1144 
 Thyroidectomy has a high cure rate for the hyperthyroidism of GD. Total 1145 
thyroidectomy has a nearly 0% risk of recurrence, whereas subtotal thyroidectomy may 1146 
have an 8% chance of persistence or recurrence of hyperthyroidism at 5 years (194-197).  1147 
The most common complications following near-total or total thyroidectomy are 1148 
hypocalcemia due to hypoparathyroidism (which can be transient or permanent), 1149 
recurrent or superior laryngeal nerve injury (which can be temporary or permanent), 1150 
postoperative bleeding, and complications related to general anesthesia. 1151 
■ RECOMMENDATION 28 1152 
If surgery is chosen as the primary therapy for GD, the patient should be referred to a 1153 
high-volume thyroid surgeon. Strong recommendation, moderate-quality evidence. 1154 
 Improved patient outcome has been shown to be independently associated with 1155 
high thyroidectomy surgeon volume; specifically, average complication rates, length of 1156 
hospital stay, and cost are reduced when the operation is performed by a surgeon who 1157 
conducts many thyroidectomies. A significant association is seen between increasing 1158 
thyroidectomy volume and improved patient outcome; the association is robust and is 1159 
more pronounced with an increasing number of thyroidectomies (198,199). Data show 1160 
that surgeons who perform more than 25 thyroid surgeries per year have superior patient 1161 
clinical and economic outcomes compared to those who perform fewer; complication 1162 
rates are 51% higher on average when surgery is performed by low-volume 1163 
surgeons (62,199,200).   The surgeon should be thoroughly trained in the procedure, 1164 
have an active practice in thyroid surgery, and have conducted a significant number of 1165 
thyroidectomies with a low frequency of complications. Following thyroidectomy for GD 1166 
in the hands of high-volume thyroid surgeons, the rate of permanent hypoparathyroidism 1167 
has been determined to be <2%, and permanent recurrent laryngeal nerve (RLN) injury 1168 
occurs in <1% (201). The frequency of bleeding necessitating reoperation is 0.3%–0.7% 1169 
(202). Mortality following thyroidectomy is between 1 in 10,000 and 5 in 1,000,000 1170 
(203). 1171 
 [F3] Postoperative care 1172 
■ RECOMMENDATION 29 1173 
Following thyroidectomy for GD, alternative strategies may be undertaken for 1174 
management of calcium levels: serum calcium ± intact parathyroid hormone levels can 1175 
be measured, and oral calcium and calcitriol supplementation administered based on 1176 
these results, or prophylactic calcium with or without calcitriol prescribed empirically. 1177 
Weak recommendation, low-quality evidence. 1178 
 Successful prediction of calcium status after total thyroidectomy can be achieved 1179 
using the slope of 6- and 12-hour postoperative calcium levels (204-210). Postoperative 1180 
routine supplementation with oral calcium and calcitriol decreases development of 1181 
hypocalcemic symptoms and intravenous calcium requirement, allowing for safer early 1182 
discharge (211). Low iPTH levels (<10–15 pg/mL) in the immediate postoperative 1183 
setting appear to predict symptomatic hypocalcemia and need for calcium and calcitriol 1184 
(1,25 vitamin D) supplementation (212,213). However, normal levels of serum iPTH may 1185 
not predict eucalcemia for GD patients (214). Vitamin D insufficiency may serve as an 1186 
underlying cause.   1187 
 1188 
 Patients can be discharged if they are asymptomatic and their serum calcium 1189 
levels corrected for albumin are 8.0 mg/dL (2.0 mmol/L) or above and are not falling 1190 
over a 24-hr period. The use of ionized calcium measurements are preferred by some, and 1191 
are helpful if the patient has abnormal levels of serum proteins.  Intravenous calcium 1192 
gluconate should be readily available and may be administered if patients have worsening 1193 
hypocalcemic symptoms despite oral supplementation and/or their concomitant serum 1194 
calcium levels are falling despite oral repletion. In patients with severe hypocalcemia, 1195 
teriparatide administration has yielded encouraging preliminary results (elimination of 1196 
symptoms and earlier hospital discharge), but more data are needed before it can be 1197 
considered for clinical practice (215). Persistent hypocalcemia in the postoperative period 1198 
should prompt measurement of serum magnesium and possible magnesium repletion 1199 
(216,217). In addition to reduced serum calcium levels, reduced serum phosphate and 1200 
increased serum potassium levels may be observed in hungry bone syndrome. Following 1201 
discharge, serum iPTH levels should be measured in the setting of persistent 1202 
hypocalcemia to determine if permanent hypoparathyroidism is truly present or whether 1203 
‘‘bone hunger’’ is ongoing. As the patient reaches eucalcemia, calcium and calcitriol 1204 
therapy can be tapered.  1205 
 Technical remarks: Calcium supplementation can be accomplished with oral 1206 
calcium (usually calcium carbonate, 1250–2500 mg, equivalent to 500-1000 mg 1207 
elemental calcium) four times daily, tapered by 500 mg of elemental calcium every 2 1208 
days, or 1000 mg every 4 days as tolerated. In addition, calcitriol may be started at a dose 1209 
of 0.5 mcg daily and continued for 1–2 weeks (218) and increased or tapered according to 1210 
the calcium and/or iPTH level. Patients can be discharged if they are asymptomatic and 1211 
have stable serum calcium levels. Postoperative evaluation is generally conducted 1–2 1212 
weeks following discharge with continuation of supplementation based on clinical 1213 
parameters. 1214 
■ RECOMMENDATION 30 1215 
ATD should be stopped at the time of thyroidectomy for GD, and beta-adrenergic 1216 
blockers should be weaned following surgery. Strong recommendation, low-quality 1217 
evidence. 1218 
■ RECOMMENDATION 31 1219 
Following thyroidectomy for GD, L-thyroxine should be started at a daily dose 1220 
appropriate for the patient’s weight (0.8 µg/lb or 1.6 µg/kg), with elderly patients 1221 
needing somewhat less, and serum TSH measured 6–8 weeks postoperatively. Strong 1222 
recommendation, low-quality evidence. 1223 
 Technical remarks: If TSH was suppressed preoperatively, a free T4 and TSH 1224 
should be measured 6-8 weeks postoperatively, since recovery of the pituitary-1225 
thyroid axis is occasionally delayed.  The appropriate dosing of L-thyroxine will vary 1226 
with patient BMI (219), and the percent of levothyroxine absorbed from the gut. Once 1227 
stable and normal, TSH should be measured annually or more frequently if clinically 1228 
indicated. 1229 
■ RECOMMENDATION 32 1230 
Communication among different members of the multidisciplinary team is essential, 1231 
particularly during transitions of care in the pre- and postoperative settings. Strong 1232 
recommendation, low-quality evidence.  1233 
 It is important to assure that adequate communication occurs between the medical 1234 
team and the treating surgeon to assure that euthyroidism is achievable prior to surgical 1235 
intervention; in addition, if the patient is noted to have significant vitamin D deficiency, 1236 
preoperative vitamin D repletion could be performed and surgery scheduled to permit 1237 
this. Important intraoperative findings and details of postoperative care, including 1238 
calcium supplementation needs and management of surgical hypothyroidism, should be 1239 
communicated by the surgeon to the patient and the other physicians who will be 1240 
important in the patient’s postoperative care (220).  1241 
 1242 
[G] How should thyroid nodules be managed in patients with GD? 1243 
■ RECOMMENDATION 33 1244 
If a thyroid nodule is discovered in a patient with GD, the nodule should be evaluated 1245 
and managed according to recently published guidelines regarding thyroid nodules in 1246 
euthyroid individuals. Strong recommendation, moderate-quality evidence. 1247 
 Thyroid cancer occurs in GD with a frequency of 2% or less (221). Thyroid 1248 
nodules larger than 1–1.5 cm should be evaluated before RAI therapy. If a radioactive 1249 
iodine scan is performed, any nonfunctioning or hypo-functioning nodules should be 1250 
considered for fine needle aspiration (FNA), as these may have a higher probability of 1251 
being malignant (62). If the cytopathology is suspicious or diagnostic of malignancy, 1252 
surgery is advised after normalization of thyroid function with ATDs. Surgery should 1253 
also be considered for indeterminate cytology. Disease-free survival at 20 years is 1254 
reported to be 99% after thyroidectomy for GD in patients with small (≤1 cm) coexisting 1255 
thyroid cancers (222). 1256 
 The use of thyroid ultrasonography in all patients with GD has been shown to 1257 
identify more nodules and cancer than does palpation and 123I scintigraphy. However, 1258 
since most of these cancers are papillary microcarcinomas with minimal clinical impact, 1259 
further study is required before routine ultrasound (which may lead to surgery) can be 1260 
recommended (223,224). 1261 
  Technical remarks: The ATA recently published updated management guidelines 1262 
for patients with thyroid nodules and differentiated thyroid cancer (225). 1263 
  1264 
[H] How should thyroid storm be managed? 1265 
■ RECOMMENDATION 34  1266 
The diagnosis of thyroid storm should be made clinically in a severely thyrotoxic 1267 
patient with evidence of systemic decompensation.  Adjunctive use of a sensitive 1268 
diagnostic system should be considered.  Patients with a Burch-Wartofsky Point Scale 1269 
(BWPS) of ≥ 45 or Japanese Thyroid Association (JTA) categories of TS1 or TS2 1270 
with evidence of systemic decompensation require aggressive therapy.  The decision 1271 
to use aggressive therapy in patients with a BWPS of 25-44 should be based on 1272 
clinical judgment.  Strong recommendation, moderate-quality evidence. 1273 
■ RECOMMENDATION 35  1274 
A multimodality treatment approach to patients with thyroid storm should be used, 1275 
including beta-adrenergic blockade, antithyroid drug therapy, inorganic iodide, 1276 
corticosteroid therapy, cooling with acetaminophen and cooling blankets, volume 1277 
resuscitation, nutritional support, respiratory care and monitoring in an intensive care 1278 
unit, as appropriate for an individual patient. Strong recommendation, low-quality 1279 
evidence. 1280 
 Life-threatening thyrotoxicosis or thyroid storm is a rare disorder characterized by 1281 
multisystem involvement and mortality rates in the range of 8-25% in modern series 1282 
(25,72,226,227). A high index of suspicion for thyroid storm should be maintained in 1283 
patients with thyrotoxicosis associated with any evidence of systemic decompensation. 1284 
Diagnostic criteria for thyroid storm in patients with severe thyrotoxicosis were first 1285 
proposed in 1993 and subsequently widely adopted as the Burch-Wartofsky Point Scale 1286 
for thyroid storm (26,72,186,226,228). These criteria (Table 6) include hyperpyrexia, 1287 
tachycardia, arrhythmias, congestive heart failure, agitation, delirium, psychosis, stupor 1288 
and coma, as well as nausea, vomiting, diarrhea, hepatic failure, and the presence of an 1289 
identified precipitant (26). Points are awarded in the BWPS system based on the severity 1290 
of individual manifestations, with a point total of  ≥ 45 consistent with thyroid storm, 25-1291 
44 points classified as impending thyroid storm, and < 25 points making thyroid storm 1292 
unlikely.  Recently, an additional empirically defined diagnostic system has been 1293 
proposed by the Japanese Thyroid Association (JTA) (72). The JTA system uses 1294 
combinations of similar clinical features to assign patients to the diagnostic categories 1295 
thyroid storm 1 (TS1) or thyroid storm 2 (TS2).  1296 
 Data comparing these two diagnostic systems suggest an overall agreement, but a 1297 
tendency toward under-diagnosis using the JTA categories of TS1 and TS2, compared to 1298 
a BWPS ≥ 45 (72,186,226,227). In a recent study including 25 patients with a clinical 1299 
diagnosis of thyroid storm, the BWPS was ≥ 45 in 20 patients and 25-44 in the remaining 1300 
five, but these latter five patients (20%) were not identified using the JTA system (226).  1301 
 Importantly, in the same series, among 125 patients hospitalized with a clinical 1302 
diagnosis of compensated thyrotoxicosis but not in thyroid storm, 27 (21.6%) had a 1303 
BWPS ≥ 45, and 21 (16.8%) were either TS1 or TS2, suggesting similar rates of over-1304 
diagnosis with these two systems.  However, an additional 50 patients (40%) hospitalized 1305 
with a clinical diagnosis of thyrotoxicosis without thyroid storm would have been 1306 
diagnosed as having impending thyroid storm by the BWPS, which reinforces that a 1307 
BWPS in the 25-44 range does not supplant clinical judgment in the selection of patients 1308 
for aggressive therapy. 1309 
 In summary, the diagnosis of thyroid storm remains a clinical one that is 1310 
augmented by current diagnostic systems.  A BWPS ≥ 45 appears more sensitive than a 1311 
JTA classification of TS1 or TS2 in detecting patients with a clinical diagnosis of thyroid 1312 
storm, but patients with a BWPS of 25-44 represent a group in whom the decision to use 1313 
aggressive therapy should be based on sound clinical judgment, and not based solely on 1314 
diagnostic category, in order to avoid over-treatment and the resultant risk of drug 1315 
toxicity.  At a minimum, patients in this intermediate category should be observed closely 1316 
for deterioration.  Care should be taken with either system to avoid inappropriate 1317 
application to patients without severe thyrotoxicosis as each of the manifestations of 1318 
thyroid storm, with the possible exception of severe hyperpyrexia, may also be seen in 1319 
the presence of any major illness, many of which are also known precipitants of thyroid 1320 
storm (186).  1321 
 Precipitants of thyroid storm in a patient with previously compensated 1322 
thyrotoxicosis include abrupt cessation of ATDs, thyroidectomy, or nonthyroidal surgery 1323 
in a patient with unrecognized or inadequately treated thyrotoxicosis, and a number of 1324 
acute illnesses unrelated to thyroid disease (72,186,228). Thyroid storm occasionally 1325 
occurs following RAI therapy.  1326 
 Aggressive treatment for thyroid storm involves the early targeting of each 1327 
pharmacologically accessible step in thyroid hormone production and action (Table 7). 1328 
Treatment strategy for thyroid storm can be broadly divided into 1) therapy directed 1329 
against thyroid hormone secretion; 2) measures directed against the peripheral action of 1330 
thyroid hormone at the tissue level; 3) reversal of systemic decompensation; 4) treatment 1331 
of the precipitating event or intercurrent illness; and 5) definitive therapy (26). A number 1332 
of therapeutic measures are specifically intended to decrease T4-to-T3 conversion, such as 1333 
the preferential use of PTU over MMI (229,230), glucocorticoid therapy (231), and the 1334 
use of beta adrenergic blocking agents such as propranolol, with selective ability to 1335 
inhibit type 1 deiodinase (232). For example, an early article comparing acute changes in 1336 
thyroid hormone level after initiation of PTU or MMI found that T3 levels dropped by 1337 
approximately 45% in the first 24 hours of PTU therapy compared to an approximately 1338 
10-15% decrease after starting MMI (229). Both plasmapheresis/ plasma exchange and 1339 
emergency surgery have been used to treat thyroid storm in patients who respond poorly 1340 
to traditional therapeutic measures (233,234).  1341 
 Prevention of thyroid storm involves recognition and active avoidance of common 1342 
precipitants, patient education to avoid abrupt discontinuation of ATD therapy, and 1343 
ensuring that patients are euthyroid prior to elective surgery, labor and delivery, or other 1344 
acute stressors. 1345 
 Technical remarks: Treatment with inorganic iodine (SSKI/Lugol’s solution), or 1346 
oral cholecystographic agents (235) leads to rapid decreases in both T4 and T3 levels. 1347 
Combined with ATDs in patients with severe thyrotoxicosis, these agents result in rapid 1348 
clinical improvement (120). Unfortunately, the oral radiographic contrast agents ipodate 1349 
and iopanoic acid are not currently available in many countries. 1350 
 1351 
[I] Is there a role for iodine as primary therapy in the treatment of GD?      1352 
 Prior to the introduction of ATDs, iodine was commonly reported to ameliorate 1353 
the hyperthyroidism associated with GD (236,237).  Iodine acutely lowers thyroid 1354 
hormone concentrations by reducing hormone secretion (238,239), and inhibits its own 1355 
organification (the Wolff-Chaikoff effect) (240).  However, reports of escape from these 1356 
beneficial effects of iodine (241), as well as reports of iodine induced hyperthyroidism in 1357 
patients with nodular goiter (242), discouraged the use of iodine in GD.  Recent studies 1358 
have suggested a potential role for iodine in patients who have had adverse reactions to 1359 
ATD and who also have a contraindication or aversion to RAI or surgery (243,244). 1360 
 1361 
RECOMMENDATION 36 1362 
Potassium iodide may be of benefit in select patients with hyperthyroidism due to GD, 1363 
who have adverse reactions to ATDs, and have a contraindication or aversion to RAI 1364 
therapy (or aversion  to repeat RAI therapy) or surgery.  Treatment may be more 1365 
suitable for patients with mild hyperthyroidism, or a prior history of RAI therapy.  No 1366 
recommendation, insufficient evidence to assess benefits or risks. 1367 
 Among 44 Japanese patients who had adverse reactions to ATD and who were 1368 
treated with KI alone, 66% were well-controlled for an average of 18 years (range 9-28 1369 
years), and 39% achieved a remission after 7 years (range 2-23 years) (243).  Among the 1370 
responders, the doses used were between 13 and 100 mg, and were adjusted depending 1371 
upon biochemical response.  Among 15 nonresponders, 11 (25% of all patients) escaped 1372 
the inhibitory effects of iodine and 4 patients did not respond at all to KI.   None of the 1373 
patients had side effects.  Initial free T4 concentration and goiter size did not predict a 1374 
response to therapy. Among 20 Japanese patients with mild hyperthyroidism initially 1375 
treated with KI alone, and matched using propensity score analysis with patients treated 1376 
with MMI alone, 85% of the patients treated with KI alone had normal thyroid function at 1377 
6 months and 1 year, comparable to that of the matched controls treated with MMI (244).  1378 
Most patients were treated with 50 mg KI daily.   1379 
 The inhibitory effects of iodine are greater in patients with a prior history of RAI 1380 
exposure (245) suggesting a role for KI in patients who remain hyperthyroid after one 1381 
dose of RAI and prefer to avoid a second dose.  The use of KI prior to thyroidectomy for 1382 
GD is discussed in section [F1], the use of KI as adjunctive therapy following RAI is 1383 
discussed in section [D1], the use of KI in combination with MMI for treating GD is 1384 
discussed in section [E1], and the use of KI in hyperthyroidism complicating pregnancy 1385 
is discussed in section [T]. 1386 
 1387 
[J] How should overt hyperthyroidism due to TMNG or TA be managed? 1388 
■ RECOMMENDATION 37 1389 
We suggest that patients with overtly TMNG or TA be treated with RAI therapy or 1390 
thyroidectomy. On occasion, long-term, low-dose treatment with MMI may be 1391 
appropriate. Weak recommendation, moderate-quality evidence. 1392 
 There are two effective and relatively safe definitive treatment options for 1393 
TMNG and TA, RAI therapy and thyroid surgery. The decision regarding treatment 1394 
should take into consideration a number of clinical and demographic factors, as well as 1395 
patient preference. The goal of therapy is the rapid and durable elimination of the 1396 
hyperthyroid state. 1397 
 For patients with TMNG, the risk of treatment failure or need for repeat 1398 
treatment is <1% following near-total and/total thyroidectomy (246,247), compared 1399 
with a 20% risk of the need for retreatment following RAI therapy (246,248). 1400 
Euthyroidism is achieved within days after surgery (246,247). On the other hand, the 1401 
risk of hypothyroidism and the requirement for exogenous thyroid hormone therapy is 1402 
100% after near-total/total thyroidectomy. For patients with TMNG who receive RAI 1403 
therapy, the response is 50–60% by 3 months, and 80% by 6 months (246,248,249). In 1404 
a large study of patients with TMNG treated with RAI, the prevalence of 1405 
hypothyroidism was 3% at 1 year and 64% at 24 years (250). Hypothyroidism was 1406 
more common among patients under 50 years of age, compared with those over 70 1407 
years (61% vs. 36% after 16 years). In a more recent study, the prevalence of 1408 
hypothyroidism was 4% at 1 year and 16% at 5 years (251).  1409 
 In large retrospective series of patients with TMNG presenting with 1410 
compressive symptoms, all patients undergoing total thyroidectomy had resolution of 1411 
these symptoms after treatment, whereas only 46% of patients undergoing RAI had 1412 
improvement in such symptoms (252). This may be due in part to the fact that very 1413 
large goiters treated with high-activity radioactive iodine only decrease in size by 30%–1414 
50% (253). 1415 
 For patients with TA, the risk of treatment failure is <1% after surgical resection 1416 
(ipsilateral thyroid lobectomy or isthmusectomy) (254). Typically, euthyroidism is 1417 
achieved within days after surgery. The prevalence of hypothyroidism varies from 2-1418 
3% following lobectomy for TA, although rates of hypothyroidism after lobectomy for 1419 
non-toxic nodules have been reported to be as high as 20% (254-256), and lower after 1420 
isthmusectomy in the unique circumstance where the TA is confined to the thyroid 1421 
isthmus. For patients with TA who receive RAI therapy there is a 6%–18% risk of 1422 
persistent hyperthyroidism and a 3%- 5.5% risk of recurrent hyperthyroidism 1423 
(254,257). There is a 75% response rate by 3 months and 89% rate by 1 year following 1424 
RAI therapy for TA (225,257,258). The prevalence of hypothyroidism after RAI is 1425 
progressive and hastened by the presence of antithyroid antibodies or a nonsuppressed 1426 
TSH at the time of treatment (257,259,260). A study following 684 patients with TA 1427 
treated with RAI reported a progressive increase in overt and subclinical 1428 
hypothyroidism (259). At 1 year, the investigators noted a 7.6% prevalence, with 28% 1429 
at 5 years, 46% at 10 years, and 60% at 20 years. They observed a faster progression to 1430 
hypothyroidism among patients who were older and who had incomplete TSH 1431 
suppression (correlating with only partial extranodular parenchymal suppression) due to 1432 
prior therapy with ATDs. The nodule is rarely eradicated in patients with TA 1433 
undergoing RAI therapy, which can lead to the need for continued surveillance 1434 
(225,257,260).  1435 
 Potential complications following near-total/total thyroidectomy include the risk 1436 
of permanent hypoparathyroidism (<2.0%) or RLN injury (<2.0%) (261,262). There is 1437 
a small risk of permanent RLN injury with surgery for TA (254). Following RAI 1438 
therapy, there have been reports of new-onset GD (up to 4% prevalence) (263), as well 1439 
as concern for thyroid malignancy (254,264,265) and a very minimal increase in late 1440 
non-thyroid malignancy (265). Overall, the success rate of RAI (definitive 1441 
hypothyroidism or euthyroidism) is high: 93.7% in TA and 81.1% in TMNG patients 1442 
(266). 1443 
 Technical remarks: Once the diagnosis has been made, the treating physician 1444 
and patient should discuss each of the treatment options, including the logistics, 1445 
benefits, expected speed of recovery, drawbacks, side effects, and costs. This sets the 1446 
stage for the physician to make a recommendation based upon best clinical judgment 1447 
and for the final decision to incorporate the personal values and preferences of the 1448 
patient.  Autonomy is an uncommon cause of hyperthyroidism in pregnancy and there 1449 
is a lack of studies in this setting.  However, considering the theoretical risks associated 1450 
with surgery or ATD therapy (has to be used throughout pregnancy and there is a 1451 
tendency to overtreat the fetus), the optimal therapy might be definitive therapy with 1452 
RAI or surgery in advance of a planned pregnancy. Most experts prefer to avoid the use 1453 
of RAI within 6 months of a pregnancy; it should be used with caution if at all. 1454 
 The panel agreed that TMNG and TA with high nodular RAI uptake and widely 1455 
suppressed RAI uptake in the perinodular thyroid tissue are especially suitable for RAI 1456 
therapy. However, there are insufficient data to make a recommendation based on these 1457 
findings. 1458 
 1459 
Factors that favor a particular modality as treatment for TMNG or TA (Table 1460 
8): 1461 
a. RAI therapy: Advanced patient age, significant comorbidity, prior surgery or 1462 
scarring in the anterior neck, small goiter size, RAIU sufficient to allow therapy, 1463 
and lack of access to a high-volume thyroid surgeon (the latter factor is more 1464 
important for TMNG than for TA). 1465 
b. Surgery: Presence of symptoms or signs of compression within the neck, concern 1466 
for coexisting thyroid cancer, coexisting hyperparathyroidism requiring surgery, 1467 
large goiter size (>80 g), substernal or retrosternal extension, RAIU insufficient 1468 
for therapy, or need for rapid correction of the thyrotoxic state (252). 1469 
c. ATDs: Advanced age, comorbities with increased surgical risk or associated with 1470 
decreased life-expectancy, and not good candidates for ablative therapy. 1471 
Contraindications to a particular modality as treatment for TMNG or TA: 1472 
a. RAI therapy: Definite contraindications to the use of radioactive iodine include 1473 
pregnancy, lactation, coexisting thyroid cancer, individuals unable to comply with 1474 
radiation safety guidelines and used with caution in women planning a pregnancy 1475 
within 4–6 months. 1476 
b. Surgery: Factors weighing against the choice of surgery include significant 1477 
comorbidity such as cardiopulmonary disease, end-stage cancer, or other 1478 
debilitating disorders, or lack of access to a high volume thyroid surgeon. 1479 
Pregnancy is a relative contraindication and should only be used in this 1480 
circumstance when rapid control of hyperthyroidism is required and ATDs cannot 1481 
be used. Thyroidectomy is best avoided in the first and third trimesters of 1482 
pregnancy because of teratogenic effects associated with anesthetic agents and 1483 
increased risk of fetal loss in the first trimester, and increased risk of preterm 1484 
labor in the third. Optimally, thyroidectomy should be performed in the latter 1485 
portion of the second trimester. Although it is the safest time, it is not without risk 1486 
(4.5%–5.5% risk of preterm labor) (67,68). 1487 
c. Definite contraindications to ATD therapy include previous known major adverse 1488 
reactions to ATDs. 1489 
Factors that may impact patient preference: 1490 
a. RAI therapy: Patients with either TMNG or TA choosing RAI therapy would likely 1491 
place relatively higher value on the avoidance of surgery and attendant 1492 
hospitalization or complications arising from either surgery or anesthesia; also, 1493 
patients with TMNG would place greater value on the possibility of remaining 1494 
euthyroid after RAI treatment. 1495 
b. Surgery: Patients choosing surgery would likely place a relatively higher value on 1496 
definitive control of hyperthyroid symptoms, avoidance of exposure to 1497 
radioactivity and a lower value on potential surgical and anesthetic risks; patients 1498 
with TMNG choosing surgery would place a lower value on the certain need for 1499 
lifelong thyroid hormone replacement whereas patients with TA who choose 1500 
surgery would place greater value on the possibility of achieving euthyroidism 1501 
without hormone replacement.  1502 
c. ATDs: Patients choosing ATDs would likely place a relatively higher value on 1503 
avoidance of exposure to radioactivity and on potential surgical and anesthetic 1504 
risks and a lower value on the certain need for lifelong thyroid ATD therapy. 1505 
 1506 
 [K] If RAI therapy is chosen, how should it be accomplished? 1507 
[K1] Preparation of patients with TMNG or TA for RAI therapy. 1508 
■ RECOMMENDATION 38 1509 
Because RAI treatment of TMNG or TA can cause a transient exacerbation of 1510 
hyperthyroidism, beta-adrenergic blockade should be considered even in 1511 
asymptomatic patients who are at increased risk for complications due to worsening of 1512 
hyperthyroidism, i.e. elderly patients and patients with co-morbidities. Weak 1513 
recommendation, low-quality evidence.  1514 
 Medical management before RAI therapy should be tailored to the patient’s 1515 
risk for complications if hyperthyroidism worsens, based on the severity of the 1516 
hyperthyroidism, patient age, and comorbid conditions. Worsened chemical 1517 
hyperthyroidism with increased heart rate and rare cases of supraventricular 1518 
tachycardia, including atrial fibrillation and atrial flutter, have been observed in patients 1519 
treated with RAI for either TMNG or nontoxic multindoular goiter (MNG) (267-269). 1520 
In susceptible patients with pre-existing cardiac disease or in the elderly, this may 1521 
produce significant clinical worsening (268). Therefore, the use of beta-blockers to 1522 
prevent post-treatment tachyarrhythmias should be considered in all patients with 1523 
TMNG or TA who are older than 60 years of age and those with cardiovascular disease 1524 
or severe hyperthyroidism (31). The decision regarding the use of MMI pretreatment is 1525 
more complex and is discussed below.  1526 
■ RECOMMENDATION 39 1527 
In addition to beta-adrenergic blockade (see Recommendation 2 and 38) pretreatment 1528 
with MMI prior to RAI therapy for TMNG or TA should be considered in patients 1529 
who are at increased risk for complications due to worsening of hyperthyroidism, 1530 
including the elderly and those with cardiovascular disease or severe hyperthyroidism. 1531 
Weak recommendation, low-quality evidence. 1532 
■ RECOMMENDATION 40 1533 
In patients who are at increased risk for complications due to worsening of 1534 
hyperthyroidism, resuming ATDs 3-7 days after RAI administration should be 1535 
considered. Weak recommendation, low quality evidence. 1536 
 Young and middle-aged patients with TMNG or TA generally do not require 1537 
pretreatment with ATDs (MMI) before receiving RAI, but may benefit from beta-1538 
blockade if symptoms warrant and contraindications do not exist. 1539 
 Technical remarks: If an ATD is used in preparation for RAI therapy in patients 1540 
with TMNG or TA, caution should be taken to avoid RAI therapy when the TSH is 1541 
normal or elevated to prevent direct RAI treatment of perinodular and contralateral 1542 
normal thyroid tissue, which increases the risk of developing hypothyroidism. However, 1543 
if volume reduction is a goal, at the expense of an increased risk of hypothyroidism, 1544 
pretreatment with MMI, allowing the TSH to rise slighty prior to RAI administration, 1545 
results in greater volume reduction after fixed doses of RAI (270). Similarly, a recent 1546 
meta-analysis indicated that the application of rhTSH before RAI therapy in non-toxic or 1547 
TMNG results in greater thyroid volume reduction but higher hypothyroidism rates than 1548 
RAI therapy alone (271). Unless volume reduction is an important goal, rhTSH 1549 
administration before RAI therapy of TMNG is not generally recommended as it could 1550 
possibly exacerbate hyperthyroidism (272), it represents an off-label use, and mainly 1551 
stimulates RAI uptake in TSH-sensitive perinodular tissues (273).  1552 
[K2] Evaluation of thyroid nodules before RAI therapy 1553 
■ RECOMMENDATION 41 1554 
Nonfunctioning nodules on radionuclide scintigraphy or nodules with suspicious 1555 
ultrasound characteristics should be managed according to published guidelines 1556 
regarding thyroid nodules in euthyroid individuals. Strong recommendation, 1557 
moderate-quality evidence. 1558 
 Thorough assessment of suspicious nodules within a TMNG, according to the 1559 
published guidelines (225,274), should be completed before selection of RAI as the 1560 
treatment of choice. The prevalence of thyroid cancer in TMNG historically has been 1561 
estimated to be about 3% (247).  More recently, it has been estimated to be as high as 1562 
9%, which is similar to the 10.6% prevalence noted in nontoxic MNG (275). 1563 
 Technical remarks: Both the ATA and AACE, the latter in conjunction with the 1564 
European Thyroid Association and Associazione Medici Endocrinologi, and the Latin 1565 
American Thyroid Society have published management guidelines for patients with 1566 
thyroid nodules (225,274,276,277). 1567 
[K3] Administration of RAI in the treatment of TMNG or TA 1568 
■ RECOMMENDATION 42 1569 
Sufficient activity of RAI should be administered in a single application to alleviate 1570 
hyperthyroidism in patients with TMNG. Strong recommendation, moderate-1571 
quality evidence.  1572 
 The goal of RAI therapy, especially in older patients, is elimination of the 1573 
hyperthyroid state. Higher activities of RAI, even when appropriately calculated for the 1574 
specific volume or mass of hyperthyroid tissue, result in more rapid resolution of 1575 
hyperthyroidism and less need for retreatment, but a higher risk for early 1576 
hypothyroidism. One study showed a 64% prevalence of hypothyroidism 24 years after 1577 
RAI therapy for TMNG, with a higher prevalence among patients who required more 1578 
than one treatment (250). The prevalence of hypothyroidism following RAI therapy is 1579 
increased by normalization or elevation of TSH at the time of treatment resulting from 1580 
ATD pretreatment or use of rhTSH, and by the presence of antithyroid antibodies (278). 1581 
 The activity of RAI used to treat TMNG, calculated on the basis of goiter size to 1582 
deliver 150–200 µCi (5.55-7.4 MBq) per gram of tissue corrected for 24-hour RAIU, is 1583 
usually higher than that needed to treat GD. In addition, the RAIU values for TMNG may 1584 
be lower, necessitating an increase in the applied activity of RAI. Radiation safety 1585 
precautions may be onerous if high activities of RAI are needed for large goiters. Both 1586 
pretreatment with MMI allowing the TSH to rise slightly (270), or the off-label use of 1587 
rhTSH (271), may reduce the total activity of RAI needed, but increase the risk of 1588 
hypothyroidism (see prior discussion section [K1]).  1589 
 Technical remarks: Enlargement of the thyroid is very rare after RAI treatment. 1590 
However, patients should be advised to immediately report any tightening of the neck, 1591 
difficulty breathing, or stridor following the administration of RAI. Any compressive 1592 
symptoms, such as discomfort, swelling, dysphagia, or hoarseness, which develop 1593 
following RAI therapy, should be carefully assessed and monitored, and if clinically 1594 
necessary, corticosteroids can be administered. Respiratory compromise in this setting is 1595 
extremely rare and requires management as any other cause of acute tracheal 1596 
compression. 1597 
■ RECOMMENDATION 43 1598 
Sufficient activity of RAI should be administered in a single application to alleviate 1599 
hyperthyroidism in patients with TA. Strong recommendation, moderate-quality 1600 
evidence.  1601 
 RAI administered to treat TA can be given either as a fixed activity of 1602 
approximately 10–20 mCi (370-740 MBq) or an activity calculated on the basis of nodule 1603 
size using 150–200 µCi (5.5-7.4 MBq) RAI per gram corrected for 24-hour RAIU (278). 1604 
A long-term follow-up study of patients with TA, where patients with nodules <4 cm 1605 
were administered an average of 13 mCi (481 MBq) and those with larger nodules an 1606 
average of 17 mCi (629 MBq), showed a progressive increase in hypothyroidism over 1607 
time in both groups, suggesting that hypothyroidism develops over time regardless of 1608 
activity adjustment for nodule size (259). A randomized trial of 97 patients with TA 1609 
compared the effects of high (22.5 mCi / 833 MBq) or low (13 mCi / 481 MBq) fixed 1610 
activity RAI, with a calculated activity that was either high (180–200 µCi/g / 6.7-7.4 Bq) 1611 
or low (90–100 µCi/g / 3.3-3.7 Bq) and corrected for 24-hour RAIU (279). This study 1612 
confirmed previous reports showing an earlier disappearance of hyperthyroidism and 1613 
earlier appearance of hypothyroidism with higher RAI activity. Use of a calculated 1614 
activity allowed for a lower RAI activity to be administered for a similar efficacy in the 1615 
cure of hyperthyroidism. 1616 
[K4] Patient follow-up after RAI therapy for TMNG or TA 1617 
■ RECOMMENDATION 44 1618 
Follow-up within the first 1–2 months after RAI therapy for TMNG or TA should 1619 
include an assessment of free T4, total T3 and TSH. Biochemical monitoring should be 1620 
continued at 4–6 week intervals for 6 months, or until the patient becomes 1621 
hypothyroid and is stable on thyroid hormone replacement. Strong recommendation, 1622 
low-quality evidence.  1623 
 RAI therapy for TMNG results in resolution of hyperthyroidism in approximately 1624 
55% of patients at 3 months and 80% of patients at 6 months, with an average failure rate 1625 
of 15% (246-248). Goiter volume is decreased by 3 months, with further reduction 1626 
observed over 24 months, for a total size reduction of 40% (248). For TA, 75% of 1627 
patients were no longer hyperthyroid at 3 months, with nodule volume decreased by 35% 1628 
at 3 months and by 45% at 2 years (257). Risk of persistent or recurrent hyperthyroidism 1629 
ranged from 0% to 30%, depending on the series (246-248,257). Long-term follow-up 1630 
studies show a progressive risk of clinical or subclinical hypothyroidism of about 8% by 1631 
1 year and 60% by 20 years for TA (259), and an average of 3% by 1 year and 64% by 24 1632 
years for TMNG (250). 1633 
 Graves’ disease might develop after RAI for TMNG in up to 4% of patients (280). 1634 
Such patients develop worsening hyperthyroidism within a few months of RAI therapy. 1635 
Treatment with additional RAI is effective. 1636 
 Technical remarks: If thyroid hormone therapy is necessary, the dose required 1637 
may be less than full replacement due to underlying persistent autonomous thyroid 1638 
function. 1639 
[K5] Treatment of persistent or recurrent hyperthyroidism following RAI therapy for 1640 
TMNG or TA 1641 
■ RECOMMENDATION 45 1642 
If hyperthyroidism persists beyond 6 months following RAI therapy for TMNG or 1643 
TA, retreatment with RAI is suggested. In selected patients with minimal response 3 1644 
months after therapy additional RAI may be considered. Weak recommandation, 1645 
low-quality evidence. 1646 
 Technical remarks: In severe or refractory cases of persistent hyperthyroidism 1647 
due to TMNG or TA, following treatment with RAI, surgery may be considered. As 1648 
some patients with mild hyperthyroidism following RAI administration will continue to 1649 
improve over time, use of MMI with close monitoring may be considered to allow 1650 
control of the hyperthyroidism until the RAI is effective. 1651 
 1652 
[L] If surgery is chosen, how should it be accomplished? 1653 
[L1] Preparation of patients with TMNG or TA for surgery 1654 
■ RECOMMENDATION 46 1655 
If surgery is chosen as treatment for TMNG or TA, patients with overt 1656 
hyperthyroidism should be rendered euthyroid prior to the procedure with MMI 1657 
pretreatment, with or without beta-adrenergic blockade. Preoperative iodine should not 1658 
be used in this setting. Strong recommendation, low-quality evidence. 1659 
 Risks of surgery are increased in the presence of thyrotoxicosis. Thyrotoxic crisis 1660 
during or after the operation, can result in extreme hypermetabolism, hyperthermia, 1661 
tachycardia, hypertension, coma, or death. Therefore, prevention with careful preparation 1662 
of the patient is of paramount importance (281,282). The literature reports a very low risk 1663 
of anesthesia-related mortality associated with thyroidectomy (254,283). Preoperative 1664 
iodine therapy is not indicated due to the risk of exacerbating the hyperthyroidism (284). 1665 
Usually hyperthyroidism is less severe in patients with TMNG, so that in most cases, 1666 
patients with allergy to ATDs can be prepared for surgery, when necessary, with beta-1667 
blockers alone. 1668 
[L2] The surgical procedure and choice of surgeon 1669 
■ RECOMMENDATION 47 1670 
If surgery is chosen as treatment for TMNG, near-total or total thyroidectomy should 1671 
be performed. Strong recommendation, moderate-quality evidence. 1672 
 Recurrence can be avoided in TMNG if a near-total or total thyroidectomy is 1673 
performed initially (285).  This procedure can be performed with the same low rate of 1674 
complications as a subtotal thyroidectomy (286-289). Reoperation for recurrent or 1675 
persistant goiter results in a 3- to 10-fold increase in the risk of permanent vocal cord 1676 
paralysis or hypoparathyroidism (290,291). 1677 
■ RECOMMENDATION 48 1678 
Surgery for TMNG should be performed by a high-volume thyroid surgeon. Strong 1679 
recommendation, moderate-quality evidence. 1680 
 TMNG is more common in older patients. Data regarding outcomes following 1681 
thyroidectomy in elderly patients have shown conflicting results. Overall, however, 1682 
studies conducted at the population level have demonstrated significantly higher rates 1683 
of postoperative complications, longer length of hospital stay, and higher costs among 1684 
elderly patients (198). Data showing equivalent outcomes among the elderly usually 1685 
have come from high-volume centers (292). There are robust data demonstrating that 1686 
surgeon volume of thyroidectomies is an independent predictor of patient clinical and 1687 
economic outcomes (i.e., in-hospital complications, length of stay, and total hospital 1688 
charges) following thyroid surgery (198,199,293). The recommendation for referral to a 1689 
high-volume surgeon is essentially the same as that described in section [F2] for the 1690 
choice of surgeon in GD. 1691 
■ RECOMMENDATION 49 1692 
If surgery is chosen as the treatment for TA, a thyroid ultrasound should be done to 1693 
evalutate the entire thyroid gland. An ipsilateral thyroid lobectomy, or isthmusectomy 1694 
if the adenoma is in the thyroid isthmus, should be performed for isolated TAs. Strong 1695 
recommendation, moderate-quality evidence. 1696 
 A preoperative thyroid ultrasound is useful, as it will detect the presence of 1697 
contralateral nodularity that is suspicious in appearance or that will necessitate future 1698 
surveillance, both circumstances in which a total thyroidectomy may be more 1699 
appropriate. Lobectomy removes the TA while leaving normal thyroid tissue, allowing 1700 
residual normal thyroid function in the majority of patients. One large clinical series for 1701 
TA demonstrated no surgical deaths and low complication rates (254). In patients who 1702 
wish to avoid general anesthesia or who have significant comorbidities, the risk of 1703 
anesthesia can be lowered further when cervical block analgesia with sedation is 1704 
employed by thyroid surgeons and anesthesiologists experienced in this approach (294). 1705 
Patients with positive antithyroid antibodies preoperatively have a higher risk of 1706 
postoperative hypothyroidism (256,278). 1707 
■ RECOMMENDATION 50 1708 
We suggest that surgery for TA be performed by a high-volume surgeon. Weak 1709 
recommendation, moderate-quality evidence. 1710 
 While surgeon experience in the setting of TA is of somewhat less importance 1711 
than in TMNG, it remains a factor to consider in deciding between surgery and RAI 1712 
therapy. High-volume thyroid surgeons tend to have better outcomes following 1713 
lobectomy than low-volume surgeons, but the differences are not statistically 1714 
significant (198). High-volume surgeons may be more comfortable with performing the 1715 
thyroid lobectomy under cervical block analgesia with sedation.  1716 
[L3] Postoperative care 1717 
■ RECOMMENDATION 51 1718 
Following thyroidectomy for TMNG, serum calcium ± iPTH levels should be 1719 
measured, and oral calcium and calcitriol supplementation administered based on the 1720 
results. Weak recommendation, low-quality evidence. 1721 
 Technical remarks: The management of hypocalcemia following thyroidectomy 1722 
for TMNG is essentially the same as that described in section [F3] for postoperative 1723 
management in GD. Severe or prolonged preoperative hyperthyroidism, and larger size 1724 
and greater vascularity of the goiter (more typically seen in GD) increases the risk of 1725 
postoperative hypocalcemia. 1726 
■ RECOMMENDATION 52 1727 
MMI should be stopped at the time of surgery for TMNG or TA. Beta-adrenergic 1728 
blockade should be slowly discontinued following surgery. Strong recomendation, 1729 
low-quality evidence. 1730 
     Technical remarks: The duration over which beta-adrenergic blockade should 1731 
be tapered should take into account the preoperative free T4 concentration, the 1732 
heart rate, and the week-long half-life of T4.  Additionally, patients taking 1733 
higher doses of beta-blockers will require a longer taper. 1734 
■ RECOMMENDATION 53 1735 
Following thyroidectomy for TMNG, thyroid hormone replacement should be started 1736 
at a dose appropriate for the patient’s weight (0.8 mcg/lb or 1.6 mcg/kg) and age, with 1737 
elderly patients needing somewhat less. TSH should be measured every 1–2 months 1738 
until stable, and then annually. Strong recommendation, low-quality evidence. 1739 
 Technical remarks: The appropriate dosing of L-thyroxine will vary with patient 1740 
BMI (219). If a significant thyroid remnant remains following thyroidectomy, 1741 
because such a remnant may demonstrate autonomous production of thyroid 1742 
hormone, immediate postoperative doses of thyroid hormone should be initiated at 1743 
somewhat less than full replacement doses and subsequently adjusted based on 1744 
thyroid function testing. 1745 
■ RECOMMENDATION 54 1746 
Following lobectomy for TA, TSH and estimated free T4 levels should be obtained 4–1747 
6 weeks after surgery, and thyroid hormone supplementation started if there is a 1748 
persistent rise in TSH above the normal range. Strong recommendation, low-quality 1749 
evidence. 1750 
 Technical remarks: After lobectomy for TA, serum calcium levels do not need to 1751 
be obtained, and calcium and calcitriol supplements do not need to be administered.  1752 
Thyroid hormone replacement is required in about 15-20% of patients following thyroid 1753 
lobectomy (295).  Serum TSH levels may have been suppressed or normal prior to 1754 
lobectomy, depending on the degree of preoperative preparation with ATDs.  TSH levels 1755 
may remain in the high normal range for 3-6 months following lobectomy; therefore, 1756 
continued monitoring in an asymptomatic patient for 4-6 months postoperatively is 1757 
reasonable, since there may be eventual recovery of normal thyroid function (296).  1758 
[L4] Treatment of persistent or recurrent disease following surgery for TMNG or TA 1759 
■ RECOMMENDATION 55 1760 
RAI therapy should be used for retreatment of persistent or recurrent hyperthyroidism 1761 
following inadequate surgery for TMNG or TA. Strong recommendation, low-1762 
quality evidence. 1763 
 Persistent or recurrent hyperthyroidism following surgery is indicative of 1764 
inadequate surgery. As remedial thyroid surgery comes at significantly increased risk of 1765 
hypoparathyroidism and RLN injury, it should be avoided, if possible, in favor of RAI 1766 
therapy (290,291). If this is not an option, it is essential that the surgery be performed by 1767 
a high-volume thyroid surgeon. 1768 
 1769 
[M] If ATDs are chosen as treatment of TMNG or TA, how should the therapy be 1770 
managed? 1771 
 ATDs do not induce remission in patients with nodular thyroid disease. Therefore, 1772 
discontinuation of treatment results in relapse (262,297). However, prolonged (life-long) 1773 
ATD therapy may be the best choice for some individuals with limited life-expectancy 1774 
and increased surgical risk, including residents of nursing homes or other care facilities 1775 
where compliance with radiation safety regulations may be difficult. 1776 
■ RECOMMENDATION 56 1777 
Long-term MMI treatment of TMNG or TA might be indicated in some elderly or 1778 
otherwise ill patients with limited life-expectancy, in patients who are not good 1779 
candidates for surgery or ablative therapy, and in patients who prefer this option.  1780 
Weak recommendation, low-quality evidence. 1781 
 1782 
 Technical remarks: The required dose of MMI to restore the euthyroid state in 1783 
TMNG or TA patients is usually low (5-10 mg/day). Because long-term, low-dose ATD 1784 
treatment in nodular hyperthyroidism can be difficult to regulate, frequent (every 3 1785 
months) monitoring is recommended initially, especially in the elderly (298), until 1786 
stability has been documented after which testing frequency can be decreased.   1787 
 1788 
[N] Is there a role for ethanol or radiofrequency ablation in the management of TA or 1789 
TMNG? 1790 
■ RECOMMENDATION 57 1791 
Alternative therapies such as ethanol or radiofrequency ablation of TA and TMNG can 1792 
be considered in select patients where RAI, surgery or long-term ATD are 1793 
inappropriate, contraindicated, or refused, and expertise in these procedures is 1794 
available. No recommendation, insufficient evidence to assess benefits and risks. 1795 
[N1] Ethanol ablation 1796 
 Reports that support the efficacy of percutaneous ethanol injection (PEI) under 1797 
sonographic guidance to treat TA and TMNG come largely from Europe (299-301).  1798 
Experience in the United States is limited.  A typical protocol involves the injection of 1799 
ethanol (average dose 10 ml, depending on size of the area to be ablated) into the TA or 1800 
autonomous area of a TMNG.  In one study, the average patient required 4 sessions at 2 1801 
week intervals (299). One hundred twenty-five patients with TA were followed for an 1802 
average of 5 years; 2.4% refused further treatment due to pain, and 3.2% had 1803 
complications including transient recurrent laryngeal nerve palsy, abscess or hematoma 1804 
(299).  Ninety-three percent of patients achieved a functional cure (no uptake on RAI 1805 
scintigraphy), and 92% had a > 50% reduction in nodule size (299).  In another study of 1806 
both TA and TMNG, 78 percent achieved a functional cure, all nodules regressed, and 1807 
there was no recurrent hyperthyroidism during 5-years of follow-up (300).  Ethanol 1808 
ablation also has been used following RAI to reduce nodule size (301). However, its use 1809 
has been limited due to pain associated with extravasation of the ethanol to extranodular 1810 
locations, and other adverse effects which have included transient thyrotoxicosis, 1811 
permanent ipsilateral facial dysethesia, paranodular fibrosis interfering with subsequent 1812 
surgery (302), and toxic necrosis of the larynx and adjacent skin (303). 1813 
[N2] Radiofrequency ablation 1814 
 Both radiofrequency ablation (RFA) and laser therapy have been used to treat 1815 
thyroid nodules.  A meta-analysis demonstrated that RFA resulted in larger reductions in 1816 
nodule size with fewer sessions than laser (304).  A retrospective multi-center report of 1817 
RFA for TA in 44 patients utilized an 18 g electrode under ultrasound guidance with a 1818 
mean follow-up of 20 months (305).  An 82% reduction in nodule volume was achieved, 1819 
but 20% of nodules remained autonomous on scintigraphy, and 18% of patients remained 1820 
hyperthyroid.  All patients complained of pain during the procedure, but there were no 1821 
complications (305).   A Korean study compared the use of RFA to surgery for non-toxic 1822 
nodules (306).  RFA was associated with an 85% reduction in nodule size, the cost was 1823 
similar to surgery, there were fewer complications (recurrent laryngeal nerve injury or 1824 
hypoparathyroidism: 6% for surgery and 1% for RFA), and no patient who received RFA 1825 
became hypothyroid (306).  Advocates of RFA argue that it preserves normal thyroid 1826 
function compared to surgery or RAI (307). However, additional data are needed to 1827 
determine the success at correcting hyperthyroidism in patients with TA and TMNG. The 1828 
use of RFA should be limited to centers where clinicians have received adequate training 1829 
in the technique.  1830 
 1831 
[O] How should GD be managed in children and adolescents? 1832 
[O1] General approach 1833 
■ RECOMMENDATION 58 1834 
Children with GD should be treated with MMI, RAI therapy, or thyroidectomy. RAI 1835 
therapy should be avoided in very young children (<5 years). RAI therapy in children 1836 
is acceptable if the activity is >150 µCi/g (5.55 MBq/g) of thyroid tissue, and for 1837 
children between 5 and 10 years of age if the calculated RAI administered activity is 1838 
<10 mCi (<473 MBq). Thyroidectomy should be chosen when definitive therapy is 1839 
required, the child is too young for RAI, and surgery can be performed by a high-1840 
volume thyroid surgeon. Strong recommendation, moderate-quality evidence. 1841 
 The treatment of pediatric patients with GD varies considerably among 1842 
institutions and practitioners. It is important to recognize that lasting remission after 1843 
ATD therapy occurs in only a minority of pediatric patients with GD, including 1844 
children treated with ATDs for many years. In determining the initial treatment 1845 
approach, the patient’s age, clinical status, and likelihood of remission should be 1846 
considered. Patient and parent values and preferences should also be strongly 1847 
considered when choosing one of the three treatment modalities. 1848 
 Because some children will go into remission, MMI therapy for 1 year is still 1849 
considered first-line treatment for most children. However, the majority of pediatric 1850 
patients with GD will eventually require either RAI or surgery. When ATDs are used in 1851 
children, only MMI should be used, except in exceptional circumstances. If clinical 1852 
characteristics suggest a low chance of remission at initial presentation (see [P6] below) 1853 
MMI, RAI, or surgery may be considered initially. If remission is not achieved after a 1854 
course of therapy with ATDs, RAI or surgery should be considered. Alternatively, MMI 1855 
therapy may be continued long-term, or until the child is considered old enough for 1856 
surgery or RAI. 1857 
 Properly administered, RAI is an effective treatment for GD in the pediatric 1858 
population  (308-310). RAI is widely used in children, but still viewed as controversial by 1859 
some practitioners owing primarily to concern over cancer risks (311,312). Although 1860 
there are sparse clinical data relating to RAI use in children with GD and subsequent 1861 
thyroid cancer (313), it is known that risks of thyroid cancer after external irradiation are 1862 
highest in children <5 years of age, and they decline with advancing age (314,315); see 1863 
discussion of RAI therapy and cancer risk in [P3] below. In comparison, activities of RAI 1864 
used with contemporary therapy are not known to be associated with an increased risk of 1865 
thyroid neoplasm in children. 1866 
 Thyroidectomy is an effective treatment for GD, but is associated with a higher 1867 
complication rate in children than adults (316-318). Thyroidectomy should be performed 1868 
in those children who are too young for RAI, provided that surgery can be performed by 1869 
a high-volume thyroid surgeon, preferably with experience in conducting thyroidectomies 1870 
in children. 1871 
 Technical remarks: There may be circumstances in which RAI therapy is 1872 
indicated in young children, such as when a child has developed a reaction to ATDs, 1873 
proper surgical expertise is not available, or the patient is not a suitable surgical 1874 
candidate. 1875 
 1876 
[P] If ATDs are chosen as initial management of GD in children, how should the 1877 
therapy be managed? 1878 
[P1] Initiation of ATD therapy for the treatment of GD in children 1879 
■ RECOMMENDATION 59 1880 
MMI should be used in children who are treated with ATD therapy. Strong 1881 
recommendation, moderate-quality evidence. 1882 
 Technical remarks: MMI comes in 5 or 10 mg tablets and can be given once 1883 
daily, even in patients with severe hyperthyroidism. Although many practitioners give 1884 
MMI in divided doses, data in adults do not support a need for such and show that 1885 
compliance with once-daily MMI therapy is superior to multiple daily doses of PTU 1886 
(83% vs. 53%) (319). The MMI dose typically used is 0.2–0.5 mg/kg daily, with a range 1887 
from 0.1–1.0 mg/kg daily (320-322). One approach is to prescribe the following whole 1888 
tablet or quarter to half-tablet doses: infants, 1.25 mg/day; 1–5 years, 2.5–5.0 mg/day; 5–1889 
10 years, 5–10 mg/day; and 10–18 years, 10–20 mg/day. With severe clinical or 1890 
biochemical hyperthyroidism, doses that are 50–100% higher than the above can be used. 1891 
 Although there may be a tendency to use higher rather than lower doses of MMI 1892 
at treatment onset, data in adults show only modest benefit of higher doses, and only in 1893 
severe thyrotoxicosis (free T4 > 7 ng/dl (0.554 pmol/L)) (115).  Because most side effects 1894 
of MMI are dose-related, and occur within the first 3 months of treatment (128), high 1895 
doses of MMI (e.g., >30 mg for an adolescent or adult) should rarely be used initially. 1896 
 When thyroid hormone levels normalize, MMI doses can be reduced by 50% or 1897 
more to maintain a euthyroid state (112). Alternatively, some physicians elect not to 1898 
reduce the MMI dose and add levothyroxine to make the patient euthyroid, a practice 1899 
referred to as ‘‘block and replace.’’ However, because meta-analyses suggest a higher 1900 
prevalence of adverse events using block-and-replace regimens than dose titration 1901 
(119,323), likely due to higher doses of MMI and the dose-related complications 1902 
associated with MMI (324), we suggest that this practice be avoided. However, it may 1903 
have utility in rare patients, after addressing compliance, who are inadequately 1904 
controlled on one dose of MMI, then become hypothyroid after a minimal dose 1905 
increase. 1906 
 Practitioners should also monitor the weight of children treated with ATDs.  1907 
Excessive weight gain within 6 months of treatment is seen in children treated for GD, 1908 
and the gain in weight can persist (325).  Parents and patients should be counseled about 1909 
this possibility and nutrition consultation considered if excessive weight gain occurs. 1910 
 1911 
■ RECOMMENDATION 60 1912 
Pediatric patients and their caretakers should be informed of side effects of ATD 1913 
preferably in writing, and the necessity of stopping the medication immediately and 1914 
informing their physician if they develop pruritic rash, jaundice, acolic stools or dark 1915 
urine, arthralgias, abdominal pain, nausea, fatigue, fever, or pharyngitis. Strong 1916 
recommendation, low-quality evidence. 1917 
■ RECOMMENDATION 61 1918 
Prior to initiating ATD therapy, we suggest that pediatric patients have, as a baseline, 1919 
complete blood cell count, including white blood cell count with differential, and a 1920 
liver profile including bilirubin, transaminases, and alkaline phosphatase. Weak 1921 
recommendation, low-quality evidence. 1922 
 PTU is associated with an unacceptable risk of hepatotoxicity in children, with a 1923 
risk of liver failure of 1 in 2000–4000 children taking the medication (326,327). PTU can 1924 
cause fulminant hepatic necrosis that may be fatal; liver transplantation has been 1925 
necessary in some patients taking PTU (326). It is for this reason that the FDA issued a 1926 
black box warning regarding the use of PTU (328), noting that 32 (22 adult and 10 1927 
pediatric) cases of serious liver injury have been associated with PTU use (326,328).  1928 
Furthermore, since the recommendation was issued that PTU use in children be avoided, 1929 
we are unaware of any published cases of PTU-related liver failure (327). 1930 
 Because PTU-induced liver injury is of rapid onset and can be rapidly 1931 
progressive, biochemical monitoring of liver function tests and transaminase levels has 1932 
not been shown to be useful in surveillance for PTU-related liver injury. When neither 1933 
prompt surgery nor RAI therapy are options, and ATD therapy is necessary in a patient 1934 
who has developed a minor toxic reaction to MMI, a short course of PTU use can be 1935 
considered. When surgery is the planned therapy and MMI cannot be administered, if the 1936 
patient is not too thyrotoxic (and the hyperthyroidism is due to GD), the hyperthyroid 1937 
state can be controlled before surgery with beta blockade and SSKI (50 mg iodide/ drop) 1938 
3–7 drops (0.15–0.35 mL) by mouth, given three times a day for 10 days before surgery.  1939 
Prior to surgery it is desirable to have the free T4, or total T4 and total T3 levels in the 1940 
normal or subnormal range. Alternatively, if the surgery cannot be performed within a 1941 
few weeks, a short course of PTU may be administered with the child closely monitored 1942 
clinically for signs of hepatic dysfunction including nausea, anorexia, malaise and 1943 
abdominal pain. 1944 
 MMI may also be associated with hepatotoxicity in children, but this tends to be 1945 
milder and is typically cholestatic rather than hepatocellular (326).  There is at least one 1946 
reported case of cholestatic jaundice in a child (326). However, there have been reports of 1947 
hepatocellular toxicity with MMI in adults (134).   1948 
 MMI may also be associated with antineutrophil cytoplasmic antibody (ANCA) 1949 
positive vasculitis (329), although this occurs far less frequently than with PTU.  Patients 1950 
of Asian origin seem to be more susceptible to this adverse reaction, and it can develop 1951 
after months to years of therapy.  Many PTU-treated patients also develop ANCA 1952 
positivity on treatment, but remain asymptomatic (330).  Typical manifestations of 1953 
ANCA positive vasculitis are: polyarthritis, purpuric skin lesions, and occasionally 1954 
pulmonary and/or renal involvement.  Discontinuation of the drug generally results in 1955 
resolution of the symptoms, but in more severe cases, glucocorticoids or other 1956 
immunosuppressive therapy may be needed. 1957 
 Technical remarks: It is advisable to provide information concerning side effects 1958 
of ATDs to the patient or caretaker in writing. See Recommendation 14 Technical 1959 
remarks for a discussion regarding the utility of obtaining complete blood count and liver 1960 
profile before initiating MMI therapy. 1961 
[P2] Symptomatic management of Graves’ hyperthyroidism in children 1962 
■ RECOMMENDATION 62 1963 
Beta adrenergic blockade is recommended for children experiencing symptoms of 1964 
hyperthyroidism, especially those with heart rates in excess of 100 beats per minute. 1965 
Strong recommendation, low-quality evidence. 1966 
 In children in whom the diagnosis of Graves’ hyperthyroidism is strongly 1967 
suspected or confirmed, and who are showing significant symptoms, including, but not 1968 
limited to, tachycardia, muscle weakness, tremor, or neuropsychological changes, 1969 
treatment with atenolol, propranolol, metoprolol, or other beta-blockers leads to a 1970 
decrease in heart rate and symptoms of GD. In those with reactive airway disease, cardio 1971 
selective beta-blockers such as atenolol or metoprolol can be used cautiously (331), with 1972 
the patient monitored for exacerbation of asthma. 1973 
[P3] Monitoring of children taking MMI 1974 
 After initiation of MMI therapy, thyroid function tests (free T4, total T3, TSH) are 1975 
obtained at 2-6 weeks, the dose is adjusted if indictated, and thyroid function tests are 1976 
measured again at 4-6 weeks, and then every 2–3 months once the dose is stablized. 1977 
Depending on the severity of hyperthyroidism and the MMI dose, it can take several 1978 
months for elevated thyroid hormone levels to fall into the normal range. Serum TSH 1979 
may remain suppressed for several months after starting therapy and is therefore not a 1980 
good parameter to monitor therapy early in the course.   1981 
■ RECOMMENDATION 63 1982 
ATDs should be stopped immediately, and white blood counts measured in children 1983 
who develop fever, arthralgias, mouth sores, pharyngitis, or malaise. Strong 1984 
recommendation, low-quality evidence. 1985 
 Although MMI has a better overall safety profile than PTU, MMI is associated 1986 
with minor adverse events that may affect up to 20% of children (332). MMI-related 1987 
adverse events include allergic reactions, rashes, myalgias, and arthralgias (333,334), as 1988 
well as hypothyroidism from overtreatment. Side effects from MMI usually occur within 1989 
the first 3 months of starting therapy, but adverse events can occur later. In children, the 1990 
risks of MMI-related cholestasis and hepatocellular injury appear to be much less than 1991 
that observed in adults (326). 1992 
 Agranulocytosis has been reported in about 0.3% of adult patients taking MMI or 1993 
PTU (128,324,335). Data on the prevalence of agranulocytosis in children are 1994 
unavailable, but it is estimated to be very low. In adults, agranulocytosis is dose 1995 
dependent with MMI, and rarely occurs at low doses (e.g., 5-10 mg/day) (128,324,335). 1996 
When agranulocytosis develops, 95% of the time it occurs in the first 100 days of therapy 1997 
(128,324,335).  The overall rate of side effects from ATDs (both major and minor) in 1998 
children has been reported to be 6%–35% (332,334,336,337). 1999 
 Technical remarks: While routine monitoring of white blood counts may 2000 
occasionally detect early agranulocytosis, it is not recommended because of the rarity of 2001 
the condition and its sudden onset, which is generally symptomatic. It is for this reason 2002 
that measuring white cell counts during febrile illnesses and at the onset of pharyngitis 2003 
has become the standard approach for monitoring. 2004 
[P4] Monitoring of children taking PTU 2005 
■ RECOMMENDATION 64 2006 
In general, PTU should not be used in children.  But, if used the medication should be 2007 
stopped immediately and liver function and hepatocellular integrity assessed in 2008 
children who experience anorexia, pruritus, rash, jaundice, light-colored stool or dark 2009 
urine, joint pain, right upper quadrant pain or abdominal bloating, nausea, or malaise. 2010 
Strong recommendation, low-quality evidence. 2011 
 Technical remarks: PTU should be discontinued if transaminase levels (obtained 2012 
in symptomatic patients or found incidentally) reach 2–3 times the upper limit of normal. 2013 
After discontinuing the drug, liver function tests (i.e., bilirubin, alkaline phosphatase, and 2014 
transaminases) should be monitored weekly until there is evidence of resolution. If there 2015 
is no evidence of resolution, referral to a gastroenterologist or hepatologist is warranted. 2016 
[P5] Management of allergic reactions in children taking MMI 2017 
■ RECOMMENDATION 65 2018 
Persistent minor cutaneous reactions to MMI therapy in children should be managed 2019 
by concurrent antihistamine treatment or cessation of the medication and changing to 2020 
therapy with RAI or surgery. In the case of a serious adverse reaction to an ATD, 2021 
prescribing the other ATD is not recommended. Strong recommendation, low-2022 
quality evidence. 2023 
 If children develop serious adverse reactions to MMI, RAI or surgery should be 2024 
considered because the risks of PTU are viewed to be greater than the risks of radioactive 2025 
iodine or surgery. In special circumstances, where the patient is viewed to be at risk for 2026 
thyroid storm and ATD therapy is needed in a child with a serious adverse reaction to 2027 
MMI, PTU may be considered for short-term therapy to control hyperthyroidism.  In this 2028 
setting, families should be informed of the risks of PTU.  2029 
[P6] Duration of MMI therapy in children with GD 2030 
■ RECOMMENDATION 66 2031 
If MMI is chosen as the first-line treatment for GD in children, it may be tapered in 2032 
those children requiring low doses after 1-2 years to determine if a spontaneous 2033 
remission has occurred, or it may be continued until the child and caretakers are  2034 
ready to consider definitive therapy, if needed. Strong recommendation, moderate-2035 
quality evidence. 2036 
 The issue of how long ATDs should be used in children before considering either 2037 
RAI or surgery is a topic of controversy and warrants further study. Prospective studies in 2038 
adults show that if remission does not occur after 12–18 months of therapy, there is a 2039 
lower chance of remission occurring with prolonged therapy (338). In children, when 2040 
ATDs are used for 1–2 years, remission rates are generally 20%–30%, with remission 2041 
defined as being euthyroid for 1 year after cessation of therapy (333,339,340). 2042 
Retrospective studies have suggested that the chance of remission after 2 years of ATDs 2043 
is low if the thyroid gland is large (more than 2.5 times normal size for age), the child is 2044 
young (<12 years) or not Caucasian, serum TRAb levels are above normal on therapy, or 2045 
free T4 are substantially elevated at diagnosis (>4 ng/dL; 50 pmol/L) (339). One 2046 
prospective study suggested that likelihood of remission could best be predicted by the 2047 
initial response to ATDs, with achievement of euthyroid state within 3 months, 2048 
suggesting higher likelihood. Younger children and those with high initial thyroid 2049 
hormone levels were also found to be less likely to achieve remission within 2 years in 2050 
the prospective studies (334,337). 2051 
 Remission rates in children treated with ATDs for longer than 2 years have been 2052 
reported. Although two decades ago it was suggested that 25% of children with GD go 2053 
into remission with every 2 years of continued treatment (341), other studies of larger 2054 
cohorts of pediatric patients with GD treated with ATDs for extended periods have not 2055 
revealed similar remission rates (333,339,342). Of 120 pediatric patients treated with 2056 
ATDs at one center, after 1 year of therapy with ATDs, 25% were in remission; after 2 2057 
years, 26%; after 4 years, 37%; and after 4–10 years, 15%. Importantly, 30% of the 2058 
children who went into remission eventually relapsed (333). In another large cohort of 2059 
184 medically treated children, after 1 year of therapy with ATDs, 10% were in 2060 
remission; after 2 years, 14%; after 3 years, 20%; and after 4 years, 23% (339,342). 2061 
 More recently, in a retrospective analysis from Japan of 1,138 children, 723 were 2062 
continued on long term ATD treatment, 271 underwent surgery or RAI, and 144 dropped 2063 
out. Of the 639 patients of the 723 who discontinued ATD treatment, 46.2% achieved 2064 
remission, and 34.2% relapsed. The prevalence of adverse events associated with MMI 2065 
and PTU were 21.4% and 18.8%, respectively (343).  2066 
 In comparison, other recent studies of long term remission rates of pediatric GD 2067 
treated with ATDs are very low (<20%), especially with longer follow-up, in cohorts 2068 
from Germany (344) and Denmark (345). 2069 
 Data also suggest that there are age-related differences in responsiveness to 2070 
ATDs. In one study that compared outcomes of 32 prepubertal and 68 pubertal children, 2071 
remission occurred in only 17% of prepubertal children treated 5.9±2.8 years, compared 2072 
with 30% of pubertal individuals treated 2.8±1.1 years (340). In another report, the 2073 
course of GD was compared in 7 prepubertal, 21 pubertal, and 12 postpubertal children 2074 
(336). Remission was achieved in 10 patients (28%) with similar rates among the three 2075 
groups, whereas the time to remission tended to be longer in the small proportion of 2076 
prepubertal children (median age, 6 years) (336). 2077 
 Persistence of GD in children is correlated with the persistence of TRAbs. A 2078 
recent study found that TRAb levels normalized after 24 months in only 18% of pediatric 2079 
patients on ATDs (346). There were no data showing that there was normalization of 2080 
TRAb levels when patients were on ATDs for a longer time. Therefore, it appears that 2081 
TRAb levels persist longer in children than in adults (346). Whereas monitoring of TRAb 2082 
levels while on ATDs has been shown to be useful in adult patients for predicting the 2083 
likelihood of remission or relapse of GD after stopping the medication (172), this 2084 
approach has yet to be validated in children. 2085 
 Whereas most studies, including recent large database reports (343), show that the 2086 
vast majority of patients treated for GD with ATDs do not go into remission, a recent 2087 
prospective report from France shows that with prolonged ATD use, remission rates of up 2088 
to 49% could be achieved.  This study reported remision rates of 20%, 37%, 45%, and 2089 
49% after 4, 6, 8, and 10 years follow-up of 154 children treated with ATDs (337).  The 2090 
use of MMI in this group of children was associated with a very low rate of medication 2091 
side-effects (337).  Thus, whereas many practitioners will treat for 1-2 years with MMI, 2092 
these data suggest that treatment for longer periods is also reasonable, as long as side-2093 
effects to medication do not occur. 2094 
■ RECOMMENDATION 67 2095 
Pediatric patients with GD who are not in remission following at least 1–2 years of 2096 
MMI therapy should be considered for treatment with RAI or thyroidectomy. 2097 
Alternatively, if children are tolerating ATD therapy, ATDs may be used for extended 2098 
periods.  This approach may be especially useful for the child not considered to be a 2099 
candidate for either surgery or RAI.  Individuals on prolonged ATDs therapy (>2 2100 
years) should be reevaluated every 6-12 months and when transitioning to adulthood.  2101 
Strong recommendation, low-quality evidence. 2102 
 If remission is not achieved upon stopping MMI after at least 1 or 2 years of 2103 
therapy, RAI or surgery should be considered, depending on the age of the child. 2104 
Alternatively, practitioners can continue MMI for extended periods, as long as adverse 2105 
drug effects do not occur and the hyperthyroid state is controlled.  As noted above, 2106 
adverse reactions typically occur within the first few months of therapy. 2107 
 2108 
[Q] If radioactive iodine is chosen as treatment for GD in children, how should it be 2109 
accomplished? 2110 
[Q1] Preparation of pediatric patients with GD for RAI therapy 2111 
■ RECOMMENDATION 68 2112 
We suggest that children with GD having total T4 levels of >20 ug/dL (260 nmol/L) or 2113 
free T4 >5 ng/dL (60 pmol/L) who are to receive RAI therapy be pretreated with MMI 2114 
and beta-adrenergic blockade until total T4 and/or free T4 normalize before proceeding 2115 
with RAI treatment. Weak recommendation, low-quality evidence. 2116 
 Although the frequency of short-term worsening of hyperthyroidism following 2117 
pretreatment with ATD therapy is not known, there are rare reports of pediatric patients 2118 
with severe hyperthyroidism who have developed thyroid storm after receiving RAI 2119 
(347,348).  2120 
 Technical remarks: When children receiving MMI are to be treated with RAI, the 2121 
medication should be stopped 2-3 days before treatment (349). At that time patients 2122 
should be placed on beta-blockers (if not already taking) until total T4 and/or free T4 2123 
levels normalize following RAI therapy, which generally takes 2-4 months. Although 2124 
some physicians restart ATDs after treatment with RAI (80), this practice is seldom 2125 
required in children (309,310,350). Thyroid hormone levels in children begin to fall 2126 
within the first week following RAI therapy. ATDs can complicate assessment of post-2127 
treatment hypothyroidism, since it could be the result of the MMI rather than the RAI 2128 
therapy. 2129 
[Q2] Administration of RAI in the treatment of GD in children 2130 
■ RECOMMENDATION 69 2131 
If RAI therapy is chosen as treatment for GD in children, sufficient RAI should be 2132 
administered in a single dose to render the patient hypothyroid. Strong 2133 
recommendation, moderate-quality evidence. 2134 
 The goal of RAI therapy for GD is to induce hypothyroidism, rather than 2135 
euthyroidism, as lower administered activities of RAI result in residual, partially 2136 
irradiated thyroid tissue that is at increased risk for thyroid neoplasm development (351). 2137 
Because of an increased risk of thyroid nodules and cancer associated with low-level 2138 
thyroid irradiation in children (314,352-354), and poor remission rates with low-2139 
administered activities of RAI (88-90), it is important that RAI activities >150 µCi (> 2140 
5.55 MBq/g) rather than smaller activities of RAI be administered to achieve 2141 
hypothyroidism (312). With large glands (50–80 g), RAI activities of 131I 200–300 µCi/g 2142 
(7.4-11.1 MBq/g) may be needed (349). The administered activity of RAI to patients with 2143 
very large goiters is high, and there is a tendency to underestimate the size of the gland 2144 
(and thereby administer insufficient RAI activities to these patients) (90). Therefore, 2145 
surgery may be preferable to RAI in children with goiters larger than 80 g. 2146 
 Physicians at some centers administer a fixed dose of about 15 mCi RAI to all 2147 
children (350), whereas others calculate the activity from estimation or direct 2148 
measurement of gland size and 123I uptake (349). To assess thyroid size, particularly in 2149 
the setting of a large gland, ultrasonography is recommended (355). There are no data 2150 
comparing outcomes of fixed versus calculated activities in children; in adults, similar 2151 
outcomes have been reported with the two approaches (356). One potential advantage of 2152 
calculated versus fixed dosing is that it may be possible to use lower administered 2153 
activities of RAI, especially when uptake is high and the thyroid is small. Calculated 2154 
dosing also will help assure that an adequate administered activity is given. 2155 
 When RAI activities >150 µCi/g (>5.55 MBq/g) are administered, 2156 
hypothyroidism rates are about 95% (88,339,349). While there are reports that 2157 
hyperthyroidism can relapse in pediatric patients rendered hypothyroid with RAI, this is 2158 
very infrequent. 2159 
 Technical remarks: RAI is excreted by saliva, urine, perspiration, tears, and 2160 
stool. Significant radioactivity is retained within the thyroid for several days. It is 2161 
therefore important that patients and families be informed of and adhere to local radiation 2162 
safety recommendations following RAI therapy. After RAI therapy, T3, T4, and/or free T4 2163 
levels should be obtained every month. Because TSH levels may remain suppressed for 2164 
several months after correction of the hyperthyroid state, TSH determinations may not be 2165 
useful in this setting for assessing hypothyroidism. Hypothyroidism typically develops by 2166 
2–3 months post-treatment (333,349,350), at which time levothyroxine should be 2167 
prescribed. 2168 
[Q3] Side-effects of RAI therapy in children 2169 
 Side effects of RAI therapy in children are uncommon apart from the lifelong 2170 
hypothyroidism that is the goal of therapy.  Fewer than 10% of children complain of mild 2171 
tenderness over the thyroid in the first week after therapy; it can be treated effectively 2172 
with acetaminophen or nonsteroidal antiinflammatory agents for 24–48 hours (310,349). 2173 
 If there is residual thyroid tissue in young children after RAI treatment, there is a 2174 
theoretical risk of development of thyroid cancer. Detractors of the use of RAI therapy in 2175 
children point to the increased rates of thyroid cancer and thyroid nodules observed in 2176 
young children exposed to radiation from nuclear fallout at Hiroshima or after the 2177 
Chernobyl nuclear reactor explosion. However, these data do not apply directly when 2178 
assessing risks of RAI therapy. The risk of thyroid neoplasia is greatest with exposure to 2179 
low-level external radiation (0.1–25 Gy; ~ 0.09–30 µCi/g or 3.33-1110 Bq/g) 2180 
(314,315,352,354,357), not with the higher administered activities used to treat GD. It is 2181 
also important to note that iodine deficiency and exposure to radionuclides other than 2182 
RAI may have contributed to the increased risk of thyroid cancer in young children after 2183 
the Chernobyl reactor explosion (315). Notably, thyroid cancer rates were not increased 2184 
among 3,000 children exposed to RAI from the Hanford nuclear reactor site in an iodine-2185 
replete region (358). Increased thyroid cancer rates also were not seen in 6,000 children 2186 
who received RAI for the purpose of diagnostic scanning (359). 2187 
 There is no evidence to suggest that children or adults treated for GD with more 2188 
than 150 µCi/g (5.55 MBq/g) of RAI have an increased risk of thyroid cancer directly 2189 
attributable to RAI. While there are several studies of this issue in adults treated with RAI 2190 
for GD (see section [D2]), few studies have focused on populations exposed to RAI for 2191 
the treatment of GD in childhood or adolescence. 2192 
 In one study, an analysis was carried out of 602 individuals exposed to RAI below 2193 
20 years of age in Swedish and U.S. populations (360). The average follow-up period 2194 
was 10 years, and the mean administered activity of RAI to the thyroid was 88 Gy 2195 
(approximately 80 µCi/g or 2.96 MBq/g equivalent), an activity known to be associated 2196 
with thyroid neoplasia and below that recommended for treatment of GD. Two cases of 2197 
thyroid cancer were reported compared to 0.1 cases expected over that period of time. 2198 
Effects on the development of nonthyroid cancers were not examined. 2199 
 The pediatric study with the longest follow-up reported 36-year outcomes of 116 2200 
patients, treated with RAI between 1953 and 1973 (100). The patients ranged in age at 2201 
treatment from 3 to 19 years. No patient developed thyroid cancer or leukemia. There 2202 
was no increase in the rate of spontaneous abortion or in the number of congenital 2203 
anomalies in offspring. It is important to note that sample size was small; thus, the 2204 
statistical power was inadequate to address this issue fully. 2205 
 Total body radiation dose after RAI varies with age, and the same absolute 2206 
activities of RAI will result in more radiation exposure to a young child than to an 2207 
adolescent or adult (361). At present, we do not have dosimetry information regarding 2208 
RAI use in children with GD to assess total body exposure in children. Using phantom 2209 
modeling, it has been estimated that at 0, 1, 5, 10, and 15 years of age, and adulthood, 2210 
respective total body radiation activities are 11.1, 4.6, 2.4, 1.45, 0.90, and 0.85 rem (1 2211 
rem = 0.1 Sv) per mCi of RAI administered (361). Based on the Biological Effects of 2212 
Ionizing Radiation Committee VII analysis of acute, low-level radiation exposure (362) , 2213 
the theoretical lifetime attributable risk of all-cancer incidence and all-cancer mortality 2214 
for a large population of treated children can be estimated (Table 9). 2215 
 To date, long-term studies of children treated with RAI for GD have not revealed 2216 
an increased risk of nonthyroid malignancies. If a small risk exists, a sample size of more 2217 
than 10,000 children who were treated at <10 years of age would be needed to identify 2218 
the risk, likely exceeding the number of such treated children. Based on cancer risk 2219 
projections from estimated whole-body, low-level radiation exposure as related to age, it 2220 
is theoretically possible that there may be a low risk of malignancies in very young 2221 
children treated with RAI. Thus, we recommended above that RAI therapy be avoided in 2222 
very young children (<5 years) and that RAI be considered in those children between 5 2223 
and 10 years of age when the required activity for treatment is <10 mCi (<370 MBq). It is 2224 
important to emphasize that these recommendations are based on theoretical concerns 2225 
and further direct study of this issue is needed. The theoretical risks of RAI use must 2226 
therefore be weighed against the known risks inherent in thyroidectomy or prolonged 2227 
ATD use when choosing among the three different treatment options for GD in the 2228 
pediatric age group. 2229 
 The activity of RAI administered should be based on thyroid size and uptake, and 2230 
not arbitrarily reduced because of age in young individuals. Attempts to minimize the 2231 
RAI activity will result in undertreatment and the possible need for additional RAI 2232 
therapy and radiation exposure. 2233 
 2234 
[R] If thyroidectomy is chosen as treatment for GD in children, how should it be 2235 
accomplished? 2236 
[R1] Preparation of children with GD for thyroidectomy 2237 
■ RECOMMENDATION 70 2238 
Children with GD undergoing thyroidectomy should be rendered euthyroid with the 2239 
use of MMI. A potassium iodide containing preparation should be given in the 2240 
immediate preoperative period. Strong recommendation, low-quality evidence. 2241 
 Surgery is an acceptable form of therapy for GD in children. Thyroidectomy is the 2242 
preferred treatment for GD in young children (<5 years) when definitive therapy is 2243 
required, and the surgery can be performed by a high-volume thyroid surgeon. In 2244 
individuals with large thyroid glands (>80 g), the response to RAI may be poor (88,90) 2245 
and surgery also may be preferable for these patients. When performed, near-total or total 2246 
thyroidectomy is the recommended procedure (363). 2247 
 Technical remarks: MMI is typically given for 1–2 months in preparation for 2248 
thyroidectomy. Potassium iodide (50 mg iodide/drop) can be given as 1-2 drops (i.e., 2249 
0.05–0.1 mL) three times daily for 10 days before surgery.  SSKI can be mixed in juice or 2250 
milk. 2251 
■ RECOMMENDATION 71 2252 
If surgery is chosen as therapy for GD in children, total or near-total thyroidectomy 2253 
should be performed. Strong recommendation, moderate-quality evidence. 2254 
■ RECOMMENDATION 72 2255 
Thyroidectomy in children should be performed by high-volume thyroid surgeons. 2256 
Strong recommendation, moderately-quality evidence. 2257 
 Surgical complication rates are higher in children than in adults, with higher rates 2258 
in younger than in older children (316,318). Postoperatively, younger children also 2259 
appear to be at higher risk for transient hypoparathyroidism than adolescents or adults 2260 
(316,318).   2261 
 Post-operative hypocalcemia requiring intravenous calcium infusions appears to 2262 
occur more frequently than in in adults.  Data from one center suggests that if calcitriol is 2263 
started three days before surgery (0.25 or 0.5 mcg, bid), the need for post-operative 2264 
calcium infusions is markedly reduced, leading to reduction in the length of stay (318).  2265 
The calcitriol is then weaned over the first two post-operative weeks (318). 2266 
 In addition, complication rates are twofold higher when thyroidectomy is 2267 
performed by pediatric or general surgeons who do not have extensive current experience 2268 
in this procedure than when performed by high-volume thyroid surgeons (316). Further 2269 
support for the notion that thyroidectomy for GD in children should be performed by 2270 
experienced thyroid surgeons comes from reports of institutional experience showing low 2271 
complication rates at high-volume centers (318,364). In circumstances where local 2272 
pediatric thyroid surgery expertise is not available, referral of a child with GD to a high-2273 
volume thyroid surgery center that also has pediatric experience is indicated, especially 2274 
for young children. A multidisciplinary health-care team that includes pediatric 2275 
endocrinologists and experienced thyroid surgeons and anesthesiologists is optimal. 2276 
 2277 
[S] How should subclinical hyperthyroidism (SH) be managed? 2278 
[S1] Prevalence and causes of SH 2279 
 The prevalence of SH in an adult population depends on age, gender, and iodine 2280 
intake.  In a representative sample of U.S. subjects without known thyroid disease, 0.7% 2281 
had suppressed TSH levels (< 0.1 mU/L), and 1.8% had low TSH levels (< 0.4 mU/L) 2282 
(365).  Similar rates have been reported in studies from Europe, with higher levels in 2283 
women and older subjects (366,367).  The differential diagnosis of an isolated low or 2284 
suppressed TSH level includes exogenous thyroid hormone use, nonthyroidal illness, 2285 
drug effects, and pituitary/hypothalamic disease, all of which need to be ruled out before 2286 
the diagnosis of SH can be established in a patient with an isolated low or suppressed 2287 
TSH level.  In addition, mean serum TSH levels are lower in black non-Hispanic 2288 
Americans, some of whom may have slightly low TSH levels without thyroid disease 2289 
(365).  Finally, some otherwise healthy older persons may have low serum TSH levels, 2290 
low normal serum levels of free T4 and total T3, and no evidence of thyroid or pituitary 2291 
disease, suggesting an altered set point of the pituitary-thyroid axis (368,369). 2292 
 The natural history of SH is variable (367,370-377), with annualized rates of 0.5 – 2293 
7% progression to overt hyperthyroidism and 5 – 12% reversion to normal TSH levels.  2294 
In one study (372), 51.2% of patients had spontaneously developed a normal TSH when 2295 
first checked at some time within 5 years (mean time to repeat TSH 13 months).  2296 
Progression from SH to overt hyperthyroidism appears more likely if the TSH is 2297 
suppressed (< 0.01 mU/L), rather than low but detectable (0.01 – 0.4 mU/L) (375-377).  2298 
Patients with GD rather than a TMNG as the cause of SH may be more likely to 2299 
spontaneously remit (367,378).  In patients at high risk of complications from SH, TSH 2300 
and free T4 should be repeated within 2-6 weeks.  For all other patients, it is important to 2301 
document that SH is a persistent problem by repeating the serum TSH at 3-6 months, 2302 
prior to initiating therapy. In clinical series, TMNG is the most common cause of SH, 2303 
especially in older persons (367,376,377).  The second most common cause of SH is GD, 2304 
which is more prevalent in younger persons, and is also common in patients who 2305 
previously received ATD therapy.  Other unusual causes include solitary autonomously 2306 
functioning nodules, and various forms of thyroiditis, the latter of which would be more 2307 
strictly termed ‘‘subclinical thyrotoxicosis.’’ 2308 
[S2] Clinical significance of SH 2309 
 Since SH is a mild form of hyperthyroidism, it is not surprising that deleterious 2310 
effects seen in overt hyperthyroidism might also occur in SH.  There have been a large 2311 
number of recent studies elucidating these effects: 2312 
1. Overall mortality.  A number of longitudinal studies have examined correlations 2313 
between SH and overall mortality, with variable results.  Some studies report 2314 
increased overall mortality rates in SH subjects (374,379-383), especially older 2315 
subjects, while others indicate no relation (384-387).  Limitations of some of 2316 
these studies include sample sizes, age ranges, length of follow-up, and diagnosis 2317 
of SH by a single TSH measurement.  A recent meta-analysis of individual-level 2318 
data from 52,674 participants, pooled from 10 cohorts and providing greater 2319 
power, concluded that SH confers a 24% increased risk of overall mortality 2320 
(388). 2321 
2. Cardiovascular disease.  A recent large study of 26,707 people followed for 12 2322 
years reported increased cardiovascular mortality with SH (389).  Some other, 2323 
smaller studies have reached similar conclusions (374,383), although other 2324 
smaller studies have failed to find a correlation (380,381,384,386).  There have 2325 
been two recent meta-analyses that examined this question, one of study-level 2326 
data of 17 cohorts (390) and the other of individual-level data in 52,674 2327 
participants (388).  Both analyses concluded that SH confers an increased risk of 2328 
cardiovascular mortality, with hazard ratios of 1.52 (390) and 1.29 (388).  In the 2329 
individual-level meta-analysis, relative risks did not differ based on age, gender, 2330 
pre-existing cardiovascular disease, or the presence of cardiovascular risk 2331 
factors.  However, the risk was greater in subjects with TSH levels < 0.1 2332 
compared to those with TSH levels 0.1 – 0.4 mU/L. 2333 
 Some of these studies, including the meta-analyses, have also examined 2334 
non-fatal cardiovascular events in SH, with similar increased risks 2335 
(383,388,390,391).  The most recent data indicate that SH subjects appear to be at 2336 
particular risk for the development of heart failure (381,388,392), especially older 2337 
subjects (381,392) and those with lower TSH levels (392).  Mechanistic correlates 2338 
of these findings include increased left ventricular (LV) mass and impaired LV 2339 
function in SH that improve with treatment (393-396).  In addition, two studies 2340 
have shown impaired glucose tolerance and decreased insulin sensitivity in SH, 2341 
suggesting this may contribute to increased cardiovascular risk (397,398). 2342 
 Arrhythmias are another concern in SH.  Sawin et al first reported a 2.8-2343 
fold increased risk of atrial fibrillation in SH subjects over age 60 years in 1994 2344 
(399), and subsequent studies have confirmed that the risk of arrhythmias, 2345 
particularly atrial fibrillation, is increased in SH (381,384,388,391,400,401). In 2346 
the largest study to date (586,460 people followed for a median of 5.5 years), the 2347 
highest relative risk for atrial fibrillation occurred in younger subjects, possibly 2348 
because other causes predominate with age, and in subjects with lower TSH levels 2349 
(401).  However, absolute incidence rates of atrial fibrillation were much lower in 2350 
younger subjects:  for example, women under the age of 65 years had atrial 2351 
fibrillation incidence rates of 2.3 events per 1,000 person-years (relative risk of 2352 
1.89 compared to age-matched euthyroid women), while women 65 years and 2353 
older had incidence rates of 22.7 per 1,000 person-years (relative risk of 1.27 2354 
compared to age-matched euthyroid women).  Similar trends were seen for men.  2355 
A further population-based study found that SH increased the risk for stroke in 2356 
subjects over age 50 years with a hazard ratio of 3.39 (402), although a recent 2357 
meta-analysis of stroke risk in SH found insufficient number of events to draw 2358 
definitive conclusions (403).  Complementing these epidemiologic studies, 2359 
investigations of smaller numbers of subjects with SH have revealed increased 2360 
heart rate at rest and during exercise, decreased heart rate variability, and 2361 
increased frequency of atrial and ventricular premature beats, which improve with 2362 
treatment of SH (393,394,404,405).   2363 
 Taken together, these data provide a strong argument for the treatment of 2364 
SH in older subjects to avoid dysrhythmias and possible subsequent stroke.  2365 
Whether younger patients should be treated for the same preventive indications is 2366 
less clear.  The most recent data provide evidence that relative risks of 2367 
cardiovascular mortality and atrial fibrillation are elevated in younger, as well as 2368 
older, patients with SH.  However, the absolute risks of these events are very low 2369 
in younger patients, so the risk/benefit ratio of treating younger SH patients is not 2370 
clear. Clinical judgement should be used in these cases, and treatment decisions 2371 
individualized. 2372 
3. Osteoporosis and fractures.  Most studies of endogenous SH show decreased 2373 
bone mineral density in post-menopausal women, but not in men or pre-2374 
menopausal women (406).  However, it is not clear that this translates to 2375 
increased fracture risk.  A number of population-based studies have reported that 2376 
certain groups of subjects with SH have increased fracture rates, including all 2377 
adults (407), postmenopausal women (408), men (409), or subjects who progress 2378 
to overt hyperthyroidism over time (391).  The most recent and by far the largest 2379 
individual study to date (231,355 people) reported a hazard rate for all major 2380 
osteoporotic fractures combined (hip, humerus, forearm, spine) of 1.13 2381 
(confidence intervals 1.014-1.26).  Risk increased with duration of SH, such that 2382 
after a median follow-up of 7.5 years, 13.5% of subjects with a low TSH level 2383 
had experienced at least one major osteoporotic fracture, compared to 6.9% of 2384 
subjects with a normal TSH level (407).    Other studies have not found increased 2385 
fracture rates in SH subjects (410-412).  A recent participant-level meta-analysis 2386 
of 13 cohorts (70,298 participants, median follow-up of 12.1 years) concluded 2387 
that SH subjects had significantly elevated hazard ratios of 1.36 for hip fractures 2388 
(6 vs. 4.9 fractures per 1,000 person-years) and 1.28 for any fractures (14.4 vs 2389 
11.2 fractures per 1,000 person-years) (413).  Risks were further increased if 2390 
TSH levels were < 0.1, compared to 0.1 – 0.44 mU/L, and if SH was due to 2391 
endogenous etiologies, rather than thyroid hormone administration.  Risks did 2392 
not differ when stratified by age, although absolute fracture rates were lower in 2393 
younger subjects.  There are smaller, nonrandomized trials that have shown 2394 
improvement in bone mineral density with therapy of SH with antithyroid drugs 2395 
or radioactive iodine (414-417).   2396 
4. Mood and cognition.  A large body of literature has investigated possible 2397 
correlations between SH and cognitive decline (reviewed in (418), more recent 2398 
studies (419,420)).  Approximately equal numbers of studies report significant 2399 
associations between SH and measures of cognitive decline and the development 2400 
of dementia, vs. no associations.  Therefore, at this time, no conclusions 2401 
regarding this issue can be reached.  There appears to be no correlation between 2402 
SH and depression (421-423). 2403 
5. Physical functioning.  Four studies have investigated whether SH is 2404 
associated with self-reported functional capacity or objective measures of 2405 
physical functioning (420,423-425).  Three could find no correlation, while the 2406 
fourth found a correlation between SH and lower physical performance in men 2407 
only (425).   Another uncontrolled study showed an increase in muscle mass and 2408 
muscle strength in middle-aged women with SH after treatment with RAI or 2409 
thyroidectomy (426).  2410 
  [S3] When to treat SH 2411 
■ RECOMMENDATION 73 2412 
When TSH is persistently <0.1 mU/L, treatment of SH is recommended in all 2413 
individuals ≥ 65 years of age; in patients with cardiac risk factors, heart disease or 2414 
osteoporosis; in postmenopausal women who are not on estrogens or bisphosphonates; 2415 
and in individuals with hyperthyroid symptoms. Strong recommendation, moderate-2416 
quality evidence. 2417 
■ RECOMMENDATION 74 2418 
When TSH is persistently < 0.1 mU/L, treatment of SH should be considered in 2419 
asymptomatic individuals < 65 years of age without the risk factors listed in 2420 
recommendation 73.  Weak recommendation, moderate-quality evidence. 2421 
 Treatment of SH is controversial, since few intervention studies to show benefit 2422 
have been performed, especially for clinically important endpoints such as cardiovascular 2423 
events, atrial fibrillation, and fractures. Additionally, none of these studies included a 2424 
control arm.  Thus the evidence rests only with small uncontrolled studies that have 2425 
shown improvements in cardiac structure and function, heart rate and the frequency of 2426 
premature atrial and ventricular beats, bone mineral density, and muscle strength (393-2427 
396,405,414-417,426). In 2004, a panel of experts determined that the evidence for 2428 
benefit was sufficient to warrant therapy of SH in older individuals whose serum TSH 2429 
level was <0.1 mU/L (427). This was based primarily on the studies showing an 2430 
increased rate of atrial fibrillation and altered skeletal health with a suppressed level of 2431 
TSH described above.  Emerging epidemiologic data since then on risks for overall and 2432 
cardiovascular-specific mortality, summarized above, have strengthened this argument, 2433 
even in the absence of interventional data. The European Thyroid Association recently 2434 
reviewed these data and published guidelines for the treatment of subclinical 2435 
hyperthyroidism which are largely concordant with recommendations presented here 2436 
(428). 2437 
 There are insufficient data for or against treatment of SH in younger persons or 2438 
premenopausal women with SH and serum TSH <0.1 mU/L. One uncontrolled study of 2439 
middle-aged patients showed an improvement in hyperthyroid symptoms with therapy 2440 
(393). Although this study did not include younger individuals, the task force elected to 2441 
recommend treatment of SH patients younger than 65 years of age with persistent TSH 2442 
<0.1 mU/L and hyperthyroid symptoms.  In the absence of symptoms or risk factors, 2443 
treatment decisions must be individualized.  2444 
 Technical remarks: A TSH level of <0.1 mU/L on repeated measurement over a 2445 
3–6-month period is considered to be persistent, effectively ruling out transient thyroiditis 2446 
as a cause. The thyroid disorder underlying SH should be diagnosed, and is most 2447 
commonly TMNG, GD, or TA. 2448 
■ RECOMMENDATION 75 2449 
When TSH is persistently below the lower limit of normal but ≥ 0.1 mU/L, treatment 2450 
of SH should be considered in individuals ≥ 65 years of age and in patients with 2451 
cardiac disease, osteoporosis, or symptoms of hyperthyroidism.  Weak 2452 
recommendation, moderate-quality evidence. 2453 
■ RECOMMENDATION 76 2454 
When TSH is persistently below the lower limit of normal but ≥ 0.1 mU/L, 2455 
asymptomatic patients under age 65 without cardiac disease or osteoporosis can be 2456 
observed without further investigation of the etiology of the subnormal TSH or 2457 
treatment.  Weak recommendation, low-quality evidence. 2458 
 A number of the epidemiologic studies listed above performed analyses for SH 2459 
subjects with low but detectable TSH levels (generally 0.1 to 0.4 mU/L).  Some of these 2460 
studies reported increased risks of overall mortality in older subjects (380,429), 2461 
cardiovascular events (391), heart failure (381), and atrial fibrillation in all subjects (401) 2462 
or in older subjects (384), and vertebral fractures in older women (408). However, there 2463 
are no interventional data for or against treatment of individuals with serum TSH levels 2464 
between 0.1 and the lower limit of the reference range. Therefore, treatment decisions 2465 
must be individualized, based on the limited epidemiologic evidence and patient risk 2466 
factors.  The task force felt that the limited data are stronger for older subjects, and 2467 
therefore treatment should be considered for older subjects, but is not recommended for 2468 
subjects < 65 years of age.  However, younger subjects should be monitored at regular 6-2469 
12 month intervals, and treatment should be considered if the TSH persistently decreases 2470 
to < 0.1 mU/L.  In patients with symptoms of hyperthyroidism, a trial of beta-adrenergic 2471 
blockers may be useful to determine whether symptomatic therapy might suffice. 2472 
 Technical remarks: A TSH level between 0.1 and 0.4 mU/L on repeated 2473 
measurement over a 3–6-month period is considered persistent, effectively ruling out 2474 
transient thyroiditis as a cause. The thyroid disorder underlying SH with TSH persistently 2475 
within this range should be diagnosed before considering treatment to avoid treating 2476 
patients with transient, functional disorders related to acute illness, drugs, and other 2477 
causes of low TSH. A summary of factors to consider when deciding whether or not to 2478 
treat a patient with SH is provided (Table 10). 2479 
[S4] How to treat SH 2480 
■ RECOMMENDATION 77 2481 
If SH is to be treated, the treatment should be based on the etiology of the thyroid 2482 
dysfunction and follow the same principles as outlined for the treatment of overt 2483 
hyperthyroidism. Strong recommendation, low-quality evidence. 2484 
 The treatment of SH is similar to the treatment of overt hyperthyroidism.  2485 
• RAI is appropriate for most patients, especially in older patients when TMNG 2486 
is a frequent cause of SH. There are no data to inform whether elderly patients 2487 
with SH would benefit from pretreatment with ATDs to normalize thyroid 2488 
function before RAI therapy. Given the low risk of exacerbation (71), the risks 2489 
of ATD therapy may outweigh any potential small benefit.  2490 
• A course of ATD therapy is a reasonable alternative to RAI in patients with 2491 
GD and SH, especially in younger patients, since remission rates are highest 2492 
in persons with mild disease (109).  2493 
• Some patients with SH due to GD may remit spontaneously without therapy 2494 
(375-377), so that continued observation without therapy is reasonable for 2495 
younger patients with SH due to GD. A small subset of elderly patients with 2496 
persistently low TSH and no evidence of true thyroid dysfunction can be 2497 
followed without intervention, especially when the serum free T4 and total T3 2498 
levels are in the lower half of the normal range. Treatment with beta-2499 
adrenergic blockade may be sufficient to control the cardiovascular-related 2500 
morbidity from SH, especially that of atrial fibrillation (430). 2501 
 Technical remarks: Some patients with SH due to mild GD may remit 2502 
spontaneously and may be followed without therapy with frequent (every 3-6 months) 2503 
monitoring of thyroid function. In select patients with SH due to TMNG who have 2504 
compressive symptoms, or in whom there is concern for malignancy, surgery is also an 2505 
option. 2506 
[S5] End points to be assessed to determine effective therapy of SH 2507 
 The goal of therapy for SH is to render the patient euthyroid with a normal TSH. 2508 
Since the rationale for therapy of SH is to a large degree preventive, there are few end 2509 
points that can be used to document that therapy has been successful.    Based on the 2510 
original indication for treatment, it is reasonable to follow hyperthyroid symptoms or 2511 
bone density (393,414-416); otherwise, the major end point is a TSH level within the age-2512 
adjusted reference range. 2513 
 2514 
[T] How should hyperthyroidism in pregnancy be managed? 2515 
 Normal pregnancy leads to changes in thyroid physiology that are reflected by 2516 
altered thyroid function testing. In early pregnancy, these changes can mimic biochemical 2517 
hyperthyroidism that does not require therapy (431). Hyperthyroidism due to GD occurs 2518 
in 0.5-1.0 % of women in the reproductive age range (432), and 0.1-0.2 % of them are 2519 
treated with ATD during pregnancy (433,434). Both the thyrotoxicosis and therapy of the 2520 
disease may seriously complicate the course and outcome of pregnancy. In these 2521 
guidelines, we will address only the most common issues related to hyperthyroidism in 2522 
pregnancy, pending full guidelines on thyroid disease and pregnancy that are currently 2523 
being updated by the ATA. 2524 
[T1] Diagnosis of hyperthyroidism in pregnancy 2525 
■ RECOMMENDATION 78 2526 
The diagnosis of hyperthyroidism in pregnancy should be made using serum TSH 2527 
values, and either total T4 and T3 with total T4 and T3 reference ranges increasing to 2528 
1.5 times above the nonpregnant range by the 2nd and 3rd trimester or free T4 and total 2529 
T3 estimations with trimester-specific normal reference ranges. Strong 2530 
recommendation, low-quality evidence. 2531 
 The diagnosis of hyperthyroidism in pregnancy can be challenging. In the vast 2532 
majority of patients, the disease is caused by a primary thyroid abnormality, and the 2533 
principal finding will be a suppressed serum TSH, with serum free T4  (or total T4) and/or 2534 
T3 levels above the reference range (overt hyperthyroidism), or within the reference range 2535 
(SH). A key point is that reference ranges for thyroid function tests are different during 2536 
different stages of pregnancy, and these changes may be assay-dependent.  2537 
 An understanding of pregnancy-related variations in thyroid function tests is 2538 
important in making the diagnosis of hyperthyroidism in pregnancy. Serum TSH levels 2539 
may be below the non-pregnant reference range in the first half of a normal-term 2540 
pregnancy (435,436), and especially so in gestational weeks 9-13, where a subset of 2541 
pregnant women may develop suppressed serum TSH (437-439). The decrease in TSH in 2542 
early pregnancy is the result of stimulation of the normal thyroid by high levels of serum 2543 
human chorionic gonadotropin (hCG) (440), and occasionally the biochemical findings 2544 
developing may correspond to overt thyrotoxicosis (gestational hyperthyroidism 2545 
discussed below). However, low serum TSH levels with normal free T4 (or total T4) in 2546 
early pregnancy do not indicate disease in need of therapy. During the second half of 2547 
pregnancy, the lower limit of normal for TSH in the non-pregnant population can be used 2548 
(441). 2549 
 Free T4 and T3 measured in an equilibrium dialysate or an ultrafiltrate of serum 2550 
around week 10 of pregnancy may be slightly higher (5–10%) than non-pregnancy 2551 
values, corresponding to the period of high serum hCG and low serum TSH. From 2552 
normal or slightly elevated levels, a gradual decrease occurs during pregnancy, and late 2553 
third trimester reference values are 10–30% below non-pregnancy values (442). 2554 
 Serum total T4 and T3 increase in parallel in early pregnancy, primarily due to 2555 
increases in TBG. In one longitudinal study, the increase in T4 and T3 reference ranges 2556 
were observed to occur at a rate of 5% of non-pregnant values per week over the 10 week 2557 
period of gestation weeks 7-16 (443). After this 50% increase, total T4 and T3 values 2558 
remain stable with reference range limits 1.5 times above non-pregnancy ranges over the 2559 
remaining weeks of pregnancy (442,443). Total T4 and T3 values may be combined with 2560 
a T3 uptake test or measurements of TBG to adjust for pregnancy-associated variations in 2561 
TBG. Such ‘‘free T4 index’’ or ‘‘TBG adjusted T4’’ values may be useful for diagnosing 2562 
hyperthyroidism in pregnancy, however, trimester-specific normal reference ranges 2563 
should be established for each individual test and assay used. In the absence of these, 2564 
consideration should be given to utilizing total T4 and T3 levels and multiply the non-2565 
pregnancy reference range by 1.5 after week 16, as discussed above.  2566 
 Excluding patients with TSH suppression or gestational thyrotoxicosis 2567 
during the first trimester, GD is the most common cause of hyperthyroidism during 2568 
pregnancy (431,444); nodular thyroid disease is less common. Hyperthyroidism caused 2569 
by a hCG-producing molar pregnancy or a choriocarcinoma presents with a diffuse 2570 
hyperactive thyroid similar to GD, but without eye signs and without TRAb being 2571 
detectable in serum. In these patients, serum hCG will be higher than expected, and the 2572 
cause can be identified by obstetrical investigation. 2573 
 Technical remarks: The reliability of automated analog-based assays for free T4 2574 
and free T3 has been questioned for more than 25 years (445), but these estimates are 2575 
currently widely used because of their suitability for large scale automatic analyses 2576 
within short time periods. In many clinics, they are the standard of measurement in 2577 
pregnancy. Because pregnancy may influence results of these assays from different 2578 
manufacturers in different ways, and in some assays give spuriously low results (446), 2579 
method-specific reference ranges for each trimester of pregnancy should be used and 2580 
provided by the manufacturer (447,448). If trimester specific references for free T4 (and 2581 
free T3) are not provided, and total T4 (and T3) assays are not locally available, samples 2582 
for thyroid function testing in pregnancy should be send to a reference laboratory.  2583 
[T2] Management of hyperthyroidism in pregnancy 2584 
 Table 11 provides a summary of the recommendations concerning management of 2585 
GD during pregnancy. 2586 
■ RECOMMENDATION 79 2587 
Transient hCG-mediated TSH suppression in early pregnancy should not be treated 2588 
with antithyroid drug therapy. Strong recommendation, low-quality evidence. 2589 
 Once the diagnosis of hyperthyroidism is made in a pregnant woman, attention 2590 
should focus on determining the etiology and whether it warrants treatment. Clinical 2591 
features that indicate the presence of hyperthyroidism include failure to gain weight, heat 2592 
intolerance, excessive sweating, and tachycardia, beyond that normally associated with 2593 
pregnancy. 2594 
 The two most common types of biochemical hyperthyroidism that occur during 2595 
pregnancy are gestational hyperthyroidism (e.g., hCG-mediated transient TSH 2596 
suppression) and GD. Gestational hyperthyroidism is a generally asymptomatic, mild and 2597 
self-limiting biochemical hyperthyroidism that may be observed in the first trimester of 2598 
normal pregnancy. The disorder lacks the characteristics of Graves’ disease (431), and is 2599 
presumably caused by the high serum hCG of early pregnancy (440). It is not associated 2600 
with adverse pregnancy outcomes (449). More severe degrees of gestational 2601 
hyperthyroidism are associated with hyperemesis; affected women may develop 2602 
biochemically overt hyperthyroidism and clinical symptoms and signs of 2603 
hyperthyroidism. Complicated cases of gestational hyperthyroidism should be referred to 2604 
medical centers with expertise in treating these patients. 2605 
 Technical remarks: There is no evidence that treatment of gestational 2606 
hyperthyroidism with ATDs is beneficial and use of ATD in early pregnancy has been 2607 
associated with an increase in risk of birth defects. In these patients, physical examination 2608 
and repeat thyroid function tests at intervals of 3–4 weeks is recommended. In the case of 2609 
very symptomatic disease, a trial of beta blocker therapy (propranolol or metroprolol, but 2610 
not atenolol (450,451)) for this transient disorder may be considered. 2611 
■ RECOMMENDATION 80 2612 
ATD therapy should be used for overt hyperthyroidism due to GD during pregnancy. 2613 
PTU should be used when ATD therapy is given during the first trimester. MMI 2614 
should be used when ATD therapy is started after the first trimester. Strong 2615 
recommendation, low-quality evidence. 2616 
 Untreated or insufficiently treated hyperthyroidism may seriously complicate 2617 
pregnancy (452-454), and patients with this disorder should be treated at centers with 2618 
specific expertise in this area. GD as the cause of hyperthyroidism in pregnancy may be 2619 
diagnosed from typical clinical findings, including the presence of GO and/or serum 2620 
TRAb in a hyperthyroid patient. Approximately 5% of patients with newly diagnosed 2621 
Graves’ hyperthyroidism are TRAb negative in older assays (47,455), and 3% are 2622 
negative in third generation assays (57), especially those with milder disease. 2623 
 A small increase in incidence of GD was found in early pregnancy in one study 2624 
(456), and this fits the clinical observation that existing GD may occasionally worsen in 2625 
early pregnancy (457). On the other hand, the incidence of GD drops dramatically in late 2626 
pregnancy (456), which is consistent with the notion that thyroid autoimmunity improves 2627 
in the second half of pregnancy (458).  2628 
 Women who were treated with ATDs for GD and considered in remission after 2629 
such previous therapy, and become pregnant, have a small risk of recurrence and should 2630 
have their thyroid function tested in early pregnancy. In contrast, the risk of relapse (as 2631 
well as the risk of thyrotoxicosis from postpartum destructive thyroiditis) during the 2632 
postpartum period is relatively high (459), and it remains elevated for more than one year 2633 
(456).  2634 
 ATDs have much the same effect on thyroid function in pregnant as in non-2635 
pregnant women. Both ATDs and TRAb pass the placenta and can affect the fetal 2636 
thyroid. On the other hand, T4 and T3 cross the placenta only in limited amounts, because 2637 
of degradation by high deiodinase type 3 activities in the placenta (460). 2638 
 PTU generally has been preferred in pregnancy because of concerns about well-2639 
documented teratogenicity associated with MMI, first described in 1972 (461). Defects 2640 
that may be observed in 2-4 % of exposed children (462,463) have included aplasia cutis, 2641 
choanal atresia, esophageal and other types of gut atresias, abdominal wall abnormalities 2642 
including omphalocale, eye, heart, and urinary tract malformations. Moreover, typical 2643 
facial features of MMI-exposed children have been described in case reports (464). In a 2644 
US study, 31 % of women who had received MMI around the time of conception had 2645 
elective termination of pregnancy versus 9 % of those who received PTU, and it was 2646 
hypothesized that fear of MMI associated birth defects had led to the decision to 2647 
terminate pregnancy (465).  2648 
 Recently, an increase in the rate of birth defects (2.3 % above the background 2649 
rate) was also observed after PTU exposure in early pregnancy (463), but these defects 2650 
tended to be less severe than with MMI and included preauricular sinuses and cysts and 2651 
urinary tract abnormalities (466). In a large group of children selected because they had 2652 
major birth defects and had been exposed to some type of medication in early pregnancy, 2653 
children exposed to PTU had a significantly higher frequency of situs inversus and 2654 
cardiac outflow abnormalities than children exposed to other drugs (467), but these types 2655 
of defects have not been observed in excess in studies comparing PTU exposed children 2656 
with non-selected control children. Similar to other teratogenic drugs (468) the period of 2657 
highest risk for birth defects from ATDs is gestational weeks 6-10 (469). 2658 
 Concerns about rare but potentially fatal PTU-related hepatotoxicity have led The 2659 
U.S. Food and Drug Administration to recommended that PTU be reserved for patients 2660 
who are in their first trimester of pregnancy, or who are allergic to or intolerant of MMI 2661 
(157,470)  2662 
 MMI and PTU both appear in breast milk in only small concentrations and studies 2663 
of breast-fed infants of mothers taking ATDs have demonstrated normal thyroid function 2664 
and subsequent normal intellectual development (109). However, because of the potential 2665 
for hepatic necrosis in either mother or child from maternal PTU use, MMI is the 2666 
preferred ATD in nursing mothers. 2667 
 As discussed in other sections of these guidelines, small doses of beta-adrenergic 2668 
blocking agents are in general useful to reduce pulse rate and the hyperadrenergic 2669 
symptoms of thyrotoxicosis during the time period from start of ATD therapy until the 2670 
patient has become euthyroid. These agents have been studied extensively when used for 2671 
treating hypertension in pregnancy, and no major side-effects have been detected, 2672 
although fetal growth restriction has been associated with the prolonged use of especially 2673 
atenolol (431,471). Therapy with propranolol (e.g. 10-20 mg every eight hour) or 2674 
metopolol (e.g. 100 mg once daily) are useful and can be considered safe for short 2675 
periods of time to relieve symptoms in pregnant women suffering from thyrotoxicosis. 2676 
■ RECOMMENDATION 81 2677 
In women who develop hyperthyroidism during their reproductive age range, the 2678 
possibility and timing of future pregnancy should be discussed. Because of the risks of 2679 
the hyperthyroid state on pregnancy and fetal outcome, we suggest that women should 2680 
postpone pregnancy until they have become euthyroid with therapy. Strong 2681 
recommendation, low-quality evidence. 2682 
 Both maternal thyroid dysfunction and therapy of the hyperthyroidism may have 2683 
negative effects on the pregnancy outcome. These factors should all be considered when 2684 
determining the choice of therapy for the patient who is currently pregnant, or in the 2685 
future may become pregnant.  2686 
 A single set of thyroid function tests within the reference range may not guarantee 2687 
euthyroidism for more than a short period during the early phase of hyperthyroidism 2688 
therapy. Two sets of tests within the reference range, taken with an interval of at least one 2689 
month and without a change of therapy is preferable to indicate euthyroidism.  2690 
■ RECOMMENDATION 82 2691 
We suggest that women with hyperthyroidism caused by GD that require high doses of 2692 
ATDs to achieve euthyroidism should be considered for definitive therapy before they 2693 
become pregnant. Weak recommendation, low-quality evidence. 2694 
 Both thyroidectomy and RAI therapy are useful for rendering patients with GD 2695 
permanently hypothyroid with the possibility of a stable euthyroid state on thyroid 2696 
hormone replacement therapy, as discussed in these guidelines. Thyroidectomy is often 2697 
followed by a decrease or disappearance of TRAb from circulation, whereas RAI is 2698 
often followed by a transient increase in TRAb. This is a potential argument in favor of 2699 
surgical thyroidectomy in women with high TRAb titers that may become pregnant 2700 
within the years to come, especially those planning therapy within the next year (172). 2701 
However, the importance of this difference in autoimmune activity for pregnancy 2702 
outcome has not been studied, and it should be weighed against the other benefits and 2703 
harms of surgery and RAI therapy. 2704 
 To predict reduction in TRAb after surgical thyroidectomy, a recent retrospective 2705 
Japanese study of 45 (41 female) patients with high TRAb (median 64 IU/L, range 5.6-2706 
400, normal for assay < 1.9 IU/L) may be useful. Patients were followed for 12 months. 2707 
Smoking and the presence of orbitopathy predicted slow disappearance of TRAb (half-2708 
life 162 days, or 357 days if both factors were present), whereas TRAb levels in serum 2709 
decreased with a half-life of 94 days in the remaining patients (472). 2710 
 Medical tradition and experience with different types of therapy for GD varies 2711 
between countries and clinics, and the risk of relapse of hyperthyroidism after ATD 2712 
withdrawal may differ considerably, depending on iodine intake, and other factors that 2713 
are only partly understood (473). Thus, advice given to women with GD on therapy in 2714 
relation to a possible future pregnancy may differ. However, irrespective of such 2715 
differences, the physician providing care to a young woman with newly diagnosed GD, 2716 
should include discussion and guidance on GD and pregnancy. The severely hyperthyroid 2717 
patient may not be in a position to fully comprehend many simultaneous messages, and a 2718 
more detailed discussion may be appropriate when the patient has become euthyroid.   2719 
■ RECOMMENDATION 83 2720 
Women with hyperthyroidism caused by GD who are well controlled on MMI and 2721 
desire pregnancy have several options: 2722 
   a) Patients could consider definitive therapy before they become pregnant. 2723 
   b) Patients could switch to PTU before trying to conceive. 2724 
   c) Patients could switch to PTU as soon as pregnancy is diagnosed. 2725 
   d) Appropriately selected patients could withdraw from ATD therapy as soon as 2726 
pregnancy is diagnosed. If ATD therapy is withdrawn, thyroid function should be 2727 
assessed weekly throughout the first trimester, then monthly. Weak 2728 
recommendation, low-quality evidence. 2729 
 The evidence is insufficient to give universal guidance on how to choose among 2730 
these options, and therefore the potential risks and benefits of each option should be 2731 
discussed with the patient, and patient values and preferences should be taken into 2732 
account.   2733 
 Each option is presented in depth in the following technical remarks:  2734 
  A. Definitive therapy before becoming pregnant. 2735 
 This strategy is discussed in Recommendation 82.  It has the advantage of 2736 
allowing the patient to become pregnant free of worry from the adverse fetal effects of 2737 
ATDs. The disadvantage is that the patient will require levothyroxine therapy while 2738 
pregnant and lifelong, and will be exposed to either the potential complications of RAI, 2739 
including worsening or induction of Graves’ orbitopathy, or the potential for undesirable 2740 
surgical outcomes.  2741 
 2742 
B. Switching from MMI to PTU before pregnancy. 2743 
 Switching from MMI to PTU before conception would eliminate the risk from 2744 
early pregnancy exposure to MMI in women where pregnancy is not recognized within 2745 
the first few weeks after conception. MMI associated birth defects occur in 2-4 % of 2746 
children exposed in early pregnancy, and abnormalities may be severe. PTU associated 2747 
birth defects are less well documented. They may occur in 2-3 % of children but they 2748 
seem to be mostly less severe. PTU is associated with liver failure with an estimated 2749 
1:10,000 risk of severe liver failure in adult patients (136). Thus, mothers must balance 2750 
the risk of PTU to themselves vs. the risk to the child. Switching to PTU before 2751 
conception may be preferred in younger women with regular menses who are expected 2752 
to be able to conceive within 1 to 3 months. In a German prospective study of 340 such 2753 
women, 68 % became pregnant within 3 months (474). 2754 
 A special variant is women who have hyperthyroidism diagnosed at a time when 2755 
they hope to become pregnant soon. There are not sufficient data to recommend for or 2756 
against starting therapy with PTU and thus bypass a phase of MMI therapy in such 2757 
patients.   2758 
C. Switching from MMI to PTU after conception. 2759 
 Alternatively, the patient may continue MMI therapy but be prepared to detect 2760 
pregnancy very early and modify therapy immediately as recommended below. 2761 
Switching to PTU as soon as pregnancy is diagnosed may be preferred in older women 2762 
and women who have conditions that may be associated with delayed conception. This 2763 
strategy may prevent prolonged use of PTU prior to conception but has the risk of fetal 2764 
exposure to MMI if the diagnosis of pregnancy is delayed. 2765 
D. Withdrawing ATD treatment after conception.  2766 
 Women with a stable euthyroid state on 5-10 mg MMI per day achieved within a 2767 
few months, and a falling TRAb level are likely candidates to withdraw from ATD 2768 
therapy in early pregnancy. 2769 
 No study has directly addressed the risk of relapse of hyperthyroidism after ATD 2770 
withdrawal in early pregnancy, and evidence comes from controlled or cohort studies of 2771 
non-pregnant patients who had been treated with ATD for varying periods before drug 2772 
withdrawal. Based on the latter studies, the risk of relapse of hyperthyroidism within a 2773 
two month interval after ATD withdrawal in TRAb negative, non-smoking patients who 2774 
have already been treated for 12-24 months is <10 % (167,475).  2775 
 On the other hand, the risk of early relapse is very high in patients who have 2776 
received ATD for less than six months, and/or still have indicators of high disease 2777 
activity such as low serum TSH, high TRAb level, signs of active GO, or need of MMI 2778 
dose in excess of 5-10 mg per day to remain euthyroid (473). 2779 
 If ATD withdrawal is followed by a relapse of hyperthyroidism, this will often 2780 
develop gradually over some weeks, but exact information on such time course in early 2781 
pregnancy is not available. This is the reason for the recommendation of frequent thyroid 2782 
function testing during the remaining 1st trimester of pregnancy, until more data on safety 2783 
becomes available. 2784 
 A subset of women with GD will experience relapse of hyperthyroidism in 2785 
pregnancy if ATD therapy is withdrawn according to recommendation 81. Frequent 2786 
testing of thyroid function will allow early detection of such relapse and initiation of 2787 
therapy with PTU (or MMI if relapse occurs in the second trimester) to keep the 2788 
mother euthyroid. The risk to the mother from such hyperthyroidism is considered 2789 
negligible. 2790 
 Considering the fetus, two recent studies performed in Japan suggest that such 2791 
transient and mild maternal hyperthyroidism will not increase the risk of malformations. 2792 
One study observed a significantly lower risk of birth defects in mothers who had been 2793 
shifted from MMI to iodine therapy in early pregnancy, even if part of the mothers in the 2794 
iodine group had developed biochemical hyperthyroidism and needed retreatment with 2795 
ATD (476). In another study from the same institution, the presence of a major birth 2796 
defect was associated with the use of MMI in early pregnancy, but not with maternal 2797 
thyroid dysfunction (462). 2798 
 A more pertinent risk may be fetal loss caused by maternal hyperthyroidism in 2799 
pregnancy (477,478). However, the risk from a brief period of mild maternal thyroid 2800 
hyperfunction in early pregnancy may be low or absent. In a large cohort of pregnant 2801 
women from the USA, low or suppressed serum TSH in early pregnancy (presumably 2802 
mostly caused by early pregnancy high hCG levels) was not associated with adverse 2803 
pregnancy outcomes (449). In the recent retrospective Japanese study of women with GD 2804 
either treated with MMI in early pregnancy or shifted from MMI to iodine therapy in 2805 
early pregnancy, there was no increase in fetal loss in the iodine group despite more cases 2806 
of maternal hyperthyroidism in this group (476).  2807 
■ RECOMMENDATION 84 2808 
We suggest that women who are treated with ATD and who may potentially become 2809 
pregnant should be instructed to perform a pregnancy test within the first days after a 2810 
missed or unusually light menstrual period. Weak recommendation, low-quality 2811 
evidence. 2812 
 The period of major risk of birth defects caused by intake of medication in 2813 
pregnancy is gestational weeks 6-10 (468), and a study of time of exposure to ATD and 2814 
risk of defects suggests this is also the major period of teratogenic effects of ATD (469). 2815 
Thus, withdrawal of ATD therapy  before week five of pregnancy may theoretically 2816 
prevent birth defects caused by ATD exposure.  2817 
 The week of pregnancy is calculated starting from the first day of the last normal 2818 
menstrual period, with conception taking place about two weeks after this. The first real 2819 
sign of pregnancy appears two weeks later, and it is a missed or unusually light menstrual 2820 
period. By this time, blood and urine concentrations of hCG have started to rise and 2821 
generally available pregnancy tests based on detection of hCG in urine normally become 2822 
positive early in gestational week five. Very early testing for pregnancy to allow 2823 
medication withdrawal before the major period of teratogenecity is recommended for 2824 
other types of drugs that may be teratogenic (479). 2825 
■ RECOMMENDATION 85 2826 
We suggest that a woman who tests positive for pregnancy according to 2827 
recommendation 84 contact the physician responsible for the ATD therapy within 24 2828 
hours  to discuss future treatment options. Weak recommendation, low-quality 2829 
evidence. 2830 
 The time window that will allow medication withdrawal or change in early 2831 
pregnancy to prevent birth defects is narrow (468,469), probably confined to gestational 2832 
week 5. Thus, pregnancy should be detected early and action has to be taken 2833 
immediately.  2834 
■ RECOMMENDATION 86 2835 
We suggest that the physician contacted according to recommendation 85 evaluate 2836 
whether ATD withdrawal in the first trimester of pregnancy is likely to cause relapse 2837 
of hyperthyroidism or not. Evaluation should be based on patient records, especially 2838 
the severity of GD at time of diagnosis and current disease activity, duration of ATD 2839 
therapy, current ATD dose requirement, and results of recent thyroid function and 2840 
TRAb testing. If risk of relapse is considered low, therapy can be withdrawn, and 2841 
followed by weekly thyroid function testing during the 1st trimester.  Weak 2842 
recommendation, low-quality evidence. 2843 
 In the majority of patients with GD, ATD therapy is followed by a gradual 2844 
remission of disease with a possibility of disappearance of TRAb from circulation (172). 2845 
When patients have been treated with ATD for 12-18 months a rapid relapse of 2846 
hyperthyroidism after ATD withdrawal becomes less likely (119), even if the frequency 2847 
of relapse may be in the order of 50 % within one year. The risk of relapse after ATD 2848 
withdrawal varies considerably among individual patients and it depends on a variety of 2849 
factors (473), as discussed in detail above.  2850 
■ RECOMMENDATION 87 2851 
We suggest that women in early pregnancy who have a high risk of recurrent or 2852 
worsening hyperthyroidism if ATD is withdrawn be shifted from MMI to PTU 2853 
immediately after diagnosing pregnancy. Weak recommendation, low-quality 2854 
evidence. 2855 
 Even if birth defects may occur after both MMI and PTU exposure in early 2856 
pregnancy (463), defects after MMI exposure are better documented. The reason for this 2857 
seems to be that MMI associated defects are more severe, whereas PTU associated 2858 
defects tend to be less severe and may not be diagnosed immediately after birth (466). 2859 
 Both MMI and PTU are effective therapies of hyperthyroidism in the majority of 2860 
patients and the major effect of both drugs is to interact with thyroid peroxidase catalyzed 2861 
thyroid hormone production (109). Apart from the differences in side-effects discussed 2862 
above, it is important to consider differences in potency per mg drug and in duration of 2863 
effect. 2864 
 A dosage ratio of MMI to PTU of 1:20 is recommended when changing from one 2865 
drug to another (115,319,480), although only two studies have examined this dosage ratio 2866 
directly (115,319). Moreover, the difference in duration of effect should be taken into 2867 
account. For example, 15 mg of MMI would be roughly equivalent to 300 mg of PTU, 2868 
but because the half-life of PTU is considerably shorter than that of MMI, the dose of 2869 
PTU should be split over the day (481,482), e.g. MMI 15 mg once daily may be 2870 
substituted with PTU 100 mg three times a day (319).  2871 
■ RECOMMENDATION 88 2872 
Women taking PTU during the 1st trimester of pregnancy according to 2873 
recommendations 80, 83 or 87 may be switched to MMI at the beginning of the 2nd 2874 
trimester, or they may continue PTU therapy for the remaining part of pregnancy if 2875 
ATD is needed. No Recommendation, insufficient evidence to assess benefits and 2876 
risks. 2877 
 The reason for the FDA black box warning against PTU therapy after the 1st 2878 
trimester of pregnancy is the risk of PTU associated liver failure. However, even if this 2879 
risk is real, the absolute risk observed in studies of US health databases was low 2880 
(433,465). Similarly, a recent Danish national registry study observed one case of 2881 
reversible liver failure among 1,103 women treated with PTU in pregnancy (129).  2882 
 The risk of side effects from PTU should be weighed against the risk of the shift 2883 
from PTU to MMI inducing a transient thyroid function abnormality in the pregnant 2884 
woman who is well controlled on PTU therapy. Starting from the 2nd trimester of 2885 
pregnancy, women with GD may start entering gradual remission of the autoimmune 2886 
abnormality, and full focus should be on the feasibility of ATD dose reduction to protect 2887 
the fetus against goiter and hypothyroidism, as discussed below. Patients who remain on 2888 
PTU during the 2nd and 3rd trimesters could have hepatic enzymes measured at the same 2889 
time that thyroid function is assessed. However, no prospective data show that this type 2890 
of monitoring is effective in preventing fulminant PTU-related hepatotoxicity. Another 2891 
aspect to consider is that both agranulocytosis and liver failure developing during MMI 2892 
and PTU therapy mostly occur during the initial three months of therapy (128), but this 2893 
risk can recur when the drug is reintroduced after a relatively long period of time (177). 2894 
For example, in a Japanese study (177) of 14 patients who developed agranulocytosis 2895 
after retreatment with the same ATD, no patient developed this adverse reaction who 2896 
restarted the drug less than 5 months after stopping the previous course of therapy. There 2897 
are no data to directly evaluate how shifting from PTU to MMI in the 2nd trimester of 2898 
pregnancy will affect the risk of these severe, but rare side effects.  2899 
Other medical treatments for hyperthyroidism during pregnancy 2900 
 Other types of medical therapy have been used to treat hyperthyroidism, such as 2901 
iodine, perchlorate, cholestyramine, cholecystographic agents, and lithium.  2902 
 Iodine in supraphysiological doses has multiple mostly inhibitory effects on the 2903 
thyroid, and it has with some success been used to treat hyperthyroid women in 2904 
pregnancy in Japan. In one study, cord and maternal sera were tested at delivery in 35 2905 
patients with GD treated with iodine (6-40 mg daily) initiated at 11-37 weeks of 2906 
gestation. Similar to ATD therapy, thyroid function at term tended to be lower in the 2907 
fetus than in the mother, but overall results of therapy were judged satisfactory, with a 2908 
low risk of inducing hypothyroidism and goiter in the fetus; only 1 of 35 neonates had 2909 
subclinical hypothyroidism at birth (483). In a recent study, outcomes of pregnancy 2910 
were retrospectively compared in 1,333 women who had continued ATD in early 2911 
pregnancy with 283 women who had shifted from ATD to iodine (median gestational 2912 
week of shift was week 6 (range 4-12)) (476). Overall, shifting had been more common 2913 
in recent years. The prevalence of major birth defects was lower in the women who had 2914 
shifted to iodine therapy (1.53 % versus 4.14 %, p<0.05). However, according to the 2915 
authors, some degree of hyperthyroidism was relatively common after shifting, and free 2916 
T4 levels were always higher in the group that had shifted to iodine. Despite this, live 2917 
births were more common in the group that had shifted than in the group that had 2918 
continued MMI therapy (91.9 % versus 85.1 %, p< 0.05). In the publication, data on 2919 
thyroid function in the MMI group are sparse, but the study may indicate that a brief 2920 
period of mild hyperthyroidism in the mother will not impair pregnancy.  2921 
 No recent data on iodine therapy for GD in pregnancy are available from outside 2922 
Japan, but before ATDs became available, experience with iodine therapy for GD in 2923 
general was extensive (484), and it corresponds to the more recent Japanese studies. The 2924 
minimal effective dose of iodine was around 6 mg day but most patients received higher 2925 
doses, iodine was effective for therapy of hyperthyroidism in patients with mild GD, but 2926 
clearly less effective than ATD in patients with more severe disease (484). Additional 2927 
data are needed before iodine therapy of pregnant women with GD can be generally 2928 
recommended.  2929 
 Perchlorate is a competitive inhibitor of iodine uptake by the thyroid, and a few 2930 
cases have been published where it was used in pregnancy (485). Apparently, 2931 
teratogenicity of perchlorate has not been demonstrated (486), but more clinical studies 2932 
on this are clearly needed. Further, this drug is not available in the United States.  2933 
 Cholestyramine binds thyroid hormones in the gut during their entero-hepatic 2934 
recirculation and has been used to treat hyperthyroidism, mostly in combination with 2935 
other drugs (487,488). Cholestyramine is not absorbed from the gut and it is not expected 2936 
to affect the fetus directly. However, binding in the gut and excretion of vitamins and 2937 
other substances of importance for pregnancy is a concern, and has led to a note of 2938 
caution by the US Food and Drug Administration. Cholecystographic drugs are not 2939 
generally available any more. Lithium may be teratogenic (489) and it should not be used 2940 
to treat hyperthyroidism in pregnancy. 2941 
    2942 
■ RECOMMENDATION 89 2943 
GD during pregnancy should be treated with the lowest possible dose of ATD needed 2944 
to keep the mother’s thyroid hormone levels at or slightly above the reference range 2945 
for total T4 and T3 values in pregnancy (1.5 times above non-pregnant reference 2946 
ranges in the 2nd and 3rd trimester), and the TSH below the reference range for 2947 
pregnancy. Similarly, free T4 levels should be kept at or slightly above the upper limit 2948 
of the pregnancy trimester reference range for the assay. Thyroid function should be 2949 
assessed at least monthly, and the ATD dose adjusted, as required. Strong 2950 
recommendation, low-quality evidence. 2951 
 Even if the mother is euthyroid during ATD therapy, there is a risk of inducing 2952 
fetal hypothyroidism and goiter during the second and third trimesters when the fetal 2953 
thyroid has begun to function (490,491). Thus, the dose of ATD should be kept as low as 2954 
possible. Block-replacement therapy consisting of ATD plus levothyroxine should not be 2955 
used in pregnancy. If a woman receiving such therapy becomes pregnant, and she is still 2956 
in need of ATD therapy, the regimen should be changed to an ATD alone (444). 2957 
 Technical remarks: Free T4 is the parameter that has been most closely correlated 2958 
with good fetal outcome. Serum TSH may still be suppressed in these patients and should 2959 
not be used as the sole guide in treatment, although normalization of maternal TSH 2960 
during ATD therapy may indicate a need to reduce the dose of ATD (444). In Japanese 2961 
studies, ATD treated maternal free T4 values had been kept above the non-pregnancy 2962 
reference range in the last part of pregnancy to avoid cases of elevated TSH in newborn 2963 
cord blood (458,491). However, with some automated free T4 assays non-pregnancy free 2964 
T4 is much higher than late pregnancy free T4 (446,492). Thus, maternal free T4 above the 2965 
non-pregnancy reference with suppressed TSH may leave the mother overtly 2966 
hyperthyroid, which is not recommended. 2967 
 Although many patients with GD may enter remission of the autoimmune 2968 
abnormality during the 2nd half of pregnancy with a need of ATD dose reduction or 2969 
withdrawal, this is not a universal phenomenon. A small group of patients suffers from 2970 
severe disease that may even progress during pregnancy, with difficult to treat 2971 
hyperthyroidism, high TRAb levels and often a considerable goiter with high blood flow. 2972 
Such patients may show a ‘high T3 - low T4 pattern’ during ATD therapy (444) 2973 
presumably caused by a high type 1 deiodinase activity in the hyperactive thyroid (493), 2974 
and preferential T3 synthesis in the hyperstimulated thyroid made iodine deficient from 2975 
ATD therapy (494). Maternal thyroid function should be monitored frequently and non-2976 
invasive assessment of fetal thyroid function (e.g. fetal heart rate, bone maturity, 2977 
and fetal goiter on ultrasound), and ATD therapy balanced to keep acceptable thyroid 2978 
function in both the mother and the fetus (444).  2979 
  ■ RECOMMENDATION 90 2980 
Pregnancy is a relative contraindication to thyroidectomy and should only be used 2981 
when medical management has been unsuccessful or ATDs cannot be used. Strong 2982 
recommendation, low-quality evidence. 2983 
 In a population based US study, pregnant women had worse clinical and 2984 
economic outcomes following thyroid (and parathyroid) surgery than non-pregnant 2985 
women, with disparities in outcomes based on race, insurance, and access to high-volume 2986 
surgeons (68). 2987 
■ RECOMMENDATION 91 2988 
 When thyroidectomy is necessary for the treatment of hyperthyroidism during 2989 
pregnancy, the surgery should be performed if possible during the second trimester. 2990 
Strong recommendation, low-quality evidence. 2991 
 Thyroidectomy is best avoided in the first and third trimesters of pregnancy 2992 
because of teratogenic effects associated with anesthetic agents and increased risk of fetal 2993 
loss in the first trimester and increased risk of preterm labor in the third. Optimally, 2994 
thyroidectomy would be performed in the latter portion of the second trimester. Although 2995 
it is the safest time, it is not without risk (4.5–5.5% risk of preterm labor) (67,68). 2996 
Evaluation by a high-risk obstetrician is advised along with counseling before surgery 2997 
regarding risks involved (68). Thyroidectomy cures the hyperthyroidism and is often 2998 
followed by a gradual reduction in circulating TRAb (495). Until such remission takes 2999 
place, TRAb produced by the mother may stimulate the thyroid of the fetus or newborn 3000 
and induce hyperthyroidism. In the setting where the mother still harbors TRAb after 3001 
thyroidectomy, close fetal monitoring for both cardiovascular and skeletal changes with 3002 
fetal ultrasound is essential. 3003 
  There are no data concerning whether SSKI or iodine should be used to prepare 3004 
pregnant patients for thyroidectomy. The risk of iodide therapy to the fetus relates to 3005 
inhibition of iodine organification via the Wolff-Chaikoff effect. The fetal thyroid gland 3006 
is particularly susceptible to the inhibitory effects of excess iodine in the second half of 3007 
gestation, and fetal goiter can occur with chronic therapy (496). However, there is no 3008 
evidence that brief iodine preparation of the mother done preoperatively to reduce thyroid 3009 
blood flow and control hyperthyroidism is harmful to the fetus. 3010 
 Technical remarks: In patients with difficult to treat hyperthyroidism, 3011 
preoperative preparation for thyroidectomy during the second trimester of pregnancy 3012 
includes 10 days of iodine (e.g., SSKI 1 drop three times a day), along with ATD therapy 3013 
and beta-blockers (propranolol  or metroprolol, but not atenolol (450,451)) to control 3014 
hyperthyroidism (497-499). In euthyroid patients with no signs of high thyroid activity, 3015 
but who are offered surgical thyroidectomy for other reasons, e.g. intolerance to ATD, 3016 
the use of iodine for surgical preparation is considered unnecessary.  3017 
[T3] The role of TRAb levels measurement in pregnancy 3018 
■ RECOMMENDATION 92 3019 
TRAb levels should be measured when the etiology of hyperthyroidism in pregnancy 3020 
is uncertain. Strong recommendation, low-quality evidence. 3021 
 The two best indicators of the activity of GD during pregnancy are thyroid 3022 
function in the untreated patient and measurement of TRAb levels in the serum. TRAb 3023 
measurement is useful in the diagnosis of GD in pregnant women with newly diagnosed 3024 
hyperthyroidism who do not have clinical signs specific for GD, keeping in mind that the 3025 
diagnostic sensitivity of good assays is around 95%, and the specificity is 99% (47). 3026 
■ RECOMMENDATION 93 3027 
 Patients who were treated with RAI or thyroidectomy for GD prior to pregnancy 3028 
should have TRAb levels measured using a sensitive assay initially during the first 3029 
trimester thyroid function testing and, if elevated, again at 18-22 weeks of gestation. 3030 
Strong recommendation, low-quality evidence. 3031 
 Measurement of TRAb levels can detect persistent TSH-receptor autoimmunity in 3032 
a pregnant woman previously treated with ablative therapy (radioactive iodine or 3033 
thyroidectomy) for GD who is now euthyroid with or without thyroid hormone 3034 
replacement (495,500). If the mother still produces TRAb, the antibodies will cross the 3035 
placenta and may affect fetal thyroid function in the last half of the pregnancy. Because 3036 
of the slow clearance of maternal immunoglobulin G (IgG) from the neonatal circulation, 3037 
thyroid dysfunction in the child may last for several months after birth. To evaluate the 3038 
risk of such complications, a TRAb level should be measured in the pregnant woman 3039 
initially during the first trimester and, if elevated, again at 18–22 weeks of gestation. If 3040 
the level is high, a program of fetal and neonatal surveillance for thyroid dysfunction 3041 
should be initiated (501).  3042 
 The advantage to initial TRAb measurement during the first trimester is that this 3043 
allows time to initiate specialty consultation and, if the levels are especially high at that 3044 
time, intervention may be required by the 2nd trimester. Whereas it has generally been 3045 
considered that isolated fetal thyrotoxicosis in a previously ablated mother who is still 3046 
producing TRAb might only start developing around weeks 20-22 of pregnancy, a recent 3047 
case report described severe fetal thyrotoxicosis that had developed already in gestational 3048 
week 18 (502). The pregnant women had previously undergone unsuccessful RAI, and 3049 
subsequently a total thyroidectomy had been performed followed by L-T4 replacement. 3050 
The mother was now euthyroid, but her TRAb values remained extremely elevated.  3051 
 TRAb measurement is not necessary in a euthyroid pregnant patient previously 3052 
found to have GD if she has an intact thyroid (i.e., not previously treated with surgery or 3053 
RAI) and she is not currently taking ATDs (495,503). 3054 
■ RECOMMENDATION 94 3055 
Patients receiving ATD for GD when becoming pregnant or found to have GD during 3056 
pregnancy should have TRAb levels measured at initial pregnancy visit or at diagnosis 3057 
using a sensitive assay and, if elevated, again at 18-22 weeks of gestation. Strong 3058 
recommendation, low-quality evidence. 3059 
 TRAb (TBII or TSI) measurement may be useful to assist in the evaluation of 3060 
disease activity in a woman being treated with ATDs for GD during pregnancy 3061 
(444,495). In many patients, GD gradually remits during pregnancy. Disappearance of 3062 
TRAb is an indication that ATD therapy may no longer be necessary, and that its 3063 
continuation may put the fetus at risk for hypothyroidism, even if the mother is euthyroid 3064 
on the medication.  3065 
■ RECOMMENDATION 95 3066 
 Patients with elevated TRAb levels at 18-22 weeks of gestation should have 3067 
TRAb remeasured in late pregnancy (weeks 30-34) to guide decisions regarding neonatal 3068 
monitoring. An exception to this is a woman with an intact thyroid who is no longer in 3069 
need of ATD therapy. Strong recommendation, low-quality evidence. 3070 
 TRAb measurement in late pregnancy can be used to assess the risk of delayed 3071 
neonatal hyperthyroidism, when the mother continues to need ATD to control 3072 
hyperthyroidism up to term. After delivery, ATD delivered to the fetus via placental 3073 
passage is rapidly metabolized by the neonate, whereas the maternal TRAb disappears 3074 
more slowly, with a half-life of around 3 weeks. Thus, a high level of TRAb in the 3075 
mother in late pregnancy is an indicator that the neonate may need to be monitored for 3076 
the onset of neonatal hyperthyroidism starting a few days after birth. In a recent study of 3077 
47 newborns to mothers who were TRAb positive in pregnancy, nine of the children had 3078 
neonatal biochemical hyperthyroidism, and five of these (9 % of all) needed ATD 3079 
therapy. All hyperthyroid neonates were born to mothers with TRAb levels ≥ 5 IU/l (> 3 3080 
times upper reference for the assay) in the 2nd trimester (sensitivity 100%, specificity 3081 
43%). All mothers who gave birth to hyperthyroid newborns required ATD therapy in 3082 
late pregnancy (504). 3083 
[T4] Postpartum thyroiditis 3084 
■ RECOMMENDATION 96 3085 
In women developing thyrotoxicosis after delivery, selective diagnostic studies should 3086 
be performed to distinguish postpartum destructive thyroiditis from postpartum GD. 3087 
Strong recommendation, low-quality evidence. 3088 
 Postpartum thyroid dysfunction occurs in up to 10% of pregnancies in the United 3089 
States. Postpartum thyroiditis is an autoimmune disorder unmasked in predisposed 3090 
women as immune surveillance rebounds after pregnancy. The classic triphasic pattern is 3091 
thyrotoxicosis at 1–6 months postpartum, followed by hypothyroidism and return to 3092 
euthyroidism at 9–12 months postpartum (505,506). However, this sequence is not 3093 
observed in every patient. Among 371 cases in 13 studies, 25% of patients were found to 3094 
have a triphasic pattern, 43% had hypothyroidism without preceding thyrotoxicosis, and 3095 
32% had thyrotoxicosis without subsequent hypothyroidism (506). In a prospective study 3096 
of pregnant women, those with positive thyroperoxidase (TPO) antibodies in the first 3097 
trimester were 27 times more likely to develop postpartum thyroiditis than were those 3098 
with negative serology (507). In this study, tobacco smoking and bottle-feeding increased 3099 
the risk of developing thyroiditis. 3100 
 Postpartum thyroiditis must be distinguished from GD to recommend proper 3101 
therapy. The postpartum surge in thyroid autoimmunity leading to postpartum thyroiditis 3102 
is also associated with a 3-4 fold increase in the incidence of GD that peaks 3-12 months 3103 
after delivery (456). In a Japanese hospital study, thyrotoxicosis caused by thyroiditis 3104 
developed earlier post-partum than GD, although some overlap existed. All patients who 3105 
developed overt thyrotoxicosis within the first three months after delivery suffered from 3106 
destructive thyroiditis, whereas GD developed after this 3 months period (508).  Goiter is 3107 
generally more pronounced in GD, and thyroid bruit or GO strongly suggest GD as well. 3108 
TRAb may occasionally be measurable in patients with postpartum thyroiditis, 3109 
suggesting that some patients may suffer from a combination of GD and destructive 3110 
thyroiditis (509), but higher TRAb values are suggestive of GD. When in vivo testing is 3111 
required to make this distinction in women who are nursing, the gamma-emitters 123-I 3112 
(half-life 13 hours) or Tc-99m- pertechnetate (half-life 6 hours) should be used rather 3113 
than the beta-emitter 131-I (half-life 8 days). The shorter half-lives of these agents (510) 3114 
will allow breast milk to be pumped and discarded for 10 half-lives (5 or 3 days 3115 
respectively) and nursing resumed, whereas breast-feeding should ideally be discontinued 3116 
3 months prior to 131-I to avoid radiation exposure to the breast, and not be resumed if 3117 
131-I is given as treatment for GD (511).  3118 
  Most often, the use of radioactive substances can be avoided and the diagnosis 3119 
can be based on a combination of clinical presentation, TRAb measurement, and 3120 
evaluation of serum T4 and T3. Thyroidal production of T3 compared with T4 is relatively 3121 
high in GD, but not in destructive thyroiditis, and T3 tends to be fractionally more 3122 
elevated above the upper reference limit than T4 in GD, whereas T4 is more elevated than 3123 
T3 in destructive thyroiditis (50). If needed, thyroid color doppler ultrasonography may 3124 
assist to distinguish between destructive thyroiditis and GD (508,512,513). 3125 
■ RECOMMENDATION 97 3126 
In women with symptomatic thyrotoxicosis from postpartum destructive thyroiditis, 3127 
the judicious use of beta-adrenergic blocking agents is recommended. Strong 3128 
recommendation, low-quality evidence. 3129 
 Treatment for postpartum thyroiditis is generally supportive in nature, with the 3130 
use of beta-adrenergic blockers such as propranolol or metroprolol to control pulse rate 3131 
and hyperadrenergic symptoms during the thyrotoxic stage (514).  The selective beta-1 3132 
adrenergic receptor-blocking agent atenolol should not be used in breast-feeding mothers 3133 
because this may lead to symptoms consistent with beta-adrenergic blockage in neonates. 3134 
This adverse effect presumably develops because atenolol is <5% bound to maternal 3135 
plasma proteins (vs. 93 % binding of propranolol), and thus accumulates in milk, and 3136 
because of low kidney excretion of atenolol in small children with immature renal 3137 
function (515).  Levothyroxine therapy may be beneficial, at least transiently, for women 3138 
with symptomatic hypothyroidism or having TSH levels >10 mU/L (506). 3139 
 Technical remarks: Because propranalol and metoprolol are secreted into breast 3140 
milk in only very low levels, no special monitoring is needed for breastfed infants of 3141 
mothers on these medications (514). 3142 
■ RECOMMENDATION 98 3143 
In pregnant women diagnosed with hyperthyroidism due to multinodular thyroid 3144 
autonomy or a solitary toxic adenoma special care should be taken not to induce fetal 3145 
hypothyroidism by ATD therapy.  Strong recommendation, low-quality evidence. 3146 
 Hyperthyroidism caused by thyroid autonomy is very common in people having 3147 
current (or previous) mild to moderate iodine deficiency (13), but it mostly develops in 3148 
patients after the age of 50 years. In the uncommon case of this type of hyperthyroidism 3149 
in a pregnant woman, pathogenic differences from GD should be considered.  3150 
 Thyroid hormone production in autonomy is dependent on iodine substrate, 3151 
but no study has addressed the effect of a change in iodine intake on thyroid 3152 
function in pregnant women with autonomy, or on the fetus.  It might be beneficial 3153 
to keep iodine intake on the low side, but care must be taken that the fetus is not 3154 
iodine deficient, especially in areas where the population is iodine deficient.  The 3155 
degree of maternal hyperthyroidism and assessment of her diet should be 3156 
considered before deciding whether to administer iodine supplements. Often the 3157 
hormone overproduction is limited in patients with autonomy (50). In mild cases there 3158 
would be a theoretical possibility that the normal pregnancy associated increase in 3159 
thyroid hormone production may catch up with the hormone production in the 3160 
autonomous areas of the thyroid, and alleviate the need for ATD therapy. On the other 3161 
hand, the high hCG levels in early pregnancy may theoretically stimulate the non-3162 
functioning normal thyroid tissue in these patients and worsen hyperthyroidism. Because 3163 
there is no TRAb production, the fetal thyroid will not be abnormally stimulated in the 3164 
second half of pregnancy as it is in GD. Thus, the fetus will not develop hyperthyroidism 3165 
in parallel with the untreated hyperthyroid mother as it happens during 2nd half of 3166 
pregnancy in GD, and neonatal hyperthyroidism is not a risk. On the other hand, the 3167 
tendency to induce fetal hypothyroidism and goiter in the 2nd half of pregnancy from 3168 
ATDs given to the mother would be even higher in this type of hyperthyroidism than in 3169 
GD. Based on this theoretical risk, surgical therapy in the 2nd trimester of pregnancy may 3170 
be considered if the hyperthyroidism turns out to require more than low dose MMI (5-10 3171 
mg per day) for control. No firm recommendations are given, because no good evidence 3172 
is available.  3173 
 3174 
[U] How should hyperthyroidism be managed in patients with Graves’ orbitopathy? 3175 
 GO is an inflammatory eye disease that develops in the orbit in association with 3176 
autoimmune thyroid disorders (516). In the majority of cases (about 90%), it occurs in 3177 
patients with current or past GD. Thyroid-associated orbitopathy, thyroid eye disease, and 3178 
Graves’ ophthalmopathy are other names used for GO. Approximately a third of patients 3179 
with Graves’ hyperthyroidism have some signs and/or symptoms of GO while only 5% 3180 
suffer from moderate-to-severe disease (517,518). In contrast to GD where women are at 3181 
higher risk, the role of gender in GO is more controversial. More recent studies do not 3182 
identify a clear gender related-risk for GO (517,518), while some older studies point to a 3183 
possible slightly increased risk for men (519,520). This variability in results might be 3184 
related to changes in smoking patterns over the years. The disease peaks in incidence in 3185 
the 5th and 6th decade of life (517,518,521,522) with a higher prevalence of severe cases 3186 
in the elderly population (517). 3187 
[U1] Assessment of disease activity and severity 3188 
 The natural history of the disease is one of rapid deterioration followed by gradual 3189 
improvement toward the baseline. This active phase is best described by the Clinical 3190 
Activity Score (CAS) (523,524), the elements of which are outlined in Table 12. The 3191 
score ranges from 0 to 10 and predicts response to anti-inflammatory therapies (523,524). 3192 
A 7-point scale, lacking the last three elements, is used when no previous assessment is 3193 
available. GO is considered active in patients with a CAS ≥ 3. However, some of the eye 3194 
changes seen in hyperthyroidism, like lid retraction or stare, are the result of the increased 3195 
sympathetic state and when present without associated eye changes are not considered to 3196 
reflect GO (69).   3197 
 The severity of the disease is best assessed using objective, quantifiable 3198 
parameters and is a useful tool for directing therapy. The main gradations of disease 3199 
severity are mild, moderate-to-severe, and sight threatening (525). Table 13 lists the 3200 
elements as agreed upon in a consensus statement by the European Group on Graves’ 3201 
Orbitopathy (EUGOGO) (525). Both activity and severity of the disease must be 3202 
considered in therapeutic decisions regarding treatment of the eye disease itself, as well 3203 
as treatment of hyperthyroidism, keeping in mind that they do not always correlate, 3204 
particularly in early and late disease. The overall evaluation and management of GO is 3205 
best done in a multidisciplinary clinic combining endocrinologists and ophthalmologists 3206 
with expertise in the condition and other specialties in consultation (e.g., ENT, radiation 3207 
therapy, plastic surgery, and endocrine surgery). 3208 
 Quality of life is clearly impaired by GO (526). The U.S. Food and Drug 3209 
Administration has endorsed QoL information as a component of any therapeutic 3210 
application. The QoL correlation with disease severity has been fair to excellent for two 3211 
GO specific instruments published to date in North American populations (527,528), 3212 
though the effect of GO therapy on these QoL scores still needs prospective data. 3213 
Presently the only instrument that has such data is the instrument extensively used in 3214 
Europe (529) that has not yet been tested in a North American population. Overall this 3215 
area is in need of more research emphasis as despite its agreed upon importance a 3216 
significant number of intervention trials in GO are still being reported without associated 3217 
QOL outcomes (530). 3218 
 In the remainder of section [U], we discuss the prevention of GO and the 3219 
management of hyperthyroidism in patients having established GO. In particular, we 3220 
focus on recommendations regarding the concurrent use of corticosteroids in patients 3221 
choosing RAI as treatment for hyperthyroidism (Table 14). 3222 
[U2] Prevention of GO 3223 
 Current therapeutic approaches to GO, including local measures, corticosteroids, 3224 
orbital radiation, and surgery (525), often fail to significantly improve the QoL of 3225 
patients with this debilitating condition. Therefore, efforts should be made to prevent the 3226 
development or progression of GO in patients with Graves’ hyperthyroidism. Identified 3227 
risk factors for GO are listed in Table 15 and most pertinent to this discussion are RAI 3228 
therapy for hyperthyroidism (531,532), untreated hyperthyroidism, smoking, high serum 3229 
pretreatment TRAb levels (normal < 1.75 IU/L, high risk for progression if  > 8.8 3230 
IU/Liter) (533), and any delay in treating hypothyroidism after therapy for 3231 
hyperthyroidism  (106,534). High pretreatment levels of T3 and T4 were each reported 3232 
to have a predictive role in GO but these conclusions were not validated by subsequent 3233 
studies (69,106,532,534) suggesting the possibility of higher TRAb values, measured on 3234 
less sensitive assays early-on, being partly responsible for this variation. 3235 
■ RECOMMENDATION 99 3236 
Euthyroidism should be expeditiously achieved and maintained in hyperthyroid 3237 
patients with GO or risk factors for the development of orbitopathy. Strong 3238 
recommendation, moderate-quality evidence. 3239 
 A number of studies have suggested that development of persistent, untreated 3240 
hypothyroidism after therapy for hyperthyroidism plays a detrimental role in the 3241 
progression of GO. An early study noted that patients who were either hypo- or 3242 
hyperthyroid had more severe GO than euthyroid patients (535). Subsequently, two 3243 
cohort studies in which patients received levothyroxine therapy early after RAI with the 3244 
specific intent of preventing hypothyroidism noted that deterioration of GO rarely 3245 
occurred (0%–2%) (534,536). A randomized study of newly diagnosed GD found that 3246 
RAI, followed by active prevention of hypothyroidism by administration of thyroid 3247 
hormone 2 weeks later, did not increase the risk of worsening GO compared to therapy 3248 
with MMI (RR of 0.95) (69). 3249 
■ RECOMMENDATION 100 3250 
We recommend clinicians advise patients with GD to stop smoking and refer them to a 3251 
structured smoking cessation program. As both firsthand and secondhand smoking 3252 
increase GO risk patients exposed to secondhand smoke should be identified and 3253 
advised of its negative impact. Strong recommendation, moderate- quality 3254 
evidence. 3255 
 Smoking is the most important known risk factor for the development or 3256 
worsening of GO, unrelated to type of therapy for GO (535), and consistent data from 3257 
several studies show a detrimental effect of smoking on GO in patients treated with 3258 
RAI (69,531). The risk is proportional to the number of cigarettes smoked per day and 3259 
former smokers have significantly lower risk than current smokers, even after adjusting 3260 
for lifetime cigarette consumption (537). 3261 
 Technical remarks: Clinicians should use smoking cessation programs based on 3262 
effective and evidence-based approaches to aid in smoking cessation and avoidance of 3263 
secondhand smoke (538,539). 3264 
[U3] Treatment of hyperthyroidism in patients with no apparent GO 3265 
■ RECOMMENDATION 101 3266 
In nonsmoking patients with GD without apparent GO, RAI therapy (without 3267 
concurrent steroids), ATDs or thyroidectomy should be considered equally acceptable 3268 
therapeutic options in regard to risk of GO.  Strong recommendation, moderate-3269 
quality evidence. 3270 
 Several randomized trials have identified the risk of GO development or 3271 
progression after RAI therapy for hyperthyroidism to be between 10% and 39% (69,540). 3272 
Focusing on the risk of new GO development that risk appears to be lower. Two 3273 
randomized controlled trials found that risk to be 6/78 (8%) for RAI, compared with 1/74 3274 
(1%) for ATDs (531) in one study, and 10/32 (32%) for RAI compared with 6/56 (11%) 3275 
for ATDs and 6/58 (10%) for surgery (532) in the older study. Fortunately, the cases of 3276 
new or worse GO are usually mild with only 6/168 patients on this second trial (4 in the 3277 
RAI group, 1 in the ATD group and 1 in the surgical group) requiring specific therapy for 3278 
GO. In contrast, one prospective but nonrandomized cohort study identified no difference 3279 
among ATD, surgery, and RAI treatment, with an overall 4.9–7.1% frequency of GO 3280 
development (541). The higher risk of GO development after RAI therapy in the majority 3281 
of studies may be related to the unique increase in TRAb levels observed following this 3282 
therapy (172). Experimental evidence suggests that these antibodies are directly involved 3283 
in GO pathogenesis (516,542,543). 3284 
 There is evidence that corticosteroids given concurrently with RAI may prevent 3285 
worsening of GO in patients with mild active eye disease (531). However, there is 3286 
insufficient evidence to recommend prophylactic treatment with corticosteroids in 3287 
nonsmoking patients who do not have clinically apparent GO. The relatively low absolute 3288 
risk of nonsmokers developing new-onset severe GO suggests that GO prevention should 3289 
not be a factor in the selection of therapy for hyperthyroidism in this group of patients 3290 
(531). Table 14 details further the use of glucocorticoids for various GO clinical 3291 
scenarios. 3292 
■ RECOMMENDATION 102 3293 
In smoking patients with GD without apparent GO, RAI therapy, ATDs, or 3294 
thyroidectomy should be considered equally acceptable therapeutic options in regard 3295 
to risk of GO. Weak recommendation, low-quality evidence. 3296 
■ RECOMMENDATION 103 3297 
There is insufficient evidence to recommend for or against the use of prophylactic 3298 
corticosteroids in smokers who receive RAI and have no evidence of GO.  No 3299 
recommendation, insufficient evidence. 3300 
 However, in two different studies, active smokers who received RAI represented 3301 
the group with the highest incidence (23–40%) of new GO or deterioration of pre-3302 
existing GO during 1 year of follow-up (69,531). 3303 
[U4] Treatment of hyperthyroidism in patients with active GO of mild severity (see 3304 
Tables 12 and 13 for definitions of disease activity and severity) 3305 
■ RECOMMENDATION 104 3306 
In patients with Graves’ hyperthyroidism who have mild active ophthalmopathy and 3307 
no risk factors for deterioration of their eye disease, RAI therapy, ATDs and 3308 
thyroidectomy should be considered equally acceptable therapeutic options. Strong 3309 
recommendation, moderate-quality evidence. 3310 
■ RECOMMENDATION 105 3311 
In the absence of any strong contraindication to GC use we suggest considering them 3312 
for coverage of GD patients with mild active GO who are treated with RAI, even in 3313 
the absence of risk factors for GO deterioration. Weak recommendation, low-quality 3314 
evidence. 3315 
 Technical remarks: The decision whether or not to administer concurrent 3316 
glucocorticoids in a particular patient choosing RAI therapy should be made in light of 3317 
risk–benefit considerations (i.e., their personal risk of worsening GO, balanced against 3318 
their risk of developing glucocorticoid side effects). Risk factors for side effects of oral 3319 
corticosteroids include poorly controlled diabetes, hypertension, osteoporosis, psychiatric 3320 
disease, and predisposition to infections. Smokers in whom the risk–benefit ratio for the 3321 
concurrent use of corticosteroids is high may be better treated with ATDs or surgery. 3322 
Besides smoking, the main risk factors for deterioration of GO to be considered in this 3323 
decision include active and progressive GO over the preceding 3 months and high serum 3324 
pretreatment TRAb levels (normal < 1.75 IU/L, high risk for GO progression if >8.8 3325 
IU/Liter) (see Table 15). 3326 
 The dose of corticosteroids validated in a randomized clinical trial for GO 3327 
prophylaxis is the equivalent of prednisone 0.4–0.5 mg/kg/day, started 1–3 days after 3328 
RAI administration, continued for 1 month, and then tapered over 2 months (525). 3329 
However, a retrospective cohort study suggested that even lower doses and shorter 3330 
duration of oral prednisone (about 0.2 mg/kg/ day for 6 weeks) may be equally effective 3331 
for prevention of GO exacerbation in patients with initially mild or absent eye disease, 3332 
(544). Currently most task force members use a minimum starting dose of 30 mg 3333 
prednisone daily and tapering to off within 6-8 weeks. Table 14 details further the use of 3334 
glucocorticoids for various GO clinical scenarios. 3335 
■ RECOMMENDATION 106 3336 
In GD patients with mild GO who are treated with RAI we recommend steroid 3337 
coverage if there are concomitant risk factors for GO deterioration. Strong 3338 
recommendation, moderate-quality evidence. 3339 
 Unfortunately, the initial data regarding the impact of various GD therapies on 3340 
GO outcome were impacted by the absence of GO activity assessment and lack of 3341 
stratification on smoking status at randomization as well as by variation in the timing of 3342 
tackling post-RAI hypothyroidism. Two early nonrandomized studies found no 3343 
differences between the three GD therapeutic modalities (541,545). 3344 
  The first randomized study of GD patients (13% with mild preexistent GO) 3345 
assigned to therapy for hyperthyroidism with antithyroid drugs, surgery or RAI (532) 3346 
found the relative risk for deterioration of eye disease to be elevated at 3.2 for RAI 3347 
compared to ATDs. There appeared to be no difference in such risk between ATDs and 3348 
surgery. A more recent large randomized controlled trial studying mainly patients with 3349 
previously treated GD showed RAI therapy to be associated with an increased risk of GO 3350 
progression (RR of 5.8 in comparison with ATDs) and found the risk to be eliminated 3351 
with concurrent corticosteroid administration (531). Finally, the most recent randomized 3352 
controlled trial (69) revealed the increased risk for new or worse GO in RAI treated 3353 
patients (38.7% of the group) compared with ATD-treated patients (21.3% of the group), 3354 
to be mainly related to development of new GO cases while worsening of preexistent GO 3355 
occurred in a similar percentage in both groups (45% for RAI and 47% for ATD). 3356 
Smoking was a strong risk factor for an undesirable GO outcome. In this last trial there 3357 
was no routine use of prophylactic glucocorticoids. Table 14 details further the use of 3358 
glucocorticoids for various GO clinical scenarios. 3359 
[U5] Treatment of hyperthyroidism in patients with active and moderate-to-severe or 3360 
sight-threatening GO (see Tables 12 and 13 for definitions of disease activity and 3361 
severity) 3362 
■ RECOMMENDATION 107 3363 
In patients with active and moderate to severe or sight-threatening GO we recommend 3364 
against RAI therapy. Surgery or ATDs are preferred treatment options for GD in these 3365 
patients. Strong recommendation, low-quality evidence. 3366 
 We are aware of no trials in patients with moderate-to-severe and active eye 3367 
disease that compare hyperthyroidism therapies for impact on GO. However, a 3368 
comparison of two different surgical approaches (total thyroidectomy vs. subtotal 3369 
thyroidectomy) for patients with moderate-to-severe GO showed that the eye disease 3370 
improved over 3 years of follow-up in all patients (546). In another series of 42 patients 3371 
with progressive GO treated with total thyroidectomy, exophthalmos was stable in 60% 3372 
of cases and improved in the remainder (547), suggesting that surgery is not detrimental 3373 
to GO and may be associated with improvement in some patients. Additionally, a more 3374 
recent study suggests that surgery might lead to a more rapid improvement in GO than 3375 
ATDs and it might thus be a better option for patients that are most concerned about GO 3376 
changes (548). Other studies suggest that ATDs may not adversely impact mild active 3377 
GO, but do not address severe GO (531). 3378 
 Alternatively, if ATDs are selected for GD therapy there is reassuring data that 3379 
long term use is relatively safe and effective at preserving euthyroidism while waiting for 3380 
GO to enter remission (66,549). 3381 
 [U6] Treatment of GD in patients with inactive GO (see Table 12 for definition of 3382 
disease inactivity) 3383 
■ RECOMMENDATION 108 3384 
 In patients with inactive GO we suggest RAI therapy can be administered without 3385 
steroid coverage. However, in cases of elevated risk for reactivation (high TRAb, CAS 3386 
≥1 and smokers) that approach might have to be reconsidered. Weak 3387 
recommendation, low-quality evidence. 3388 
 There is a low rate of GO progression or reactivation following RAI in patients 3389 
with inactive GO.  A series of 72 patients with inactive GO according to the CAS were 3390 
treated with RAI without concurrent glucocorticoid administration (536). In those whom 3391 
hypothyroidism was prevented by early thyroxine therapy, no deterioration in eye disease 3392 
was reported (536). Smoking history did not impact GO outcome in this cohort. A recent 3393 
trial from Japan (540) randomized patients without GO or inactive GO (i.e. CAS<3 or 3394 
T2-weighted imaging T2SIR ≤1) to receive either glucocorticoid prophylaxis with low 3395 
dose prednisolone (on average 0.28 mg/kg/day tapered rapidly over 6 weeks) or no 3396 
prophylaxis at all. The rate of disease progression in the absence of risk factors was low 3397 
(4.2%) and not impacted by glucocorticoid therapy. The presence of risk factors for GO 3398 
(high thyroid stimulating antibody, CAS≥1) increased that risk, again without a benefit 3399 
from low-dose steroid prophylaxis. Ultimately most GO cases were mild and only 7 cases 3400 
(2.4%) required GO-directed therapy. Whether high-dose glucocorticoid therapy would 3401 
have made a difference in these patients is not known. 3402 
  Another study retrospectively examined the impact of concurrent oral or 3403 
intravenous glucocorticoid therapy on the development or deterioration of preexistent GO 3404 
after RAI therapy for relapsing GD patients (550). They identified GO development, 3405 
deterioration or reactivation in approximately 7% of patients (6/83) considered at low risk 3406 
who were given no steroid prophylaxis. Only 2 of these cases had preexistent inactive 3407 
GO. Despite prophylaxis, 33% of patients considered at high risk who were treated with 3408 
oral glucocorticoids had worsening of GO. However, because of the lack of clarity of this 3409 
retrospective study regarding prevalence of active and inactive GO in each group and the 3410 
lack of pre-specified criteria for dose and route of steroid use in those considered at risk, 3411 
we weighed this evidence less in our deliberations regarding the above recommendation. 3412 
Table 14 details further the use of glucocorticoids for various GO clinical scenarios. 3413 
 3414 
[V] How should iodine–induced and amiodarone-induced thyrotoxicosis be managed? 3415 
[V1] Iodine-induced hyperthyroidism 3416 
■ RECOMMENDATION 109 3417 
Routine administration of ATDs before iodinated contrast media exposure is not 3418 
recommended for all patients. Weak recommendation, low-quality evidence. 3419 
 Technical remarks:  Patients deemed to be at high risk of developing iodine-3420 
induced hyperthyroidism or whose cardiac status is tenuous at baseline may be 3421 
considered for prophylactic therapy with ATDs. 3422 
 Iodine-induced hyperthyroidism (the Jod-Basedow phenomenon) is uncommon in 3423 
modern series, and generally self-limited, but may occasionally persist for months 3424 
(551,552), and may be life-threatening (553-556).  Individuals most susceptible are 3425 
elderly patients with autonomously-functioning nodular goiters (557), and less 3426 
commonly, patients with occult GD (558), or patients with a prior history of GD and in 3427 
remission after a course of ATDs (559).  Very rarely, iodine excess may trigger 3428 
thyrotoxicosis in patients with a previously normal thyroid gland (560).  Chronic iodine 3429 
deficiency increases the prevalence of autonomous thyroid nodules and therefore iodine 3430 
repletion in this setting has historically been linked to iodine-induced hyperthyroidism 3431 
(561). 3432 
 Multiple observational studies have examined changes in thyroid hormone levels 3433 
following a single exposure to intravenous iodinated contrast in both iodine-sufficient 3434 
(562-565), and deficient (566-569) regions.  A study of patients living in Boston showed 3435 
that 5 of 49 (10.2%) developed a suppressed TSH value 1-4 weeks following exposure to 3436 
a single CT study with contrast, with only one patient developing overt hyperthyroidism 3437 
(565).  Additional observational studies in the United States and Japan, involving 56 and 3438 
22 patients, respectively, found no new cases of hyperthyroidism following coronary 3439 
angiography (564) or hysterosalpingography (563), whereas an Australian study from a 3440 
region of iodine sufficiency found that 2 of 72 (2.8%) of patients developed overt 3441 
hyperthyroidism and an additional 2 developed subclinical hyperthyroidism within 8 3442 
weeks of iodinated contrast exposure (562). Overall, similar rates of iodine-induced 3443 
hyperthyroidism have been described in iodine deficient regions, including a study from 3444 
Germany in which 2 of 788 (0.25%) patients developed overt hyperthyroidism following 3445 
coronary angiography (566), a New Zealand study in which subclinical hyperthyroidism 3446 
developed in 2 of 102 (2%) patients after a CT-scan with iodinated contrast (567), a study 3447 
from Italy which found that 1.9% of 1752 patients undergoing coronary angiography 3448 
developed a suppressed TSH with normal free T4 and T3 levels (568), and finally, a 3449 
Turkish study identifying new subclinical hyperthyroidism in 5.9% of 101 patients by 8 3450 
weeks following coronary angiography (569).   3451 
 A recent case-control study in the United States found that iodinated contrast 3452 
exposure in patients without baseline thyroid abnormality resulted in hyperthyroidism 3453 
(defined only as a suppressed TSH value) with an odds ratio of 1.98 (95% CI, 1.08-3.60; 3454 
P = .03), and that 23 patients would need to be exposed before encountering one case of 3455 
iodine-induced thyrotoxicosis (570). Interestingly, a recent meta-analysis including 9 3456 
randomized-controlled trials and 8 observational studies involving iodine 3457 
supplementation of young children and pregnant women in regions of mild-moderate 3458 
iodine deficiency did not find an increased risk of thyroid dysfunction following iodine 3459 
supplementation of 200-300 micrograms daily (571).   3460 
 In summary, iodine-induced hyperthyroidism is uncommon and generally 3461 
subclinical, but can occasionally be severe. For most clinical circumstances, the 3462 
likelihood of developing overt thyrotoxicosis after iodinated contrast exposure is too low 3463 
to justify the risk of adverse effects associated with prophylactic ATD therapy.  3464 
■ RECOMMENDATION 110 3465 
Beta-adrenergic blocking agents alone or in combination with MMI should be used to 3466 
treat overt iodine-induced hyperthyroidism. Strong recommendation, low-quality 3467 
evidence. 3468 
 Treatment of iodine-induced hyperthyroidism includes avoidance of additional 3469 
iodine and administration of beta-blockers alone or with ATDs, depending on the severity 3470 
of hyperthyroidism and the clinical status of the patient.  RAI is not an option until the 3471 
iodine load has been cleared and might not be desirable given the reversibility of this 3472 
condition.  Recent data suggest that urinary iodine normalizes more rapidly than 3473 
previously believed, with a return to baseline urinary iodine excretion within 1-2 months 3474 
in most patients (565,572).  3475 
 Technical remarks: Dosing of MMI for iodine-induced thyrotoxicosis is 20–40 3476 
mg daily, given either as a daily or twice-daily dosing. There may be relative resistance 3477 
to ATD in patients with iodine-induced hyperthyroidism.  Urinary iodine (a spot urine 3478 
iodine adjusted for urine creatinine concentration or a 24-hour urine iodine) may be 3479 
monitored to assess the rate of clearance of the iodine load. 3480 
[V2] Amiodarone-induced thyrotoxicosis 3481 
■ RECOMMENDATION 111 3482 
We suggest monitoring thyroid function tests before and within the first 3 months 3483 
following the initiation of amiodarone therapy, and at 3–6 month intervals thereafter. 3484 
Weak recommendation, low quality evidence. 3485 
 Amiodarone is a drug frequently used in the treatment of refractory atrial or 3486 
ventricular tachyarrhymias. Amiodarone-induced thyrotoxicosis (AIT) occurs in up to 6% 3487 
of patients taking this medication in iodine-sufficient areas of the world (573-575) and in 3488 
up to 10% in iodine-deficient areas, such as parts of Europe (576). Studies evaluating the 3489 
adequacy of monitoring for adverse effects from amiodarone have shown suboptimal 3490 
results (577,578). 3491 
         Two distinct mechanisms have been proposed in the development of AIT, 3492 
including an iodine-induced form of hyperthyroidism (type 1 AIT) due to the high 3493 
iodine content of amiodarone (37% by molecular weight), and a destructive 3494 
thyroiditis (type 2 AIT), due to direct toxicity of amiodarone on follicular cells. Type 3495 
1 AIT tends to occur in patients with underlying thyroid autonomy in a nodular 3496 
goiter, or GD, whereas type 2 AIT occurs as a result of direct damage or induction 3497 
of apoptosis in thyrocytes by amiodarone (579-582).  3498 
■ RECOMMENDATION 112 3499 
The decision to stop amiodarone in the setting of thyrotoxicosis should be determined 3500 
on an individual basis in consultation with the treating cardiologist, based on the 3501 
clinical manifestations and presence or absence of effective alternative antiarrhythmic 3502 
therapy. Strong recommendation, low-quality evidence. 3503 
 The need for amiodarone discontinuation is controversial because (i) this drug is 3504 
frequently the only medication able to control cardiac arrhythmia, (ii) the effects of this 3505 
fat soluble drug may persist for many months,  (iii) amiodarone may have T3-antagonistic 3506 
properties at the cardiac level and inhibit T4 to T3 conversion in the heart (583) , such that 3507 
withdrawal may actually aggravate cardiac manifestations of thyrotoxicosis (573). Deaths 3508 
from ventricular fibrillation have occurred after stopping amiodarone in patients with 3509 
AIT (584).  In addition, type 2 AIT typically responds to treatment even if amiodarone 3510 
therapy is continued (585-587), but continuation may lead to a more prolonged time to 3511 
recovery and a higher rate of future recurrences of AIT (588). 3512 
■ RECOMMENDATION 113 3513 
In clinically stable patients with AIT, we suggest testing to identify disorders 3514 
associated with iodine-induced hyperthyroidism (type 1 AIT), specifically including 3515 
toxic nodular disease and previously occult Graves’ disease. Strong 3516 
recommendation, low-quality evidence. 3517 
■ RECOMMENDATION 114 3518 
MMI should be used to treat overt thyrotoxicosis in patients with proven underlying 3519 
autonomous thyroid nodules or Graves’ disease as the cause of amiodarone-induced 3520 
thyrotoxicosis (type 1 disease), and corticosteroids should be used to treat patients 3521 
with overt amiodarone-induced thyroiditis (type 2 disease). Strong recommendation, 3522 
low-quality evidence. 3523 
■ RECOMMENDATION 115 3524 
Combined ATD and corticosteroid therapy should be used to treat patients with overt 3525 
amiodarone-induced thyrotoxicosis who are too unstable clinically to allow a trial of 3526 
monotherapy, or who fail to respond to single modality therapy, or patients in whom 3527 
the etiology of thyrotoxicosis cannot be unequivocally determined. Strong 3528 
recommendation, low-quality evidence. 3529 
   3530 
 As the pathogenesis of AIT is not fully understood, it is likely that the classic 3531 
division of AIT into two subtypes represents an oversimplification.  First, as discussed 3532 
further below, many patients are not readily classified into one of the two AIT subtypes. 3533 
Secondly, once classified as type 1 or type 2 AIT, patients often fail to respond to therapy 3534 
specifically directed to that subtype (583,589,590). Finally, findings of responsiveness of 3535 
type 2 AIT patients to measures not typically useful in destructive thyroiditis, such as 3536 
perchlorate (586,591) and oral cholecystographic agents (592,593), cannot be adequately 3537 
explained on the basis of the current classification system, although spontaneous 3538 
resolution independent of therapy is one possible explanation.  3539 
 A number of methods have been examined to distinguish type 1 from type 2 AIT, 3540 
but with the possible exception of Color flow Doppler study (CFDS), most are considered 3541 
unreliable (574).  For example, the T3-to-T4 ratio, which tends to be higher in patients 3542 
with autonomous thyroid glands than in those with destructive thyroiditis, is not helpful 3543 
in this instance due to amiodarone-associated inhibition of T4 monodeiodination (594).  3544 
Further, features historically used to distinguish the subtypes such as antibodies against 3545 
thyroid peroxidase and the presence of thyroid nodules in patients with type 1 AIT may 3546 
actually occur with both subtypes, given the prevalence of these abnormalities in the 3547 
general population.  Interleukin-6 levels and radioactive iodine uptake values, once 3548 
promoted as useful to distinguish between subtypes (590), actually overlap extensively 3549 
between the two subtypes and are therefore also not useful (594).  Several modern series 3550 
of patients with AIT make no attempt to classify patients into type 1 or type 2 disease 3551 
(585,595-598). 3552 
 Several studies have shown that increased vascularity on color-flow Doppler 3553 
study may be seen in patients with type 1, but not type 2 AIT (599-601). Two studies 3554 
showed a clear separation into type 1 and type 2 AIT, allowing successful application of 3555 
targeted therapy (599,600). However, CFDS is not universally useful (584,589)  In a 3556 
series of 24 cases of AIT, 12 patients were classified as type 2 due to an absence of 3557 
vascularity (CFDS 0) and treated with corticosteroids, but only 7 (58%) proved 3558 
responsive (584). Likewise, these authors found that among 11 patients classified as type 3559 
1 AIT based on CFDS scores of I-III, only 4 (36%) responded to antithyroid drug 3560 
therapy.  In another series of 30 patients with AIT requiring therapy, 10 (33%) patients 3561 
could not be subtyped on the basis of CFDS, including several patients with goiters but 3562 
normal vascular flow (589). In a series of 55 patients in whom a CFDS qualitative 3563 
assessment of vascular flow was used to distinguish type 1 from type 2 AIT, 81.3% of 3564 
patients determined to have type 1 AIT had pattern I vascularity (the lowest level above 3565 
zero), illustrating the skill and nuance needed to successfully make this distinction (599). 3566 
Among European thyroidologists surveyed on the use of diagnostic imaging in the 3567 
differential diagnosis of AIT, approximately 20% preferred RAIU alone, 20% preferred 3568 
CFDS alone, nearly 40% utilized both methods simultaneously, and 20% thought both 3569 
techniques were useless (602).  Recently sestamibi uptake by the thyroid, which is 3570 
diminished with thyroiditis, has been applied to distinguishing AIT subtypes with 3571 
preliminarily promising results (603,604). 3572 
 A recent retrospective report including 200 AIT patients found that the onset of 3573 
thyrotoxicosis was significantly earlier in type 1 (median 3.5 months, range 1-61 months) 3574 
than type 2 (median 30 months, range 1-95 months), p< 0.001 (605).  Since 80% of type 3575 
1 patients in this study had autonomous thyroid nodules or toxic MNG, it is not 3576 
unexpected that iodine-induced thyrotoxicosis occurred early in the course of amiodarone 3577 
therapy.  However, based on this data, a patient with late-onset of AIT in whom GD has 3578 
been excluded is more likely to have type 2 AIT.   Another observation reported in this 3579 
study is the development of AIT following amiodarone discontinuation.  Nineteen 3580 
percent of patients (38/200) developed AIT a mean of 5.5 months after the drug was 3581 
stopped, 36 of whom had type 2 AIT. 3582 
 Patients who are clinically stable and have definite evidence supporting a distinct 3583 
subtype of overt AIT may be tried on appropriate monotherapy. When identified with 3584 
certainty, type 1 AIT is best treated with MMI to prevent new hormone synthesis and, 3585 
rarely, with added potassium perchlorate (250 mg four times daily; not  available in the 3586 
United States) (590). Type 2 AIT is better treated with anti-inflammatory therapy such as 3587 
prednisone, with improvement occasionally seen as early as 1 week, and usually within a 3588 
few weeks (590). As noted above, some patients with mild type 2 AIT (approximately 3589 
20%) resolve spontaneously without stopping amiodarone or administering 3590 
corticosteroids (606,607).  3591 
 Most series of patients with AIT contain cases in which sequential therapy for 3592 
both subtypes was required before resolution of AIT occurred.  These patients are 3593 
frequently referred to as “mixed” types of AIT.  In a study of 20 patients with AIT that 3594 
included both type 1 and type 2 patients, perchlorate was administered alone for 1 month, 3595 
resulting in euthyroidism in 12 patients (7 with type 1 AIT and 5 with type 2 AIT) (591). 3596 
Corticosteroids were then given to the eight nonresponders (including 7 patients with 3597 
presumed type 1 disease), and euthyroidism was achieved in all after an average of 3598 
approximately 6 weeks (591). Patients are often reclassified retrospectively from type 1 3599 
to type 2 AIT based on a positive response to corticosteroid therapy or after an outcome 3600 
of permanent hypothyroidism, both of which would be unlikely in iodine-induced 3601 
thyrotoxicosis (598,606).  Patients recovering from apparent type 2 AIT should be 3602 
monitored for permanent hypothyroidism, which appears to occur more often with AIT 3603 
than with subacute thyroiditis (608). 3604 
 Importantly, individuals with moderate thyrotoxicosis and compromised cardiac 3605 
status should be considered for initial combined therapy rather than sequential empiric 3606 
therapy. Some centers recommend starting combined therapy with antithyroid drugs and 3607 
corticosteroids at the time of initial AIT diagnosis (594,609), and between 16-25% of 3608 
surveyed thyroidologists prefer combination antithyroid drug and corticosteroid therapy 3609 
for patients with apparent type 2 AIT (610). A rapid response to combined corticosteroid 3610 
and antithyroid drug therapy is believed to favor type 2 AIT (594) and allows a reduction 3611 
in antithyroid drugs, although some patients with type 2 AIT have a prolonged course, 3612 
particularly those with larger thyroids or worse thyrotoxicosis at the time of diagnosis 3613 
(611). A suggested approach to the management of AIT is shown in Figure 1.  3614 
 Technical remarks: The suggested starting dose of MMI in this setting is 40 mg 3615 
once daily until the patient is euthyroid (generally 3–6 months). If high doses of MMI 3616 
continue to be required, splitting the dose may be more effective. The suggested dose of 3617 
corticosteroids in this setting is equivalent to 40 mg prednisone given once daily for 2–4 3618 
weeks, followed by a gradual taper over 2–3 months, based on the patient’s clinical 3619 
response. 3620 
■ RECOMMENDATION 116 3621 
Patients with AIT who are unresponsive to aggressive medical therapy with MMI and 3622 
corticosteroids should undergo thyroidectomy. Strong recommendation, low-quality 3623 
evidence. 3624 
 Patients with AIT who fail to respond to medical therapy should be offered 3625 
thyroidectomy before they become excessively debilitated from inadequately controlled 3626 
thyrotoxicosis. The patient should be counseled that while thyroidectomy in this setting 3627 
carries with it significant morbidity and a high mortality rate (9%), delay or deferral of 3628 
surgery imparts an even higher risk of death (612). Thyroidectomy done under regional 3629 
anesthesia when available may be preferred for very ill patients (613). Several surgical 3630 
series involving patients with AIT have now been published, with generally favorable 3631 
results (612,614-616).  Patients in whom amiodarone was stopped during an episode of 3632 
AIT should be considered for definitive therapy with RAI or surgery in order to facilitate 3633 
reintroduction of amiodarone without concerns about recurrent AIT (617). 3634 
 3635 
[W] How should thyrotoxicosis due to destructive thyroiditis be managed? 3636 
 Several varieties of thyroiditis can present with temporary thyrotoxicosis as part 3637 
of a classic triphasic course (thyrotoxicosis, hypothyroidism, recovery), including 3638 
subacute thyroiditis, painless (silent) thyroiditis, acute (suppurative) thyroiditis, palpation 3639 
(traumatic) thyroiditis, postpartum thyroiditis, and drug-induced thyroiditis. In general, 3640 
thyroid dysfunction caused by thyroiditis is less severe than that seen with other forms of 3641 
endogenous thyrotoxicosis (50); RAIU is universally low during the thyrotoxic stage, 3642 
owing to leaking of preformed thyroid hormone with suppression of serum TSH 3643 
concentrations.  In this section, subacute, painless, acute and palpation thyroiditis will be 3644 
discussed; see section [T4] for a discussion of postpartum and section [X] for a 3645 
discussion of drug-induced thyroiditis. 3646 
[W1] Subacute thyroiditis 3647 
 Subacute thyroiditis, also called subacute granulomatous or de Quervain 3648 
thyroiditis, is a common cause of thyroid pain (24).   The diagnosis of subacute 3649 
thyroiditis is based on clinical history, physical examination, laboratory data, and RAIU. 3650 
Subacute thyroiditis presents with moderate-to-severe pain in the thyroid, often radiating 3651 
to the ears, jaw, or throat. The pain may begin focally and spread from one side to the 3652 
other of the gland over several weeks. Patients may have a prodrome of malaise, low-3653 
grade fever, pharyngitis symptoms, and fatigue. The thyroid may be slightly enlarged, 3654 
and is firm and painful to palpation.  Subacute thyroiditis is thought to be due to a sequela 3655 
of an upper respiratory viral infection that involves the thyroid gland.  3656 
 About 50% of patients with subacute thyroiditis have an initial thyrotoxic phase 3657 
due to unregulated release of preformed thyroid hormone from damaged thyroid 3658 
follicular cells (24).  Therefore, early in the course of the disease, patients may have 3659 
clinical findings of thyrotoxicosis, although this is often mild.  The serum TSH level is 3660 
suppressed, and the free T4 level may be elevated preferentially to the total T3 level, in 3661 
contrast to other endogenous forms of thyrotoxicosis, although there is substantial 3662 
overlap among the etiologies (618).  In addition to laboratory evidence of thyrotoxicosis, 3663 
the erythrocyte sedimentation rate or C-reactive protein (CRP) is elevated, and mild 3664 
anemia and elevation of the white blood count (wbc) are common. Up to 25% of patients 3665 
have low concentrations of anti-thyroid antibodies (24,619,620).  RAIU is low, as is 3666 
uptake on a thyroid scintigram.  Thyroid ultrasonography shows diffuse heterogeneity, 3667 
focal hypoechoic areas, and decreased or normal color-flow Doppler, rather than the 3668 
enhanced flow characteristic of GD (621,622).  A biopsy of the thyroid gland is not 3669 
usually necessary in subacute thyroiditis.  However, if a biopsy is performed due to 3670 
uncertainty of the diagnosis, its result shows granulomatous infiltrate and giant cells, 3671 
consistent with a viral infection (24). 3672 
 The thyrotoxic phase usually lasts 3-6 weeks, ending when the thyroid stores of 3673 
preformed hormone are depleted.  About 30% of patients subsequently enter a 3674 
hypothyroid phase that can last up to 6 months.  Thyroid pain and the elevated ESR have 3675 
usually resolved by this time, and the predominant clinical features are those of 3676 
hypothyroidism with a small nontender goiter.  Most patients become euthyroid again 3677 
within 12 months of disease onset, although 5-15% have persistent hypothyroidism 3678 
(24,620,621).   In addition, recurrence rates of 1-4% have been reported (24,620,623).   3679 
■ RECOMMENDATION 117 3680 
Patients with mild symptomatic subacute thyroiditis should be treated initially with 3681 
beta-adrenergic-blocking drugs and nonsteroidal anti-inflammatory agents. 3682 
Corticosteroids should be used instead of nonsteroidal anti-inflammatory agents when 3683 
patients fail to respond, or present initially with moderate to severe pain and/or 3684 
thyrotoxic symptoms. Strong recommendation, low-quality evidence. 3685 
 Subacute thyroiditis is treated with beta-blockers and anti-inflammatory therapy. 3686 
Beta-blockers are used as needed to control thyrotoxic symptoms.  Nonsteroidal anti-3687 
inflammatory agents (NSAIDs) provide pain relief in patients with mild symptoms, and 3688 
should be considered first-line therapy. With NSAIDs, the median time for resolution of 3689 
pain is 5 weeks (range 1-20 weeks) (24).  Patients who fail to respond to full doses of 3690 
NSAIDs over several days should be treated instead with corticosteroid therapy.   3691 
Standard recommendations are to use prednisone 40 mg daily for 1–2 weeks followed by 3692 
a gradual taper over 2–4 weeks or longer, depending upon clinical response. A 3693 
retrospective review found that patients treated with corticosteroids at similar doses had 3694 
more rapid resolution of pain (mean duration, 8 days) compared with those treated with 3695 
NSAIDs (mean duration, 35 days). However, symptoms can recur as the dose of 3696 
corticosteroid is reduced (24).   A more recent study reported that a lower initial daily 3697 
dose of 15 mg of prednisolone, with tapering by 5 mg every two weeks, was effective.  3698 
However, 20% of patients required longer than 8 weeks to discontinue the glucocorticoid 3699 
(624).   Levothyroxine may be employed during the hypothyroid stage, but should be 3700 
withdrawn after 3–6 months with recovery of normal function verified by thyroid 3701 
function testing.  ATDs have no role in the treatment of subacute thyroiditis. 3702 
[W2] Painless thyroiditis 3703 
 Painless or silent thyroiditis classically presents with the same triphasic course 3704 
described for subacute thyroiditis, but with no prodrome, neck pain, or elevated ESR, 3705 
white blood cell count, or CRP (625). The postpartum period is the most common time 3706 
when painless thyroiditis is seen, but painless thyroiditis can also occur in nonpregnant 3707 
women and in men.  Painless thyroiditis has been described in some types of drug-3708 
induced thyroid dysfunction, including that associated with lithium or cytokine therapy.  3709 
Postpartum and drug-induced thyroiditis are discussed in detail in sections [T4] and [X], 3710 
respectively.  A small nontender goiter is common in all types of painless thyroiditis. 3711 
 The thyrotoxic phase occurs in 5-20% of patients and typically lasts 3-4 months.  3712 
The hypothyroid phase is more common, or at least is recognized more often, lasting up 3713 
to 6 months.  Normal thyroid function is reestablished by 12 months in most patients, but 3714 
10-20% have persistent hypothyroidism.  Recurrence rates are about 5-10%, but may be 3715 
higher in Japan, with one Japanese study reporting a long-term recurrence rate of 65% 3716 
(626).  Recurrences are managed in the same manner as the initial occurrence, but rare 3717 
patients with multiple recurrences have opted for surgery or RAI ablation of the gland 3718 
following recovery from the thyrotoxic phase (626).   3719 
 Painless thyroiditis is probably an autoimmune disease manifested by positive 3720 
anti-TPO antibodies in about 50% of patients and findings of lymphocytic infiltration on 3721 
pathology (626,627).  During the thyrotoxic phase, the serum TSH level is suppressed 3722 
and free T4 levels are elevated, often out of proportion to T3 levels.  Patients with painless 3723 
thyroiditis have a low RAIU and low uptake on a thyroid scintigram during the thyrotoxic 3724 
phase, and ultrasound often shows inhomogeneous hypoechogenic texture with decreased 3725 
blood flow.  These tests and the absence of TRAb antibodies help distinguish painless 3726 
thyroiditis from GD (628). 3727 
■ RECOMMENDATION 118 3728 
Patients with symptomatic thyrotoxicosis due to painless thyroiditis should be treated 3729 
with beta-adrenergic-blocking drugs to control symptoms. Strong recommendation, 3730 
low-quality evidence. 3731 
 Beta-adrenergic blockers can be used to treat thyrotoxic symptoms in patients 3732 
with painless thyroiditis, but ATDs have no utility, since new hormone synthesis is 3733 
already low in these patients. Rarely, corticosteroids have been used to ameliorate the 3734 
severity and the time course of thyrotoxicosis due to painless thyroiditis (629), but they 3735 
should be reserved only for more severe cases.  3736 
[W3] Acute thyroiditis 3737 
■ RECOMMENDATION 119 3738 
Acute thyroiditis should be treated with antibiotics and surgical drainage as 3739 
determined by clinical judgement.  Beta blockers may be used to treat symptoms of 3740 
thyrotoxicosis. Strong recommendation, low-quality evidence. 3741 
 Patients with acute thyroiditis (also referred to as suppurative thyroiditis or 3742 
thyroid abscess) are generally euthyroid. However, on occasion, the condition presents as 3743 
destructive thyroiditis with thyrotoxicosis (630). Ultrasound or CT examinations are 3744 
usually diagnostic, showing hypoechoic lesions in and around the affected thyroid lobe, 3745 
destruction of the lobe, and abscess formation.  However, early in the process, radiologic 3746 
examination may be nonspecific, often leading to the erroneous diagnoses of subacute 3747 
thyroiditis (631).  The etiology of acute thyroiditis is most frequently a bacterial infection 3748 
affecting the thyroid, either through hematogenous spread or direct extension through a 3749 
fistula from an infected pyriform sinus. Therapy involves systemic antibiotics as well as 3750 
abscess drainage or removal, and excision or occlusion of the offending pyriform sinus. 3751 
Thyrotoxicosis should be treated symptomatically with beta-blocking agents. As in other 3752 
forms of destructive thyroiditis, there is no role for ATDs. 3753 
[W4] Palpation thyroiditis 3754 
 In 1975, Carney et al described a nonspecific multifocal granulomatous folliculitis 3755 
in thyroid glands removed at surgery for thyroid-related or unrelated conditions (632).  3756 
They named this pathologic entity “palpation thyroiditis,” concluding that it was due to 3757 
palpation of the thyroid gland at surgery.  It was generally thought to be of little clinical 3758 
importance, except for rare case reports of patients who developed thyrotoxicosis 3759 
following manipulation of the thyroid gland during surgery (633-636).  However, a recent 3760 
study suggested that the rate of transient overt or subclinical thyrotoxicosis following 3761 
parathyroid surgery may be as high as 30%, although there was likely ascertainment bias 3762 
because not all patients had post-operative TSH levels measured (637).  There are no data 3763 
on treatment of palpation thyroiditis, although the use of beta blockers for symptomatic 3764 
thyrotoxicosis seems reasonable. 3765 
 3766 
[X] How should other causes of thyrotoxicosis be managed? 3767 
     Tables 16 and 17 summarize drug-associated and unusual causes of thyrotoxicosis. 3768 
■ RECOMMENDATION 120 3769 
Patients taking medications known to cause thyrotoxicosis, including interferon- α, IL-3770 
2, tyrosine kinase inhibitors, and lithium, should be monitored clinically and 3771 
biochemically at 6-month intervals for the development of thyroid dysfunction.  3772 
Patients who develop thyrotoxicosis should be evaluated to determine etiology and 3773 
treated accordingly. Strong recommendation, low-quality evidence. 3774 
[X1] Interferon- α and interleukin-2 3775 
 Interferon-α (IFN-α) and interleukin-2-treated patients are at increased risk for 3776 
developing thyrotoxicosis, especially those with pre-existing thyroid autoimmunity. A 3777 
recent study including 1233 patients who were euthyroid at baseline found that 79 (6.4%) 3778 
patients developed a biphasic thyroiditis and an additional 57 (4.6%) patients developed a 3779 
suppressed TSH value (638). The latter group included 33 patients with mild TSH 3780 
suppression and 24 with a TSH value < 0.1 mU/L, among whom 11 had free T4 elevation 3781 
and 5 required antithyroid drug therapy (638). Thyrotoxicosis in patients treated with 3782 
IFN-α can be due to either painless thyroiditis or GD (639). In a review of published 3783 
cases from 8 series, 69% of 49 patients with IFN-α-associated thyrotoxicosis, for whom 3784 
an etiology was identified, were found to have GD, based on either positive TRAb titers 3785 
or requirement for a prolonged course of ATDs (640). An earlier literature review found 3786 
that 2.4% of 1664 patients treated with IFN-α therapy for hepatitis C infection developed 3787 
thyrotoxicosis, although the specific etiology was not consistently identified (641).   3788 
[X2] Tyrosine Kinase Inhibitors  3789 
 The tyrosine kinase inhibitors sunitinib (642-647), sorafenib (648-650), and 3790 
nilotinib (651) have each been associated with a transient thyrotoxicosis due to 3791 
destructive thyroiditis.  One study of 69 patients treated with sorafenib for metastatic 3792 
renal cell carcinoma found that 11 (16%) developed transient thyroiditis followed by 3793 
hypothyroidism (649).  Another study found that 6 of 31 (19.3%) receiving sunitinib 3794 
therapy for metastatic renal cell carcinoma developed thyrotoxicosis, including one case 3795 
of thyroid storm (644). 3796 
[X3] Lithium 3797 
 Patients taking lithium for bipolar disorder are at a high risk of developing thyroid 3798 
dysfunction, including both hypothyroidism, and to a lesser extent, thyrotoxicosis (652). 3799 
Two published series have identified the development of thyrotoxicosis in 0.6% and 3.0% 3800 
of patients, respectively (653,654).  An epidemiological study of hyperthyroidism 3801 
occurring over a 3-year period in Denmark identified lithium-associated thyrotoxicosis as 3802 
the etiology in 0.7% of all cases (432).   A case series of 24 patients with lithium-3803 
associated thyrotoxicosis identified GD in 12 (50%), painless thyroiditis in two patients, 3804 
toxic multinodular goiter in 3 patients, and no identified etiology in 7 patients (655).  3805 
Another more recent series found that 1.4% of referrals to a thyroid clinic over a 12-year 3806 
period were for lithium related thyrotoxicosis (656).  Patients in this series had been 3807 
taking lithium for a median duration of 6 years (range 0.6-25 years), and 87% were 3808 
women.  Diagnostic evaluation found that 11 (47.8%) had GD, 9 (39%) had painless 3809 
thyroiditis, 2 had toxic MNG, and one patient had subacute thyroiditis (656).  A smaller 3810 
series described three cases of GD occurring in patients receiving lithium (657). In a 3811 
retrospective review of 100 cases of thyroiditis and 400 cases of GD occurring at a single 3812 
medical center, 6 cases of painless thyroiditis had a history of recent lithium exposure, 3813 
representing a nearly 5-fold increase compared to cases of lithium exposure in patients 3814 
with GD (19). 3815 
[X4] TSH-secreting pituitary tumors 3816 
■ RECOMMENDATION 121 3817 
The diagnosis of TSH-secreting pituitary tumor should be based on an inappropriately 3818 
normal or elevated serum TSH level associated with elevated free T4 and total T3 3819 
concentrations, generally associated with a pituitary tumor on MRI or CT, and the 3820 
absence of a family history or genetic testing consistent with thyroid hormone 3821 
resistance. Strong recommendation, low-quality evidence. 3822 
 TSH-secreting pituitary adenomas are rare tumors and represent an even rarer 3823 
cause of hyperthyroidism. Recent data from the Swedish registry reported an incidence of 3824 
0.15 per 1 million inhabitants with a prevalence of 2.8 cases per million (658). After 3825 
excluding laboratory interference with either the free T4 or TSH assay, as may occur with 3826 
T4 antibodies and heterophilic antibodies, respectively, distinction between a TSH-3827 
secreting adenoma and thyroid hormone resistance is important, since thyroid function 3828 
test results are similar, yet management is quite different for these two disorders. TSH-3829 
secreting adenomas are more likely to have concurrent alpha-subunit elevation (not 3830 
useful in postmenopausal women due to concurrent gonadotropin elevation), a blunted 3831 
TSH response to thyrotropin-releasing hormone (TRH) (when available), elevated sex-3832 
hormone-binding globulin and resting energy expenditure, and clinical evidence of 3833 
thyrotoxicosis, as well as an anatomic abnormality on MRI of the pituitary. Finally, a 3834 
response to somatostatin analog therapy with clinical improvement lends support to the 3835 
diagnosis of a TSH adenoma in cases in which diagnostic uncertainty persists.  Although 3836 
most TSH-secreting pituitary adenomas only secrete TSH, co-secretion of prolactin or 3837 
growth hormone is possible and should be assessed concurrently along with assessment 3838 
of the pituitray-adrenal axis and pituitary-gonadal axes.  3839 
 Technical remarks: Genetic testing for thyroid hormone resistance is 3840 
commercially available and may be useful in equivocal cases, especially in those patients 3841 
without family members available for thyroid function testing.  Calculation of the molar 3842 
alpha subunit/TSH ratio can be accomplished by dividing the alpha subunit concentration 3843 
(ng/mL) by TSH (mU/L) and multiplying by 10. A ratio greater than 1 favors a TSH-3844 
secreting pituitary adenoma.   3845 
 Pituitary surgery is generally the mainstay of therapy for TSH-producing pituitary 3846 
tumors. In a recent series of 68 patients undergoing transsphenoidal surgery, 75% 3847 
normalize thyroid function after surgery, 58% normalized both pituitary imaging and 3848 
TSH hypersecretion, 9% developed new deficiencies, and 3% experienced tumor 3849 
recurrence (659). The patient should be made euthyroid preoperatively. Long-term ATD 3850 
therapy and other measures directed at the thyroid, such as RAI or thyroidectomy, are 3851 
generally avoided due to theoretical concerns of tumor growth.  Preoperative adjunctive 3852 
therapy with octreotide and dopamine agonist therapy has been examined. Treatment 3853 
with octreotide results in a >50% reduction in serum TSH values in the majority of 3854 
patients treated, and a concurrent return to euthyroidism in most (43). A reduction in 3855 
tumor size has been observed in 20%–50% of patients treated with octreotide (43,660), 3856 
but less impressive results have been obtained with bromocriptine therapy (660). 3857 
However, presurgical medical treatment did not significantly improve surgical outcome 3858 
(63% vs 57% had negative tumor imaging after surgery) (659). In a recent case series of 3859 
7 patients treated with octreotide without prior surgery, mean free T4 and T3 levels were 3860 
reduced by nearly 50% in the first three months of therapy and 6 of 7 patients 3861 
experienced tumor volume reduction (661).  3862 
 Sterotactic or conventional radiotherapy has also been used in cases that prove 3863 
refractory to medical therapy.  Radiotherapy controlled thyroid hypersecretion in 37% of 3864 
patients treated with this modality, but hypopituitarism occurred in 32% of those treated 3865 
(659). For patients with TSH-producing adenomas who are considered poor surgical 3866 
candidates, primary medical therapy with octreotide can be considered (661).  Patients 3867 
who fail to respond to pituitary surgery and somatostatin analog therapy or have tumor 3868 
enlargement despite these measures are sometimes treated with radiation therapy.  3869 
■ RECOMMENDATION 122 3870 
Patients with TSH-secreting pituitary adenomas should undergo surgery performed by 3871 
an experienced pituitary surgeon. Strong recommendation, low-quality evidence. 3872 
 Technical remarks: Postoperative adjunctive therapy with octreotide and/or 3873 
external beam radiation therapy may be useful in managing patients with persistent 3874 
central hyperthyroidism after a debulking procedure for nonresectable TSH-secreting 3875 
adenomas (43). 3876 
[X5] Struma ovarii 3877 
■ RECOMMENDATION 123 3878 
Patients with struma ovarii should be treated initially with surgical resection following 3879 
preoperative normalization of thyroid hormones. Strong recommendation, low-3880 
quality evidence. 3881 
 Struma ovarii, defined as ectopic thyroid tissue existing as a substantial 3882 
component of an ovarian tumor, is quite rare, representing <1% of all ovarian tumors. 3883 
Approximately 5–10% of patients with struma ovarii present with thyrotoxicosis (662) 3884 
due to either autonomous ectopic thyroid function or the coexistence of GD, and up to 3885 
25% of struma ovarii tumors contain elements of papillary thyroid cancer. Patients 3886 
previously treated for GD may have persistent or recurrent hyperthyroidism due to the 3887 
action of TRAb on the ectopic thyroid tissue (663).  The diagnosis should be considered 3888 
in any thyrotoxic patient with a very low or absent RAI uptake over the eutopic thyroid 3889 
gland.  Other conditions that present with this constellation of findings include various 3890 
forms of thyroiditis, factitious thyrotoxicosis, and iodine-induced hyperthyroidism.  In 3891 
struma ovarii, the RAI is concentrated in the pelvic region over the teratoma. 3892 
Cosynchronous primary thyroid cancer occurred in 9% of patients in one series of 68 3893 
patients identified in the SEER database (664). Treatment of struma ovarii generally 3894 
involves surgical removal, performed both to cure the hyperthyroidism and to eliminate 3895 
the risk of untreated ectopic thyroid cancer. Preoperative treatment with beta-adrenergic-3896 
blocking agents and ATDs is warranted to restore euthyroidism before surgery. 3897 
 Technical remarks: In cases of suspected metastatic malignant struma ovarii, RAI 3898 
is generally given following surgical removal of both the ovarian tumor and the patient’s 3899 
thyroid to facilitate delivery of isotope to any potential residual malignant cells. 3900 
[X6] Choriocarcinoma 3901 
■ RECOMMENDATION 124 3902 
Treatment of hyperthyroidism due to choriocarcinoma should include both MMI and 3903 
treatment directed against the primary tumor. Strong recommendation, low-quality 3904 
evidence. 3905 
 Patients with choriocarcinoma, including molar pregnancy and testicular cancer, 3906 
may present with thyrotoxicosis due to the effect of tumor-derived hCG upon the TSH 3907 
receptor (665-668). This cross-stimulation only occurs at very high levels of hCG, since 3908 
hCG is only a weak agonist for the TSH receptor. Therefore, patients with testicular 3909 
choriocarcinoma presenting with overt thyrotoxicosis may have widely metastatic disease 3910 
at presentation (667,668). Treatment of hyperthyroidism due to choriocarcinoma involves 3911 
both treatment directed against the primary tumor and ATDs. 3912 
[X7] Thyrotoxicosis factitia 3913 
 Thyrotoxicosis factitia includes all causes of thyrotoxicosis due to the ingestion of 3914 
thyroid hormone. This may include intentional ingestion of thyroid hormone either 3915 
surreptitiously or iatrogenically, as well as unintentional ingestion either accidentally, 3916 
such as in pediatric poisoning or pharmacy error, or through ingestion of supplements 3917 
that contain thyroid hormone (669). Historically, accidental thyroid hormone ingestion 3918 
has occurred as a result of eating meat contaminated with animal thyroid tissue 3919 
(‘‘hamburger thyrotoxicosis’’) (670).  3920 
 Whereas iatrogenic causes of thyrotoxicosis factitia are easily identified, 3921 
surreptitious use of thyroid hormone may present a diagnostic quandary. Clues to this 3922 
diagnosis are an absence of goiter, a suppressed serum thyroglobulin level, and a 3923 
decreased RAI uptake.  In a patient who has circulating antithyroglobulin antibodies that 3924 
artifactually render the serum thyroglobulin undetectable in immunometric assays, the 3925 
distinction between painless thyroiditis and factitious thyrotoxicosis can be difficult.  In 3926 
both situations there will be elevated levels of T4, a high T4/T3 ratio (with exogenous 3927 
levothyroxine), a small thyroid, and a low thyroidal RAI uptake.  Thyroid ultrasound may 3928 
be helpful, as the thyroid has a heterogeneous echotexture and is normal-sized or slightly 3929 
enlarged in painless thyroiditis, while it is small with a normal echotexture in an 3930 
otherwise normal individual who is ingesting thyroid hormone surreptitiously.   Fecal 3931 
levothyroxine has been measured as a means of distinguishing surreptitious use of thyroid 3932 
hormone from painless thyroiditis (54). A disproportionately elevated T3 level suggests 3933 
that the patient may be ingesting liothyronine or a combination T4/T3 preparation.    3934 
 Severe thyrotoxicosis and rarely, thyroid storm, have been reported following 3935 
thyroid hormone overdose or poisoning.  Treatment with Cholestyramine (671) and 3936 
charcoal hemoperfusion (672) have been used in this circumstance.   3937 
[X8] Functional thyroid cancer metastases 3938 
 Thyrotoxicosis due to functional metastases in patients with thyroid cancer has  3939 
been described in a handful of cases. Typically, patients have either a very large primary  3940 
follicular cancer or widely metastatic follicular thyroid cancer, and may have coexisting  3941 
TRAb as the proximate cause of the thyrotoxicosis (673). In general, functioning  3942 
metastasis are treated with RAI with the addition of ATDs as needed for persistent  3943 
hyperthyroidism. Recombinant human TSH should be avoided in these patients. Patients  3944 
with massive metastatic FC may also exhibit T3 thyrotoxicosis, most likely due to  3945 
increased conversion of T4 to T3 by tumor expressing high type 1 and type 2 deiodinase  3946 
activities (674). Thus, occasional measurement of serum T3 in addition to FT4 and TSH is  3947 
recommended in patients with a large metastatic tumor burden, particularly if FT4  3948 
decreases on fixed doses of levothyroxine. 3949 
